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1. Executive summary
This report presents a review of risk characterisation,
the ﬁnal step in risk assessment of exposures to food
chemicals. The report is the second publication of the
project ‘‘Food Safety in Europe: Risk Assessment of
Chemicals in the Food and Diet (FOSIE)’’. The science
underpinning the hazard identiﬁcation, hazard char-
acterisation and exposure assessment steps has been
published in a previous report (Food Safety in Europe,
2002). Risk characterisation is the stage of risk assess-
ment that integrates information from exposure assess-
ment and hazard characterisation into advice suitable
for use in decision-making. The focus of this review is
primarily on risk characterisation of low molecular
weight chemicals, but consideration is also given to
micronutrients and nutritional supplements, macro-
nutrients and whole foods. Problem formulation, as
discussed here, is a preliminary step in risk assessment
that considers whether an assessment is needed, who
should be involved in the process and the further risk
management, and how the information will provide the
necessary support for risk management. In this step an
evaluation is made of whether data are available and
what level of resources are needed, as well as the time-
line for completing the assessment. The report describes
good evaluation practice as an organisational pro-
cess and the necessary condition under which risk
assessment of chemicals should be planned, performed,
scrutinised and reported. The outcome of risk char-
acterisation may be quantitative estimates of risks, if
any, associated with diﬀerent levels of exposure, or
advice on particular levels of exposure that would be
without appreciable risk to health, e.g. a guidance value
such as an acceptable daily intake (ADI). It should be
recognised that risk characterisation often is an iterative
and evolving process.
Historically, diﬀerent approaches have been adopted
for the risk characterisation of threshold and non-
threshold eﬀects. The hazard characterisation for
threshold eﬀects involves the derivation of a level of
exposure at or below which there would be no appreci-
able risk to health if the chemical were to be consumed
daily throughout life. A guidance value such as the
ADI, is derived from the no-observed-adverse-eﬀect-
level (NOAEL) or other starting point, such as the
benchmark dose (BMD), by the use of an uncertainty or
adjustment factor. In contrast, for non-threshold eﬀects
a quantitative hazard estimate can be calculated by
extrapolation, usually in a linear fashion, from an
observed incidence within the experimental dose-
response range to a given low incidence at a low dose.
This traditional approach is based on the assumption
that there may not be a threshold dose for eﬀects invol-
ving genotoxicity. Alternatively, for compounds that are
genotoxic, advice may be given that the exposure shouldbe reduced to as low as reasonably achievable
(ALARA) or practicable (ALARP). When a NOAEL
can be derived from a study in humans, this would be
utilised in the derivation of guidance values or advice.
However, there may be uncertainties related to the pos-
sible role of confounders and the precision of both the
incidence and exposure data. Individuals may be at an
increased risk because of their greater exposure or their
greater sensitivity. Risk characterisation should include
information not only on the general population, but
also on any subpopulation considered to be potentially
susceptible.
Risk characterisation considers both individuals with
average exposures and those with high exposures. High
exposure may be related to life stage, cultural practices
and/or qualitative and/or quantitative food preferences.
Inter-individual diﬀerences in toxicokinetics are an
important source of variability in response. This may
arise from diﬀerences in genetic constitution or envir-
onmental inﬂuences including diet, nutritional status,
physiological status such as pregnancy, as well as patho-
physiological states. Studies undertaken for hazard
identiﬁcation and characterisation investigate a sub-
stance in isolation, and not in combination with other
substances to which humans may be exposed at the
same time. It is recognised that food represents an
extremely complex mixture of substances. In general,
the available data indicate that interactions between
chemicals in food are unlikely to be a signiﬁcant prob-
lem for health. However, attention needs to be focused
during risk characterisation on substances that share a
common mode of action. The patterns of human expo-
sure to chemicals in food may be chronic (usually low-
level), short-term (often at higher levels) or chronic low-
level with occasional high intakes. This may necessitate
the development of guidance values for acute exposures
(the acute reference dose, ARfD) based on shorter-term
studies, in addition to an ADI-value usually based on
chronic studies. The possibility of increased risks of
chronic adverse eﬀects associated with long-term low-
level exposure, combined with occasional peak expo-
sures has generally been handled by averaging such
exposures. The signiﬁcance of intakes above the ADI is
diﬃcult to assess. Consideration in this respect has to be
given to the nature of the eﬀect, the magnitude of the
excessive intake, as well as the duration of excessive
intake, in relation to the half-life of the compound in
the body and the associated body burden. An intake
above the ADI may not necessarily be associated with
signiﬁcant adverse health outcomes since the ADI
usually is based on chronic intake and incorporates a
safety margin. However, an intake above the ADI
would have the eﬀect of eroding the safety margin by
the ratio of the ADI to the predicted excess intake.
Alternative approaches to assessment of the signiﬁcance
of intakes above the guidance value are provided byA.G. Renwick et al. / Food and Chemical Toxicology 41 (2003) 1211–1271 1213
categorical regression analysis and probabilistic meth-
ods. For non-threshold eﬀects, such as for some cancers,
that have undergone risk characterisation by the use of
quantitative low-dose hazard extrapolation, any
increase in risk with increased exposure can be readily
interpreted using the same mathematical model.
The narrative that accompanies the risk characterisa-
tion should explain the strengths and limitations of the
data. When risk characterisation is based on animal
data, the validity of such data needs to be aﬃrmed and
reported. Also, uncertainties associated with the extra-
polation of data from studies in animals to predict
human risk should be presented. Uncertainty can be
expressed numerically when intake assessment and
hazard characterisation are based on mathematical cal-
culations and/or empirical distributions. Such numerical
analyses can also be subject to sensitivity analyses, to
test the contribution of diﬀerent aspects of the database
to overall uncertainty. Knowledge regarding the inﬂu-
ence of human genetic polymorphisms on toxic respon-
ses is advancing rapidly. This has led to increasing
concern that the default uncertainty factor may not
provide adequate protection in the case of certain poly-
morphisms. The methods used for risk characterisation
of low molecular weight chemicals are applicable in
many respects to micronutrients. However, there are
some unique aspects, the most obvious ones being that
some intake is essential for life and the margins between
essential intakes and toxic intakes may, for a number of
micronutrients, be small. Since both deﬁciency and
excess of a micronutrient can cause health problems,
two guidance values for a micronutrient may be expres-
sed. The setting of a tolerable upper intake level (UL)
includes consideration of what does not cause physi-
ological perturbations as well as consideration of the
probability of an adverse eﬀect occurring at some spe-
ciﬁed level of exposure. Macronutrients, such as dietary
lipids, proteins and carbohydrates, may be present in
the food/diet in substantial amounts. Consideration
needs to be given in hazard characterisation of macro-
nutrients to tolerance and to toxicological and nutri-
tional impact. Hazard characterisation using animal
studies may not be possible because the addition of
bulky macroingredients to experimental diets, in
amounts that are exaggerated relative to the human
diet, may render such diets unpalatable and/or cause
nutritional imbalance. Because of this, the role of
human trials and observational studies are widely
viewed as particularly important for macronutrients,
addressing toxicokinetics, nutritional issues and toler-
ance. Observational epidemiological studies may also
help to identify adverse eﬀects. As for micronutrients,
there may need to be more than one guidance value for
a macronutrient. In certain instances, a margin of safety
approach may be preferable, when it is not possible in
animal studies to exaggerate the dosage suﬃciently toaccommodate the usual uncertainty factors. This project
also addresses hazard and risk characterisation related
to whole foods, except those based on GM technology,
which is dealt with in another European Union (EU)
project, ENTRANSFOOD. Whole foods may be foods
currently on the market or novel foods for which
approval is being sought. There is as yet no world-wide
consensus on the most appropriate approaches to
hazard and risk characterisation of whole foods, other
than to recommend that a case-by-case consideration
and evaluation is needed. The initial approach to novel
foods requires consideration of the extent to which the
novel food diﬀers from any traditional counterparts, or
other related products, and hence whether it can be
considered as safe as traditional counterparts/related
products (the principle of substantial equivalence). As
for macronutrients, epidemiological data identifying
adverse eﬀects, including allergic reactions, may also
exist. Human trials on whole foods, including novel
foods, will only be performed when no serious adverse
eﬀects are expected. The report ends with a discussion
of knowledge gaps in the area of risk characterisation of
exposures to chemicals in food and diet, and presents a
prioritised list of research needs.2. Introduction
In response to the need for clariﬁcation and improve-
ment of the risk assessment process, the International
Life Sciences Institute—European branch (ILSI Eur-
ope) elaborated a project proposal for a European
Concerted Action to examine critically and to develop
further the methodology of risk assessment.
The analysis of risk from the consumption of food is a
complex and emotive issue that attracts much attention.
The process of risk analysis is divided into three main
elements (risk assessment, risk management and risk
communication). In this document the focus is on risk
assessment as a scientiﬁc evaluation process. Con-
sideration of the processes of risk management, risk
communication and risk perception did not form part of
this project. It goes without saying, however, that it is of
great importance that all stakeholders involved in the
risk analysis process communicate extensively concern-
ing the diﬀerent elements. In this document, communi-
cation is identiﬁed as being of particular relevance in
’problem formulation’, a preliminary step in risk
assessment that considers and deﬁnes the questions,
issues and the plan of the process for analysing and
characterising the risk. In addition, following com-
pletion of the risk assessment, the risk assessors have
the responsibility to communicate the estimated risks
and their meaning clearly, including the assumptions
made and the uncertainties underlying the numerical
determinations.1214 A.G. Renwick et al. / Food and Chemical Toxicology 41 (2003) 1211–1271
This document reviews the risk characterisation of
chemicals in food. The science underpinning the ﬁrst
three steps of the risk assessment process (hazard iden-
tiﬁcation, hazard characterisation and exposure assess-
ment) has been published in a previous report (Food
Safety in Europe, 2002).
2.1. Aims of the project
These have been outlined in detail previously (Smith,
2002) and will be reviewed only brieﬂy here.
The project ‘‘Food Safety in Europe: Risk Assessment
of Chemicals in the Food and Diet’’ (Acronym: FOSIE)
is an EU Fifth Framework Programme Concerted
Action funded by the European Commission, Quality of
Life and Management of Living Resources Programme,
Key Action 1 on Food, Nutrition and Health.
The aims of the project can be brieﬂy summarised as:
 to explore means of improving the principles
applied to, and scientiﬁc basis of, risk assessment
with respect to food additives and contaminants,
micronutrients and nutritional supplements,
macronutrients and whole foods,
 to consider possible interactions between indivi-
dual chemicals and eﬀects of the food matrix,
 to identify the gaps in knowledge that might lead
to diﬀerences in interpretation of toxicological
and exposure data, and the research needs to
reduce these,
 to determine the nature and level of testing nee-
ded for safety evaluation relevant to the nature of
the chemical, level of use/occurrence in the diet
and human exposure,
 to add a European contribution to international
initiatives to harmonise principles, terminology
and methodology for risk assessment,
 to contribute towards a consensus on risk
assessment issues that is scientiﬁcally transparent
and justiﬁable,
 to assist risk managers in developing appro-
priate, defensible food standards that adequately
protect the safety of the consumer while allowing
for innovation in food production and processing.
There is general agreement on the stages involved in
risk assessment, though much of the work in this area
originates from safety assessment of chemicals other
than those found in foods. There is guidance for, and
considerable experience with, the risk assessment of low
molecular weight chemicals in foods, such as food
additives and pesticides (World Health Organisation,
1987, 1990, 1994) and procedures are continually
reviewed and updated. However, there is less experience
with some other categories of food chemicals (i.e.
micronutrients and nutritional supplements, macro-nutrients and whole foods). Guidance is still needed on
how the risk assessment should be performed in prac-
tice, on the requirements of each stage of the process,
and on the overall integration of the data obtained in
each step.
2.2. Way of working
In the FOSIE project, individual theme groups (ITGs)
were formed to assess the current state of the art, to
establish the science base for new risk assessment meth-
odologies and to identify gaps in current knowledge and
the research needs to ﬁll these gaps. The ITGs were
designed to address all the steps involved in risk assess-
ment. However, it was recognised that such a restrictive
separation should not limit the coverage of the essential
science, and the content of the ITG reports is, in some
cases, much broader than inferred by their titles. Six
ITGs were organised to consider the ﬁrst three steps of
the risk assessment process as follows:
 hazard identiﬁcation by methods of animal-based
toxicology,
 methods of in vitro toxicology,
 hazard characterisation of chemicals in food and
diet: dose-response, mechanisms and extrapola-
tion issues,
 mathematicalmodelling and quantitativemethods,
 assessment of intake from the diet,
 the contribution of epidemiology.
The reports from these six groups were published in a
separate issue of Food and Chemical Toxicology (Food
Safety in Europe, 2002).
A ﬁnal ITG was convened to consider risk character-
isation and was composed of recognised experts in the
ﬁeld. They began their work by reviewing the informa-
tion from previous ITGs. Individual sections were then
prepared on the essential elements of risk characterisa-
tion and group meetings were organised to review pro-
gress and revise the drafts. The risk characterisation
sections were reviewed and amended at the third plen-
ary meeting of the FOSIE project (with additional invi-
tations made to risk assessment experts and some risk
managers who had not participated in the project). The
contents of the sections following this introduction
provide an integrated, comprehensive and critical
appraisal of the processes used for the characterisation
and quantiﬁcation of risk.
2.3. Risk characterisation—the last step in the risk
assessment process
Risk characterisation has been deﬁned as follows:
(European Commission, Scientiﬁc Steering Committee,
2000): ‘‘The quantitative or semi-quantitative estimate,A.G. Renwick et al. / Food and Chemical Toxicology 41 (2003) 1211–1271 1215
including attendant uncertainties, of the probability of
occurrence and severity of adverse eﬀect(s)/event(s) in a
given population under deﬁned conditions based on
hazard identiﬁcation, hazard characterisation and
exposure assessment’’.
The risk assessment process is shown schematically in
Fig. 1 as being a branched linear process culminating in
the ﬁnal integrative step of risk characterisation. In
reality it is an iterative process where the analysis car-
ried out has to ﬁt the data that are currently available.
On occasions there is the need to characterise risk in
data-sparse situations and this will lead to the develop-
ment of estimates of risk that are subject to considerable
uncertainty; any uncertainties should be characterised
and, where possible, quantiﬁed. If an estimate asso-
ciated with high uncertainty is suﬃcient for risk man-
agement purposes then generation of additional data
may not be necessary. However, if further reﬁnement of
the risk assessment is required then additional iterations
of the process with additional data generation will be
needed, with a concomitant decrease in the degree of
uncertainty.
2.4. Scope of the document
This paper is targeted principally at risk assessors,
although the information will also be of value to those
involved in risk management and risk communication.
The document is organised to reﬂect the way that risk
characterisation is carried out, beginning with the issue
of problem formulation and working through the dataneeded to the ﬁnal step of risk characterisation and the
guidance values and/or advice for risk managers.
Finally there is a review of future challenges with
recommendations on gaps and research needs. It is the
identiﬁcation of the research needs and the subsequent
co-ordination of work to address them that will lead to
stimulation of methodological and other improvements
in the process.
It is clear that there is a widely accepted and reason-
ably mature system for the risk characterisation of low
molecular weight chemicals and this document inevi-
tably focuses on these. However, consideration is also
given to the applicability of the risk characterisation
process to other categories. The four food categories
considered were:
 chemicals of low molecular weight, or ‘‘low
relative molecular mass’’, e.g. food additives,
pesticides, contaminants,
 micronutrients and nutritional supplements, e.g.
vitamins and minerals,
 macronutrients, e.g. proteins, lipids and carbo-
hydrates,
 whole foods, e.g. new varieties of food plants or
exotic fruits.
Novel foods have not been covered as a separate cate-
gory, as this is a regulatory term relating to the degree of
previous consumption of a food in a deﬁned population.
Food processing is considered across all of the four
food categories when relevant.Fig. 1. The risk assessment paradigm.1216 A.G. Renwick et al. / Food and Chemical Toxicology 41 (2003) 1211–1271
Others topics not covered in the document are:
 risk characterisation of the nutritional impact of
macronutrients in the diet, for example in causing
obesity. This is appropriate for dietary guidelines
produced by many national and international
authorities but outside the scope of this review;
 risk characterisation of genetically modiﬁed
organisms and derived ingredients in food. A
separate EU-funded thematic network called
ENTRANSFOOD speciﬁcally covers this topic;
 risk characterisation of animal feed is only
indirectly covered with consideration of compo-
nents that may enter the human food chain;
 risk characterisation of microbiological risks for
food;
 nutritional beneﬁts of foods, these are also
subject to a EU-funded project entitled
PASSCLAIM (QLK1-2000-00086, http://europe.
ilsi.org/passclaim);
 considerations of risk versus beneﬁt.
3. Problem formulation for risk assessment
Problem formulation is the initial step in the whole
risk assessment process. Although the focus of this
paper is on risk characterisation, the ﬁnal step of the
risk assessment process, problem formulation is dealt
with here in detail since risk characterisation needs to be
in a form relevant to the problem identiﬁed initially.
The outcome of problem formulation is an analysis plan
with detailed questions for the risk assessor, on which
the risk characterisation process has to focus. Ideally,
problem formulation should be considered as an itera-
tive process involving dialogue with all stakeholders,
i.e. risk assessors, risk managers, manufacturers or pro-
ducers, consumers, and it can develop as the risk
assessment evolves.
3.1. Process of problem formulation
Problem formulation is the process by which the
issues and questions are deﬁned and the plan for ana-
lysing and characterising risk is developed. The process
can be initiated by an individual outside the scientiﬁc
and risk assessment community bringing a problem to
public attention.
A clear formulation of the problem is critical for
ensuring a useful and relevant end product of the risk
assessment process. The ﬁrst step to problem formula-
tion is a planning dialogue that clariﬁes the manage-
ment goals, the purpose and scope of the assessment
and the resources available to conduct the assessment.
The planning dialogue is an iterative process that
considers: whether a risk assessment is needed,
 who should be involved in the risk assessment
and risk management processes,
 how the assessment will provide the information
necessary to support the risk management
decision,
 whether data are available to embark on an
evaluation of risks,
 what level of resources are available, and
 what is the timeline for completing the assess-
ment.
Speciﬁc information to be gathered includes:
 a detailed inventory of prior knowledge,
 which individuals/population are the focus for
the risk assessment,
 which (geographical) areas are to be covered, or
which consumer setting,
 which route(s) of exposure are relevant, and
 which health endpoints should be considered.
Risk managers, risk assessors, and all stakeholders
(from the initial producer/grower to the ﬁnal consumer)
bring valuable and often diﬀerent perspectives to
assessment planning. As an initial activity in problem
formulation, information concerning potential expo-
sure, known or suspected hazards, observed or hypo-
thesised eﬀects, potential risks, and modifying factors is
collected. For existing food chemicals, e.g. those
requiring re-assessment, prior knowledge (see Section
2.2) is of great importance. For new substances, the
systematic collection of prior knowledge on any related
substances may aid in the planning of a testing and
research strategy.
At this stage, it may become clear that a detailed risk
assessment is not necessary, for example when the
exposures are at levels too low to be of concern (Kroes
et al., 2000; International Life Sciences Institute, 2000a).
The decision not to proceed with a full assessment will
need to be communicated clearly to all interested
parties.
If a risk assessment is deemed necessary, then feasi-
bility must be addressed. Problem formulation should be
as explicit as possible and should generally include con-
siderations of relevance (including societal values),
applicability (to the exposure scenario), and utility (to
provide useful advice to risk managers). Existing data
and the range of health endpoints can serve to identify
quantiﬁable indicators or processes (measures of expo-
sure, measures of eﬀect, toxicokinetic or toxicodynamic
data) to be used for the risk characterisation.
The process should undergo rigorous review by risk
managers, scientiﬁc peers, and other stakeholders to
ensure that all concerns have been addressed, and that
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credible characterisation of risk. The methods to be
used to evaluate the risk are ideally described in full in
an analysis plan, which is the ﬁnal product of problem
formulation. Such analysis plans should indicate the
information necessary for both risk assessors and risk
managers to be satisﬁed that the assessment will provide
the kind and quality of information necessary to make
appropriate management decisions. In practice, such
plans could require modiﬁcation if new data emerge
during the risk assessment process. The key point of the
analysis plan is that it deﬁnes clearly the question(s) that
the risk assessment has to address.
3.2. Use of prior knowledge in problem formulation
The collection and evaluation of key elements of prior
knowledge, mainly regarding possible human exposure
and possible hazards, are required for problem for-
mulation and the subsequent decision (a) as to whether
a risk assessment is necessary, and (b) whether further
speciﬁc tests or studies could enhance the risk assess-
ment. The initial step of the risk assessment process is
the complete and systematic collection of all available
information on a compound occurring in food. For
each of the categories of chemicals in food and diet, as
deﬁned in Section 2.4, diﬀerent types of information
may be the most relevant.
A methodical approach to the collection of prior
knowledge can be the ﬁrst step in improvement of the
current risk assessment process. In particular, the eval-
uation of all available information can bring into focus
gaps in knowledge and be used to target further testing,
population research, and exposure assessment studies or
surveys, where needed. It can also assist planning to
avoid duplication of eﬀort and to reduce animal use.
However, it is recognised that in some cases, where
proprietary information is involved, access to prior
knowledge may be precluded. Finally, the data compi-
lation step can help in prioritising compounds and their
reaction or degradation products for risk assessment.
These considerations are frequently neglected; it is
therefore recommended that systematic attention be
given to them.
The following general topics are addressed in this
context:
 prior knowledge on the substance,
 prior knowledge on exposure to the substance,
 prior knowledge on possible biological eﬀect(s)
of the substance.
It is important that, when collecting and evaluating
data, as far as possible its reliability and relevance are
assessed. For biological eﬀects the strength of associ-
ation should be taken into consideration and also its
biological plausibility.3.2.1. Prior knowledge on the substance
3.2.1.1. Origin of the substance: The ﬁrst information
should clarify whether the substance is of natural or
synthetic origin. The substance can either be a deﬁned
chemical entity or a mixture of compounds, e.g. plant
extracts.
If it is of natural origin, the source of the substance
needs to be suﬃciently characterised (for example, exact
genus, species and subspecies for a plant bearing a
toxin, anthropogenic or geological origins for a food
contaminant such as arsenic, etc.). Agricultural prac-
tices should be considered as these may aﬀect the levels
of natural toxicants and contaminants, possibly also of
nutrients. For micro-organisms used in the production
of the substance a clear microbiological speciﬁcation is
necessary (including species, taxonomy, origin, etc.).
If the substance originates from a chemical or other
form of production process, these have to be adequately
described in order to obtain a clear speciﬁcation of the
substance and identify steps of the production process
relevant to risk assessment.
Some substances may originate by formation during a
food production process or during storage or prepara-
tion. In these circumstances it is important to collect
available information on the physical or environmental
conditions and the chemistry leading to the formation
of the substance, as well as information on stages of the
process at which its formation might be controlled.
3.2.1.2. History of use and consumption: In the case of a
substance of natural origin, the history of human use
(for example of a herbal product) or the extent of con-
sumption or exposure via non-oral routes should be
described. For substances of synthetic origin, the history
of the synthesis or production process should be descri-
bed, as well as its role in the production of foods or
food components, to determine if the process per se
raises novel concerns. Information on current and past
use of the substance, including both food and non-food
use(s), should be collected.
3.2.1.3. Chemical identity, characterisation and specifi-
cation of the substance: The complete name of the sub-
stance, if possible according to oﬃcial nomenclature, as
well as all known alternative names or synonyms should
be listed. Available analytical information should be
evaluated to determine if it is suﬃciently reliable to
establish chemical identity, and/or to characterise the
substance, including by-products and impurities. This is
equally valid for synthetic and for natural compounds.
For complex mixtures, such as plant extracts, a reliable
and reproducible analytical ﬁngerprint that suﬃciently
characterises the mixture should be available. The ana-
lytical information should relate to what is present in
foods when the food is produced on a commercial scale,
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the basis of this information, appropriate speciﬁcations
should be developed for identity as well as chemical and
microbiological purity. All speciﬁcations need to be
appropriate to ensure that the evaluated product is
representative of that consumed, or alternatively, that
any diﬀerences can be reliably taken into account.
3.2.1.4. Effect of processing
On the substance: qualitative and quantitative knowl-
edge of the inﬂuence of food processing on the sub-
stance is needed to adequately address whether
processing results in a signiﬁcant change of chemical/
physicochemical identity and/or chemical and micro-
biological speciﬁcation as compared to the non-processed
counterpart.
On whole food: the presence of a novel substance in a
food could modify the eﬀects of a subsequent food
production process on the quality and safety of the
basic food constituents, for example a ﬂour improving
agent could deplete vitamins during dough processing. In
some cases possible interactions between the substances,
the food and the process may be deduced from knowl-
edge of the chemical characteristics of the substance.
3.2.1.5. Effect of transport and storage on the substance:
Information is necessary on the stability of the sub-
stance itself or as it occurs in food. In cases where
deﬁned storage conditions are necessary for the sub-
stance to remain stable, information is needed on these
conditions and on the time periods over which the sub-
stance is stable and complies with its speciﬁcation. The
same is true for speciﬁc transport conditions if these are
potentially inﬂuential.
3.2.2. Prior knowledge on possible exposure
The intended use or purpose of the substance or its
occurrence as a contaminant or natural toxicant has to
be deﬁned clearly, additionally all existing qualitative
and quantitative information on current and predicted
exposures needs to be collected. For the oral exposure
route, food and water are of relevance. Consideration of
other possible routes of exposure, including non-food
uses, and inclusion of these in the development of
exposure estimates should be an essential component of
problem formulation. As far as possible, data should
include information about the amount consumed per
person as well as information on the pattern of exposure
for an individual (i.e. occasional, intermittent or regular
consumption) and the pattern of exposure between
individuals (i.e. variation across population groups).
Another important consideration is whether predicted
future exposure diﬀers signiﬁcantly from current expo-
sure. The possible impact of a change in exposure has to
be evaluated, for example consideration of all sub-
groups of the population when a substance becomes
more widely consumed.3.2.3. Prior knowledge on possible biological eﬀect(s) of
the substance
3.2.3.1. Qualitative aspects: All available information
on possible adverse eﬀects of the substance itself, its by-
products or impurities, or its contaminants should be
considered. The available data should be assessed to
determine whether one or several types of eﬀects have
been observed, and to identify those that are of health
concern and of possible relevance to humans. Sources of
such data are in vivo and in vitro toxicology studies,
mechanistic studies, observational epidemiology studies
(e.g. after occupational exposure) and randomised
trials. The origin of the substance has to be considered,
as well as the possibility that the source and/or the sub-
stance derived from it can contain compounds poten-
tially detrimental to human health (including allergens).
Data would be needed also on potentially adverse
eﬀects on human health from process-related changes in
the substance or in the food containing it. Also of
interest is any knowledge on interaction(s) of the sub-
stance with nutrients or toxicants in the diet, medicines,
or other substances to which humans are exposed.
3.2.3.2. Quantitative aspects: For all of the above con-
siderations, the availability of quantitative information
needs to be examined. Where multiple eﬀects have been
observed, it may be useful to divide the health outcomes
into those that are well-established and those for which
data are suggestive but possibly more limited, more
controversial or in need of greater scrutiny.
3.2.3.3. Predicted effects: If the substance is suﬃciently
described and characterised, but insuﬃcient information
is available on known eﬀects, considerations can be
given to the prediction of possible eﬀects based on
similar known and evaluated substances (e.g. structure-
activity relationships). These comparisons can be done
on a qualitative and a quantitative level, depending on
available information and the degree of similarity to
known substances.
Key features which should be sought in assembling
data on prior knowledge are summarised in Fig. 2.Fig. 2. The systematic collection of prior knowledge.A.G. Renwick et al. / Food and Chemical Toxicology 41 (2003) 1211–1271 1219
3.3. Conclusion
Problem formulation is the initial step in the risk
assessment process and it is here that the stages of the
assessment are deﬁned and the plan for analysis and
characterisation of the risk is developed. It is an itera-
tive process requiring dialogue between stake holders.
During problem formulation the collection and eval-
uation of prior knowledge is crucial in answering basic
questions about human exposure and possible hazard
and thereby allowing the determination as to whether a
risk assessment is needed and whether it is possible.
Detailed collection and evaluation of all available
information may also help to prioritise and direct risk
assessment, as well as to target research on exposure or
health eﬀects from chemicals in food. The output of
problem formulation should be a detailed analysis plan
in which the needs of the risk manager are made explicit
at this early stage, as these are critical in deﬁning the
scope of work.
For either existing or new substances, the process of
problem formulation can be described in the following
scheme, Fig. 3.4. Good evaluation practice
Good evaluation practice (GEP) deﬁnes the organi-
sational process and the conditions under which risk
assessments of chemicals should be planned, performed,
scrutinised and reported. There are already guidelines as
to how chemicals should be investigated in order to assess
their potential to harm humans (Organisation for Eco-
nomic Co-operation and Development, 2000). In addi-
tion, good laboratory practice (GLP) procedures
(Commission of the European Communities, 1987, 1988)
set out how such studies should be monitored and con-
trolled for quality assurance purposes. GEP is intended to
be complementary to these earlier processes and should
increase the conﬁdence of the public and the scientiﬁc
community in the outcomes of risk assessment. Although
not formally established, proposals for GEP have been
published for consultation (Malmfors et al., 2001) and
this section draws on the consultation document.
There are a number of steps of the evaluation process
for chemicals that should be considered in the context of
GEP. An important initial step is the procedure for
forming the group that is to carry out the risk assess-
ment. The majority of risk assessments are undertaken
either for national or international organisations or
within industry. However, these groups may have no
formal existence beyond their meetings, or may have a
need to bring in special expertise. It is therefore impor-
tant that the procedures for the establishment of the
group and for the co-option of additional expertise are
deﬁned. Information concerning the persons conductingthe evaluation, such as their experience and aﬃliation,
should be recorded. In particular, any possible conﬂicts
of interest between members of the committee or staﬀ of
the organisation requesting the evaluation and the pro-
ducer of the chemical/food in question must be recorded
and made part of the public record. Similar records
should be developed and retained within an industrial
organisation for purposes of due diligence. Because risk
characterisation requires extensive expertise in widely
diﬀerent areas it is likely that those involved will have
gained their experience in relation to subjects, com-
pounds or areas of work which may be under discus-
sion. Therefore apparent conﬂicts of interest are
probably inevitable in the establishment of groups
undertaking risk characterisation and it is essential, for
the purposes of ensuring the transparency of the pro-
cess, that all those involved declare any possible conﬂict
of interest.
A further stage in the evaluation is the technical pro-
cess of identifying, collecting and categorising data and
verifying their compliance with established guidelines or
criteria. The importance of specifying the details of lit-
erature surveys, e.g. the databases scanned and search
strategies employed, has been emphasised (Joint Expert
Committee on Food Additives, 2000). Independent
assessment of the quality of published papers retrieved
during literature searches is important, notwithstanding
the fact that most will have undergone peer review prior
to acceptance for publication, because the primary aim
of the study may not have been related to risk assess-
ment. However, this assessment may be diﬃcult, since
journal publications generally contain fewer details than
original study reports. Unpublished detailed study
reports may be submitted to the group by industry;
there is a need to recognise that although these may not
have undergone independent external peer review,
quality assurance is usually provided for modern studies
by compliance with GLP. Such reports may have been
submitted under conditions of commercial conﬁdence;
this must be respected but, if the data are from a health-
related study, the organisation requesting the risk
assessment should insist on the right to publish an
abstract and analysis/review of the study. In such cir-
cumstances the study sponsor should be encouraged to
place the study in the public domain but, in any event,
the reviewing organisation should retain a copy of the
report. Particular care is needed in the use of meeting
abstracts, since the conclusions may change if the stud-
ies are published subsequently in full, peer-reviewed
papers. Nevertheless, the conclusions from an abstract
may have a role in the instigation of problem formula-
tion by acting as a primary alert to a potential new
hazard from food chemicals. It is also important to
recognise the biases that may occur: ﬁrstly, towards
publication of positive studies and non-publication of
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published in languages other than those familiar to the
risk assessment group.
The quality of data from laboratory studies is also
important. Considerations include whether studies have
been conducted using internationally agreed protocols,
according to GLP, with full reporting and appropriate
statistical evaluation. Study reports should contain suf-
ﬁcient information to allow the reviewer preparing the
risk characterisation to independently assess the validity
of the results. It is also the responsibility of the reviewer
to assess whether a study is scientiﬁcally appropriate toaddress the issue in hand. A well-conducted and well-
reported study may be of little relevance to the problem
formulation; nevertheless, an older study not performed
to GLP may be scientiﬁcally sound and appropriate to
the risk assessment. When reviewing human trials it is
appropriate to consider assessing the compliance of the
study protocol and the planning and conduct of the trial
with the guidelines of Good Clinical Practice (GCP) as
adopted by the United States Food and Drug Adminis-
tration (Food and Drug Administration, 1997). A need
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been suggested (Baldwin and Hoover, 1991; Shore et
al., 1992), as has their possible application to the pub-
lication of the results of epidemiology studies (Rush-
ton, 2000). However, despite the publication of
suggested guidelines (German Professional Society of
Epidemiology, 2000), the matter has not progressed
far.
In reviewing the available data it is important that its
consistency should be considered. Thus, although a risk
assessment might rely heavily on data from animal
studies it may be that epidemiological data can be used
to test the assumptions underlying extrapolation from
animals to humans. Similarly, if the dose-response rela-
tionships from epidemiological studies are used for risk
characterisation, in vitro research or in vivo studies in
animals may provide a better understanding of the
mode of action of the toxicant (Goldman, 2001; Hertz-
Picciotto, 1995). Further, the biological plausibility of
the selection of a critical eﬀect from an animal study
may be improved if there is evidence from other studies,
either in another species or of shorter duration in the
same species, which demonstrate either a similar eﬀect
or other changes which are consistent with the known
biology of the critical eﬀect.
The scrutiny and interpretation of data involve expert
judgement. Since the exercise of expert judgement is a
process in which scientiﬁc discipline and expertise,
experience in risk assessment, aﬃliation, and national or
international views are involved, it is not surprising that
diﬀerent evaluators sometimes reach diﬀerent conclu-
sions. To ensure that the judgmental part of the eval-
uation procedure is transparent, it is important not only
that the evaluation is described in detail, but also that
some indication is given of the process, including any
factors which may inﬂuence its outcome. For those
organisations conducting risk assessment on a regular
basis, general procedures on how to perform the activ-
ities involved in the evaluation procedure should be
described in writing in the form of standard evaluation
procedures. It should also be the task of management to
ensure compliance with the principles of GEP when
evaluations are conducted and described. Preferably the
organisation should use a documented quality assurance
programme to ensure proper execution of the process.
Ideally, an evaluation should follow a systematic
plan, in which the purpose of the evaluation is made
clear to all involved, the time plan for the evaluation is
set out and the evaluation methods to be used and the
nature and extent of reporting of results are all agreed.
The written outcome of the evaluation should include a
description of the purpose of the evaluation, the meth-
ods used, the results, their interpretation and conclu-
sions, together with a clear description of any
uncertainties in the evaluation. The publication of clear
written evaluations with detailed explanations for the
decisions taken should minimise any criticisms of bias.The risk assessment process is complex and the Inter-
national Programme on Chemical Safety is in the pro-
cess of developing recommendations about the
harmonisation of procedures that are used. The ulti-
mate aim of GEP is to improve the quality, reliability
and transparency of evaluations in the risk assessment
process. Although it is still in its infancy, GEP should
mature in a systematic way in the coming decade and
become as recognised and accepted as GLP and GCP.5. Risk characterisation
5.1. Introduction
Risk characterisation is the stage of risk assessment
that integrates information from exposure assessment
and hazard characterisation into advice suitable for use
in decision-making or risk management. The advice to
risk managers may take the form of a quantitative esti-
mate of the magnitude of any risk associated with dif-
ferent levels of exposure, such as the possible health
consequences of adopting diﬀerent regulatory limits in
food (see for example aﬂatoxins; Joint Expert Commit-
tee on Food Additives, 1999). Alternatively, it can take
the form of advice on particular levels of exposure that
would be without signiﬁcant adverse health eﬀects (for
example, setting a guidance value such as an ADI).
As data on exposure and hazard characterisation are
collected and/or generated, new issues may be identiﬁed
that were not recognised initially as a part of problem
formulation. For example, new data revealing an
increase in exposure may aﬀect the need for data on
hazard, and vice versa. In consequence, risk character-
isation is often an iterative and evolving process, see
Fig. 4.Fig. 4. The iterative nature of risk characterisation, with examples of
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An early step in developing the database for risk
characterisation should be the inclusion of any prior
knowledge on the chemical itself or related chemicals.
This might include information on the nature of the
chemical or substance, its speciﬁcation, structural alerts
for toxic actions, and knowledge of any structure-activ-
ity relationships with other, related chemicals. When
prior knowledge, such as data on structural analogues,
raises the possibility of a particular hazard, it is impor-
tant to ensure that there are relevant and adequate data
to address the issue (e.g. data on genotoxicity and car-
cinogenicity for chemicals with structural alerts for
these endpoints, or immunotoxicity data for proteins, or
human data in cases where problems with gastro-
intestinal tolerance may be anticipated). The use of
prior knowledge has been discussed in more detail pre-
viously (see Section 3.2. above and Barlow et al., 2002).
Once all the available data have been gathered,
consideration needs to be given to:
 whether exposure is suﬃcient to warrant a
detailed risk characterisation and if so,
 whether there are suﬃcient data to make a
thorough and meaningful appraisal.
The complexity of risk characterisation stems from
the fact that conclusions may have to be reached in the
absence of complete information. First, there is varia-
bility in the data that are used, both for exposure and
eﬀects, whether they derive from experimental or epide-
miological studies. Secondly, there is uncertainty due to
lack of complete knowledge concerning the parameters
that govern the events observed in experimental and
epidemiological studies, in particular, the fundamental
underlying mechanisms of action. Identiﬁcation and,
where possible, quantiﬁcation of variability and uncer-
tainty are now regarded as important elements in risk
characterisation. Because risk characterisation is an
iterative process, see Fig. 4, the nature of the advice to
risk managers may become more reﬁned as the quality
of the available exposure and hazard characterisation
data increases. Risk characterisation is a complex pro-
cess, with diﬀerent approaches adopted for diﬀerent
types of hazard, as indicated in Fig. 5.
For adequate hazard characterisation the data should
cover all the potentially relevant life-stages and tox-
icological endpoints, should enable the critical end-
point(s) to be identiﬁed, and should have suﬃcient
dose–response information to establish dose levels with
and without adverse eﬀects. In an ideal situation, both
laboratory and human data will be available, together
with reliable information on exposure (although this
will not be possible for new compounds/substances).
Considerable attention is given to the selection of the
adverse eﬀect most appropriate and relevant to the nat-
ure of human exposure. One of the most importantsteps is the identiﬁcation and characterisation of the
critical eﬀect(s), i.e. the hazard that is of greatest
concern, both qualitatively and especially quantita-
tively, because this will be the main focus for the risk
characterisation.
Theoretically, an ideal approach to risk characterisa-
tion might be to use in vitro data and in vivo studies in
animals and humans for the identiﬁcation of possible
hazards, and then to use data from experimental or
epidemiological studies in humans to characterise the
hazard(s) and deﬁne the dose-response relationship(s).
Because epidemiological research is done under real-
world conditions in humans, the data can be of direct
relevance to risk assessment and human health. In rea-
lity, for both practical and ethical reasons, observa-
tional epidemiological data are available in only a few
cases, and therefore hazard characterisation usually is
based primarily on data from in vitro studies and stud-
ies in animals. Animal toxicological data and epidemio-
logical data are complementary sources of information,
each of which has both strengths and weaknesses.
Risk characterisation may be separated into two dif-
ferent types, based on whether humans are exposed to
the material at the time of risk characterisation (prior
use/exposure), or whether exposure is not permitted until
after completion of the risk characterisation process (future
use/exposure). This subdivision is frequently reﬂected in
the nature and extent of the data that are available for
both exposure estimation and for hazard characterisa-
tion. Table 1 presents a summary of the main diﬀer-
ences, using, as examples, a contaminant for prior use/
exposure and a food additive for future use/exposure.
5.1.1. Prior use/exposure
When there is human exposure at the time of risk
characterisation, intake or exposure assessment can be
based on actual measurements rather than predictions
using anticipated or proposed patterns of use. The
measurement of actual intakes has been discussed
extensively in an earlier FOSIE publication (Kroes et
al., 2002). The methods suﬀer from various uncertain-
ties that should be described, where relevant, as part of
risk characterisation, including:
 the extent to which all relevant sources of expo-
sure can be taken into account,
 adequacy of any sampling strategy with respect
to foods,
 sensitivity, accuracy and precision of any analy-
tical techniques,
 adequacy of intake information with regard to
representation of population subgroups deﬁned
by life-stage, ethnicity, nutritional status or
health status,
 whether there is likely to be under- or over-
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 scenario(s) selected for estimating high consump-
tion,
 use of short-term data to predict longer-term
exposure.
For existing food chemicals, it is important to gather
all available data on hazard characterisation, including
information obtained by searching the open literature.
Appropriate and clearly described search strategies
should be used that are designed to identify relevant
experimental laboratory studies, human case reports,
epidemiological studies and exposure data. Criticalassessment of the quality of the data in published lit-
erature is important (see Section 4), because many
studies would not have been performed to GLP stan-
dards. In addition, many published human studies
would have been designed to investigate endpoints such
as nutritional beneﬁts rather than hazards, and therefore
a critical appraisal of their suitability for the planned risk
characterisation is essential.
The data available for hazard characterisation of some
food chemicals, for example with natural toxicants,
micronutrients, macronutrients and whole foods (see
Section 5.4 respectively), may be limited animal data withFig. 5. Summary of the considerations that contribute to risk characterisation.1224 A.G. Renwick et al. / Food and Chemical Toxicology 41 (2003) 1211–1271
some usable human data, including exposure data. For
some inorganic contaminants, e.g. lead and cadmium,
and organic contaminants, e.g. dioxins and poly-
chlorinated biphenyls (PCBs), there are extensive
laboratory and human epidemiological data, together
with comprehensive exposure data.
In many cases risk characterisation may have to pro-
ceed in the absence of an adequate or complete data set.
In such circumstances, and when the adverse eﬀect is
considered to show a threshold in the dose-response
relationship (see below), additional uncertainty factors
may be applied to the no observed adverse eﬀect level/
lowest observed adverse eﬀect level (NOAEL/LOAEL)
to derive a health-based guidance value. Such factors
are applied as part of hazard characterisation not risk
management, because scientiﬁc expertise is needed to
select the magnitude of the factor. Reviews of available
toxicity databases have been used to derive the default
uncertainty factors that may be applied to a LOAEL to
allow for the absence of a NOAEL (usually 3 or 10) and
to the NOAEL from a sub-chronic study to allow for
the absence of a chronic NOAEL (usually 10) (Doursonand Stara, 1983; Dourson et al., 1996; Vermeire et al.,
1999).
In contrast, the uncertainty factors that are used to
allow for missing hazard identiﬁcation data, for exam-
ple the absence of reproductive or developmental toxi-
city data, or for the severity/adversity of an endpoint
such as cancer (World Health Organization, 1994), are
not scientiﬁcally based (Renwick, 1995). A more scien-
tiﬁc approach to missing data would be to consider the
probability that the NOAEL for the compound, based
on other endpoints, would be adequate for the missing
endpoint. This could be done by tabulating the NOAEL
values for the missing endpoint for other compounds
and determining the probability that the NOAEL for
the missing endpoint for the compound under eval-
uation would be higher than the NOAEL that is based
on other endpoints; an approach that is analogous to
the threshold of toxicological concern (see Section
5.2.1.2). A number of databases, related to the develop-
ment of thresholds of toxicological concern, have been
developed for use in such analyses (Munro et al., 1996;
Cheeseman et al., 1999; Kroes et al., 2000).Table 1
Comparisons of the data available related to the extent of human exposure at the time of risk characterisationPrior use/exposure (e.g. for a contaminant) Future use/exposure (e.g. for a food additive or pesticide)Exposure assessment Exposure assessment Distribution within the food supply needs to be determined  Distribution within the food supply is deﬁned by proposed uses
 Concentrations in diﬀerent foods need to be measured  Concentrations in diﬀerent foods are based on technological need and
are speciﬁed in the application for approval Concentrations in foods may show large variations  The maximum concentrations (or residue levels for a pesticide) in
diﬀerent foods are known prior to approval Any unit-to-unit variability in the concentration present has
to be allowed for when considering peak exposures and
short-term eﬀects Intake estimates use the planned proposed maximum permitted
concentrations or residue levels combined with food intake data to
estimate a realistic worst-case intake; the planned maximum
concentrations and/or food uses would not (all) be permitted if they
resulted in an intake above the health-based guidance value Because the presence in food is not ‘‘permitted’’ and subject
to prior approval, the total intakes may exceed the
health-based guidance value; advice to risk managers may
need to indicate the magnitude of any risk as well as the
need for possible remedial measures Because the presence in food is ‘‘permitted’’ subject to prior approval,
the total intakes should not exceed the health-based guidance value; if
post-launch monitoring indicates excessive total intakes above the
guidance value, the proﬁle of approval could be revised.Hazard characterisation Hazard characterisation Many studies in animals are not performed to internationally
accepted protocols or to GLP (good laboratory practice),
and may have limited use for regulatory purposes Hazard identiﬁcation and/or hazard characterisation depend on in vitro
studies and in vivo investigations in test animals performed to
internationally accepted protocols and GLP Epidemiology data may be available for hazard identiﬁcation
and/or hazard characterisation Human trial data, from experimental studies can assess tolerability but
not safety; metabolism-toxicokinetic data can facilitate inter-species
extrapolation Dose–response assessment may be based on the data from
observational epidemiology studies or toxicity studies in
experimental animals Dose–response assessment is usually based on toxicology studies in
experimental animals Uncertainty factors may be necessary if the population
studied epidemiologically does not include all subgroups Uncertainty factors related to species diﬀerences and human variability
are normally required Additional uncertainty factors are often necessary to allow
for deﬁciencies in the database Additional uncertainty factors to allow for deﬁciencies in the database
are not normally used, as the applicant will be requested to supply any
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Because the individual uncertainty factors refer to
unrelated events, they are multiplied. The composite
uncertainty factor assumes that each area of uncertainty
is independent; the use of large uncertainty factors may
result in risk characterisation that could be highly con-
servative. The application of very high overall uncer-
tainty factors (>10,000) to databases that have multiple
deﬁciencies is considered by many to render a risk
characterisation meaningless (World Health Organization,
1994).
The most reliable examples of risk characterisation
associated with prior exposure are probably when there
is re-appraisal of an approved compound, such as an
additive or pesticide, for which there is an extensive
history of use, combined with a comprehensive hazard
characterisation database.
5.1.2. Future use/exposure
Usually in the case of chemicals intentionally devel-
oped for agricultural or food uses (additives, ﬂavour-
ings, processing aids, pesticides, food contact materials),
hazard characterisation must rely on comprehensive
laboratory data from in vitro studies and in vivo studies
in experimental animals because only limited human
data are likely to be available. Intake estimates have to
be based on predictions related to the proposed or
anticipated uses, rather than intakes measured under
real life conditions.
There are well-established procedures for situations in
which problem formulation and risk characterisation
precede human exposure. In the case of new food che-
micals that require authorisation prior to marketing, the
company wishing to market the chemical is usually
required to supply most of the information for risk
assessment. Dossiers submitted to regulatory authorities
will normally contain extensive data on hazard identiﬁ-
cation and characterisation that can be used for risk
characterisation. Intake and exposure estimates have to
be based on the expected concentrations in diﬀerent
foods and the anticipated intakes of the foods for which
approval is sought.
Regulatory authorities generally have powers to
request submission of missing or additional data to
clarify any issues that are not resolved by the available
information. When pre-marketing approval is required,
as for additives or pesticides, there is an increasing ten-
dency for advisory bodies to withhold approval of a
new substance until all the necessary data are available,
rather than give temporary approval with the utilisation
of additional uncertainty factors. In some cases, a tem-
porary ADI or a temporary tolerable daily intake (TDI)
may be allocated when there are uncertainties associated
with the hazard characterisation, which are minor in
extent and would not aﬀect risk characterisation over
the relatively short time period required to generate and
evaluate appropriate data. Under such circumstances anextra uncertainty factor of 2 is usually applied to give a
larger overall uncertainty factor for deriving the
guidance value (see threshold approaches below).
5.2. Integrating exposure assessment and hazard
characterisation into risk characterisation
Integration of the exposure assessment (based on the
exposure scenarios that were the basis for problem for-
mulation) with hazard characterisation needs to con-
sider a number of key aspects, the information for which
may evolve as the data are generated and/or collected.
5.2.1. Matching the exposure assessment with the
hazard characterisation
5.2.1.1. How much hazard information is needed? The
extent of hazard identiﬁcation and hazard characterisa-
tion data needed for risk characterisation depends on
the nature of the issues raised in problem formulation,
and the anticipated human exposure. For example, it
may not be necessary to have a comprehensive database
in cases where there is a low potential hazard, as pre-
dicted by structure-activity relationships with structural
analogues, and exposure is anticipated to be very low.
This consideration forms the basis of tiered approaches
to toxicity testing, in which the amount of hazard iden-
tiﬁcation and hazard characterisation data required by
regulatory bodies may increase as anticipated exposure
increases. This pragmatic approach recognises the con-
ﬂict between the desirability of having a comprehensive
hazard characterisation database and the desirability of
minimising unnecessary studies in animals and humans,
as well as avoiding the use of scarce research resources
for exposures of low priority: or, to put it more simply,
risk characterisation processes attempt to recognise
the diﬀerence between ‘‘need to know’’ and ‘‘nice to
know’’.
5.2.1.2. Threshold of toxicological concern: Biological
considerations and empirical evidence are consistent
with the majority of chemically-induced adverse eﬀects
having levels of intake or exposure below which no
lasting disturbances of physiological or biochemical
function are observed. This has led to the development
of the concept of a ‘‘threshold of toxicological con-
cern’’, which represents a level of human exposure
below which it can be considered there are no signiﬁcant
risks to health, even in the absence of data on the com-
pound under evaluation (Kroes et al., 2000; ILSI,
2000a). Where such an approach is adopted there is no
need for information on hazard identiﬁcation and
hazard characterisation, providing that predicted or
actual exposures are below the threshold value. In the
dietary ﬁeld, these principles have been applied to
the safety evaluation of ﬂavouring substances and
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evaluation of ﬂavouring substances by the Joint FAO/
WHO expert committee on food additives (JECFA) is
based on a decision tree that takes into account chemi-
cal structure (Cramer et al., 1978), predicted metabolism
and estimated exposure (Joint Expert Committee on
Food Additives, 1995; Munro et al., 1996). A ﬂavouring
substance on which there are no actual toxicity data can
be considered to be of no safety concern, providing that
the intake is below the appropriate threshold of tox-
icological concern that is incorporated into the decision
tree. The adoption of such an approach for this cate-
gory of food chemicals is only considered legitimate
because of the generally very low exposures to ﬂavouring
substances.
Additional consideration needs to be given when
structure-activity considerations suggest the possibility
of an eﬀect such as genotoxicity, for which there may
not be a threshold in the dose-response relationship
(see below, and Edler et al., 2002). This possibility has
been taken into account in the risk characterisation of
another group of food chemicals with potentially low
exposures, food packaging migrants. A ‘‘threshold of
regulation’’ is used by the US food and drug adminis-
tration (FDA) to review components of food contact
materials with low exposures. The threshold is set at a
dietary concentration giving a daily intake of 1.5 mg per
person. Below this threshold the FDA requires no spe-
ciﬁc toxicity testing and performs only an abbreviated
safety assessment (Food and Drug Administration,
1995). The FDA threshold of regulation was supported
by an analysis of the potencies of chemicals that had
been studied in chronic cancer bioassays in rodents. A
highly conservative, linear low-dose extrapolation from
the TD50 (the dose giving a 50% tumour incidence in
the experimental study) was used to derive the dietary
concentration predicted to be associated with a risk of
cancer of one in a million or less (Food and Drug
Administration, 1993). The concentration which gives a
human daily intake of 1.5 mg per person was estimated
to be 0.5 mg per kg of diet. Above the threshold of
regulation, a tiered approach to toxicity testing of food
packaging substances is used by the FDA, and a simi-
lar tiered approach is used by the EC Scientiﬁc Com-
mittee on Food (Scientiﬁc Committee on Food, 2000a).
An extension of the threshold of toxicological concern
concept took into account the probability of an unstu-
died chemical being a carcinogen (Munro, 1990), and
was used to derive a threshold of 1.5 mg per person per
day. This threshold was incorporated into the JECFA
decision tree for the safety evaluation of ﬂavouring
substances, and applied, for example, to the safety
evaluation of allyl 2-furoate (Joint Expert Committee
on Food Additives, 1999). Further possible reﬁnements
to allow application of the approach to a wider range of
food chemicals are currently under discussion in an
ILSI Europe Expert Group.Chemical-speciﬁc data on both exposure and hazard
are necessary when the actual, or predicted, human
intake exceeds the threshold of toxicological concern, or
is deemed to be signiﬁcant for some other reason, such
as structure-activity considerations.
5.2.2. Considerations related to exposure assessment
Intake issues important in risk characterisation are
summarised below; a comprehensive account is given in
an earlier FOSIE publication (Kroes et al., 2002).
5.2.2.1. Intake estimates in relation to intake patterns:
The reliability of risk characterisation is dependent on
the quality of the exposure data relevant to the issues
that were identiﬁed in problem formulation. As expo-
sure/intake data are collected they may reveal addi-
tional issues, such as the existence of highly exposed
subgroups of the population, which need to be taken
into account in risk characterisation.
Initial estimates of human exposure may need to be
reﬁned following hazard identiﬁcation and character-
isation. A number of important questions relating to
intake patterns should be considered, e.g.:
 Are foods containing the substance consumed
regularly or only occasionally?
 Does intermittent exposure justify the calculation
of mean intakes over time, or should risk char-
acterisation be based on intakes during the peri-
ods of actual consumption?
 Is intake relatively constant, allowing averaging
of intake levels, or is there regular intake com-
bined with occasional acute peaks, which may
have health relevance?
 Is high consumption limited to speciﬁc life-
stages, e.g. infant foods, or are relevant products
consumed in the context of targeted diets, for
example the intake of products containing phy-
tosterols to lower blood cholesterol?
There are two types of information necessary for the
generation of intake data suitable for risk characterisa-
tion. Firstly, determination of the consumption of the
foods that may contain the chemical and, secondly, the
concentrations of the chemical that may be present in
the diﬀerent foods. The intake estimate for a chemical
or ingredient arising from ingestion of any single food
item is the product of the concentration of the chemical/
ingredient in the food and the amount of the food con-
sumed. The total intake for an individual from food is
the sum of intakes from all relevant foods.
An additional consideration is whether all relevant
sources of exposure have been identiﬁed, i.e. not only
the foods expected to contain the component in question,
but also any non-food sources of exposure. These include
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and general environmental sources. For some chemicals,
assembling all of the data needed to estimate total
exposure may be diﬃcult.
5.2.2.2. Measurement of the intakes of foods that may
contain the chemical
Prior use/exposure: There is a hierarchy of methods
for estimating intake, which oﬀers increasing reliability
and relevance, but at the cost of increasing complexity
and expense. Food consumption and chemical intakes
can be estimated at the supranational level (e.g. the
intake of ﬂavours within Europe based on annual pro-
duction statistics), at the national level (e.g. national per
capita estimates), for a household (e.g. market basket
surveys) or for the individual (e.g. a food diary).
Food consumption estimated at a national level is
based on food balance sheets integrating production,
import/export, changes in stocks, and use at all levels in
agriculture, industry and trade. This approach can give
only an approximation of the intake, but this may be
suﬃcient for risk characterisation when the potential
exposures and possible risks are very low.
Household survey data are more reliable and more
relevant. They are based on the total purchases of foods
by a household, taking into account unused amounts
(e.g. processing losses or spoilage). They do not provide
an estimate of consumption by individual household
members. So-called ‘‘market basket’’ studies are surveys
that model the purchase and consumption habits of the
population in general and/or subgroups deﬁned by age
or sex. They can be based on generic foods or alter-
natively on the most commonly consumed items in
individual food categories.
The most reliable and useful data for risk character-
isation come from dietary surveys in individuals. The
simplest method is a recall study, in which the types and
amounts of foods consumed during the last one, or
several days, or the frequency of foods consumed in
the past are recorded. Clearly, such data become less
precise the longer the period of retrospective assess-
ment. Prospective diary studies documenting the actual
consumption during the observation period are more
precise. A combination of dietary recall plus a food
diary may be the most pragmatic approach (Lambe et
al., 2000).
A particularly reliable but intensive method for
assessing the intake of contaminants is by collection of a
duplicate diet, where the same amounts and types of
food consumed are also collected and subsequently
analysed for the contaminant. Such studies can inte-
grate both consumption and compositional data for the
particular individual and life-stage or lifestyle.
A common problem for risk characterisation is that
food intake surveys may not cover the full range of
potentially exposed population subgroups. For exam-
ple, infants or the elderly may not be represented.Similarly, ethnic minorities whose dietary habits vary
substantially from the main ethnic group may be inade-
quately sampled in the studies on which the intake
information is based. Finally, intake by persons with
medical conditions, some of which may aﬀect food
consumption may not be well characterised in typical
food surveys. Even for well-sampled populations, con-
sumption measurements suﬀer from inaccurate report-
ing: there is often under-reporting based on total food
energy measurements, with a reporting bias in favour of
‘‘healthy’’ foods, such as fruits and vegetables, and
against ‘‘unhealthy’’ products like alcoholic beverages
or sweets. These uncertainties need to be described in
the advice given to risk managers.
Future use/exposure. For substances that undergo risk
characterisation before they are permitted to be used,
such as food additives, veterinary medicines and pesti-
cides, the potential intake has to be estimated based on
the proposed uses. This has to take into account the
diﬀerent food types that could contain the substance
and the concentrations that would arise from the tech-
nological use of the substance in the food or, for a pes-
ticide or veterinary medicine, the concentration that
could be present as a residue in food.
For food additives, simple and highly-conservative,
‘‘budget’’ methods can be used as an initial screen to
determine if more sophisticated analyses are necessary
(Kroes et al., 2002). For example, the maximum theo-
retically possible intake can be calculated if it is
assumed that the additive will be present in all foods for
which use is requested at the maximum intended con-
centration and using the maximum likely consumptions
of relevant food categories. The results of this ‘worst
case’ method determine whether more reliable estima-
tions are necessary. If the intakes calculated by this
method are below the ADI, undertaking more complex,
but realistic calculations would be unnecessary. More
realistic intake estimates are necessary for additives
where the intakes predicted by simple conservative
methods are close to or exceed the ADI, or where there
may be subgroups within the population with high pre-
dicted intakes. Such calculations should aim to predict
the intake by individuals with both average and high
consumption of food chemicals.
Risk characterisation of agricultural pesticides is
undertaken in a manner analogous to that of food addi-
tives. The maximum residue level (MRL) permitted on
crops is based on the results of ﬁeld trials conducted
under the proposed conditions of maximum agricultural
use; food containing residues at or below the respective
MRLs are considered to be toxicologically acceptable
for chronic intake (World Health Organization, 1997).
More recently, however, it has been recognised that the
use of the MRL in intake calculations is overly con-
servative for chronic risk assessment, and now the
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The STMR is the median residue level measured in a
food crop treated with a pesticide according to good
agricultural practice, at the maximum permitted use
levels. The predicted daily intakes are compared with the
ADI, and the estimated short-term intakes are compared
with the ARfD (Section 5.3.3.1). As for food additives
the requested uses of the compound would not be
approved if the predicted intakes by individuals with
high consumption of relevant foods were above the
ADI. For residues of veterinary drugs, the MRLs in
animal tissues are calculated by dividing the ADI by the
total amounts of animal products that would be
consumed by a high consumer.
The projected ‘‘market share’’ is not taken into
account in the exposure estimates for additives because
risk characterisation focuses on the possible risks to
individuals, and some individuals may preferentially
select foods containing the compound. Determinations
of the intakes of pesticides, from residues on foods fol-
lowing agricultural use, have not taken into account the
extent of use, or market share, of diﬀerent pesticides
used for treating the same pest. Because the residues
occur randomly within the food supply, some recent
assessments of the data from surveillance programs
have used a probabilistic approach to determine the
acceptability of residue levels.
In the case of exposure assessments for chemicals
requiring pre-marketing approval, the pre-market esti-
mates of consumption of foods containing the com-
pound may be uncertain. The use of conservative
assumptions at this stage to compensate for limited
knowledge often leads to signiﬁcant overestimation of
exposure. Post-launch data collection, both on real-life
use levels and actual consumption patterns, can help to
increase the accuracy of the exposure assessments that
were used in the initial risk characterisation. Real-life
data obtained after marketing to correct these initial
assumptions may indicate that it would be possible to
remove some restrictions on use, but this may trigger
the need for a revised characterisation of risk. Con-
versely, in the case of higher individual exposures than
those initially predicted, perhaps due to a greater than
expected success of a food/substance with consumers,
restrictions on use could become necessary.
In some cases the risk characterisation considers only
a very restricted number of speciﬁc uses, because the
available toxicity data on the compound are suﬃcient to
allow restricted food use only and a generally applicable
guidance value, such as an ADI is not appropriate. An
example of this is quinine, which is approved only for
use in tonic water, and the projected intake can be
matched closely to the available hazard characterisation
data (Joint Expert Committee on Food Additives,
1993). A disadvantage of this form of advice is that any
application for an additional use would require a re-
evaluation and a new risk characterisation.5.2.2.3. Measurement of the concentrations of the che-
mical in foods: The concentrations of contaminants and
other compounds that are found to be present in food
need to be determined, prior to the risk characterisation
process, by the collection of samples of relevant foods
and their analysis for the compound. Attention needs to
be paid to whether the sampling strategy and analytical
techniques employed are adequate with respect to
anticipated concentrations and frequency of occurrence
of the substance in question. These aspects have been
reviewed by Kroes and colleagues (2002).
An important problem that can inﬂuence exposure
assessment of contaminants, and may lead to an unne-
cessarily conservative risk characterisation, relates to
how data for samples that did not contain a measurable
concentration are included in the exposure estimation.
The failure to detect a measurable concentration, i.e. a
‘‘non-detect’’ result, means that the actual concen-
tration could be anywhere between zero and the limit of
quantiﬁcation (LOQ). Diﬀerent intake estimates will be
obtained depending on whether it is assumed that all
non-detects are zero, or 50% of the LOQ, or equal to
the LOQ. This potential error in exposure assessment
and therefore risk characterisation is especially impor-
tant when the substance could occur in a wide range of
diﬀerent foods, but measurable concentrations are only
rarely detected.
The concentration of a substance measured in a food
is not always a true indication of what is available for
absorption and uptake from the gastrointestinal tract.
For example, substances that are tightly bound to the
food matrix may not be released within the gut lumen or
absorbed, whereas in other cases the food matrix may
contain precursors of the compound that are converted
to the compound during digestion and metabolism of
the matrix, but are not detected by chemical analysis of
the food for the compound per se. These diﬃculties can
be resolved by suitably designed biomarker studies (see
Section 5.2.4).
For compounds that undergo risk characterisation
prior to approval, the intended use levels and con-
centrations in food (for an additive), or the anticipated
residue levels (for a pesticide) are essential information;
the associated risk characterisation, for example whe-
ther or not the projected intakes are below the ADI/
ARfD, relates to those uses and concentrations.
5.2.3. Matching the duration of intake measurement to
the toxicity of concern
When a critical eﬀect has been identiﬁed, the intake
measurement should be appropriate for that endpoint.
In most cases, the critical eﬀect identiﬁed in hazard
characterisation using animal experiments is observed
following sub-chronic or chronic administration of the
compound, whereas practicable intake estimations tend
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a mismatch when these two sets of information are
integrated during risk characterisation.
Intake estimates based on dietary recall and/or food
diaries are usually of relatively short duration (24 h to 7
days) and, because of variability over time, tend to
overestimate the long term intake by those who con-
sume the substance and to underestimate the proportion
of the population with intermittent intake (some of
whom would be classiﬁed as consumers in a study of
longer duration). Dietary history methods and food
frequency methods are aimed at estimating long-term
consumption patterns, but do not provide reliable esti-
mates of individual intake. Short duration surveys
emphasise extreme consumption based on contents in
individual meals or due to seasonal eﬀects: these peaks
may be relevant when acute eﬀects are of concern, but need
to be put into perspective when long-term average intakes
are the type of exposure relevant for the critical endpoint.
The NOAEL for an eﬀect having a threshold in the
dose–response relationship (see below) is usually lower
after chronic administration than after short-term
treatment; in consequence any mismatch during risk
characterisation due to the use of short-term intake data
and chronic hazard characterisation will normally lead
to conservative advice. While this is not a problem if the
resulting exposure estimates are below the human gui-
dance value (e.g. an ADI), it may lead to unnecessary
concern if risk characterisation indicates that the gui-
dance value appears to have been exceeded. Recent
developments in hazard characterisation have attemp-
ted to correct this anomaly by determination of a short-
term guidance value (ARfD) more relevant to the dura-
tion of high intake. This is discussed in detail below,
under Section 5.3.3.1.
5.2.4. The use of biomarkers to deﬁne the relationship
between external and internal dose, and to bridge the gap
between exposure assessment and hazard
characterisation
Biomarkers are biologically relevant measurements
that can relate to intake (such as urinary excretion
data), internal exposure (such as urinary excretion or
plasma concentration data), eﬀect (such as serum
transaminases) or susceptibility (such as a genetic poly-
morphism). Such measurements can be used at diﬀerent
levels in risk characterisation, for example simply as a
measure of exposure, or as a way of reﬁning the con-
siderations of interspecies diﬀerence and/or human
variability in hazard characterisation. Ideally bio-
markers would be used as a way of integrating the
internal dose in potentially susceptible human sub-
groups under hazard characterisation with the internal
dose measured during exposure assessment. Such an
approach would be extremely data intensive and in rea-
lity is only likely to be possible for a small number of
substances of the greatest concern to human health.Biomarkers can provide important information for
application of the ‘‘parallelogram approach’’. In this,
data on in vitro biomarkers of the critical eﬀect for the
test species are compared with the in vivo response data
for the test species, the diﬀerence is used to extrapolate
from in vitro data for human preparations to the likely
in vivo response in humans (see Eisenbrand et al., 2002).
Usually the food component itself or an appropriately
deﬁned metabolite serves as the biomarker of exposure.
An understanding of the relationship between the bio-
marker and the fate of the substance in the body is
essential, as is information on the dose-biomarker rela-
tionship. Biomarkers of exposure are usually intended
to provide speciﬁc information about internal as
opposed to external exposure. An advantage of bio-
markers of exposure is that they take account of factors
that may aﬀect the bioavailability of a substance. They
are usually speciﬁc to the particular chemical under
evaluation, although in some cases the biomarker may
be common to a number of diﬀerent chemicals sharing
common metabolic or biochemical properties. Many
organophosphate pesticides, for example, share com-
mon urinary alkyl phosphate metabolites that have been
used as biomarkers of exposure, but it should be noted
that this may not reﬂect the diﬀering potencies of orga-
nophosphates, so cannot be used as a biomarker of
eﬀect.
Biomarkers of exposure require validation before the
magnitude of the biomarker in an individual can be
converted with any degree of conﬁdence into a level of
exposure that can be compared with the guidance
value/risk level. Validation should take into account the
time course for deﬁned exposures in relation to the
biological sampling for the biomarker measurement.
Ideally the dose-biomarker relationship should be
ascertained and the impact of inter-individual varia-
tion on the dose-biomarker relationship should be
characterised.
Biomarkers can also provide a useful bridge between
exposure assessment and hazard characterisation in
cases where other components present in the food
matrix aﬀect the bioavailability and hence the systemic
dose of the substance under consideration. Examples
include the enhancement of iron absorption by meat
and ascorbic acid and retardation of iron absorption by
milk or phytate (Scientiﬁc Committee for Food, 1993),
or the faster absorption of vitamin A when given as a
supplement compared with its absorption from liver
(Buss et al., 1994). Thus, the presence and concentra-
tions of other components known to enhance or retard
absorption of the substance under consideration may
need to be determined. More complex than under-
standing the possible interactions between two or sev-
eral identiﬁed components can be the understanding
of the impact of the overall food matrix, the number
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individual on the ‘internal dose’ and its eﬀects. Such
data, however, are rarely available. Biomarkers may
also help where there are diﬀerences in bioavailability of
the chemical when present in the human diet, compared
with the conditions in the studies in humans or in
animals that were used for hazard characterisa-
tion (e.g. studies in which the substance is given in
solution by gavage); these can create problems of inter-
pretation when these aspects are brought together in
risk characterisation.
Some biomarkers of exposure that provide useful
measurements related to the internal dose can also be
used in hazard characterisation, for example to deﬁne
interspecies diﬀerences in internal dose. Another use of
biomarkers of internal dose can be to allow the rational
use of hazard characterisation data that have been
derived using a non-oral route of administration. The
extent to which data following exposure by a non-oral
route can be extrapolated to oral intake requires careful
consideration, and non-oral data would normally only
be used in the absence of adequate hazard characterisa-
tion data following oral dosage. However, for some
substances, such as contaminants, non-oral data may be
all that is available for some eﬀects. It may therefore be
necessary to derive a systemic guidance value for expo-
sure to a substance via the food supply from non-oral
data. Biomarkers of systemic exposure after oral and
non-oral routes can be used for route-to-route correc-
tion, because they allow for diﬀerences in absorption or
bioavailability. An alternative approach under hazard
characterisation is the use of a physiologically based
toxicokinetic (PBTK) model to predict the internal dose
for each diﬀerent route.
The use of biomarkers of response or eﬀect in studies
in healthy volunteers can give valuable information,
providing, because of ethical considerations, that the
response is both non-adverse and reversible. Biomarkers
of early events should be related to, and ideally critical
for, the development of the adverse eﬀect (hazard) that
is the basis for the risk assessment (Renwick andWalton,
2001). In vivo animal experimentation is an important
step in the validation of such early event biomarkers in
relation to the generation of the ultimate adverse eﬀect.
For example, measurement of the inhibition of plasma
cholinesterase represents a biomarker for total exposure
to organophosphate and carbamate pesticides, whereas
inhibition of erythrocyte acetylcholinesterase is con-
sidered a biomarker of eﬀect. It is important that the
biomarker response occurs at similar or lower doses
than would the adverse eﬀect: such relationships can be
addressed in special studies in animals.
5.2.5. The inﬂuence of the nature of the hazard and
hazard characterisation on risk characterisation
5.2.5.1. Quality of the hazard database: The reliability
of risk characterisation is dependent on the quality ofthe hazard database relevant to the issues raised in
problem formulation.
Hazards may be identiﬁed from human studies, ani-
mal-based toxicology and in vitro toxicology, as well as
being inferred by structure-activity considerations.
Hazard characterisation has to address two main
aspects for each endpoint:
 qualitative considerations of the importance and
relevance of the health endpoints for humans,
and
 quantitative considerations of the dose-response
relationship and its application to the human
population.
These aspects have been addressed in more detail in
earlier FOSIE publications (Barlow et al., 2002; Dybing
et al., 2002; Edler et al., 2002).
As experimental and epidemiological data are col-
lected they may reveal additional issues, such as highly
sensitive life-stages These need to be taken into account
and may even become the focus of the advice to risk
managers.
The importance of human data in hazard identiﬁca-
tion is well recognised. There are many advantages to
using human data, for example the outcomes are those
that humans will experience, the populations under
study are usually exposed by the relevant route, namely
ingestion, and the chemical exposures occur at con-
centrations present in the food supply. For these rea-
sons such data usually take precedence over animal
data. For some agents, hazards have been identiﬁed by
epidemiological studies before they were detected in
laboratory animals. The contribution of epidemiology
to risk assessment has been reviewed in more detail in
an earlier FOSIE publication (van den Brandt et al.,
2002). However, human epidemiology ﬁndings are not
always suitable for risk characterisation. The accuracy
and precision of the exposure data in observational epi-
demiology studies are not always optimal, and the
results can be aﬀected by bias and confounding. In
addition available epidemiology data may not be ade-
quate, because adverse eﬀects identiﬁed in animal stud-
ies were not investigated, or the duration of exposure,
the life-stage exposed or the length of follow-up were
insuﬃcient for the hazard to be expressed. Therefore,
although human data can provide the most secure
advice, it has to be appreciated by both risk managers
and all stakeholders that in most cases risk character-
isation has to be based on other types of data, mostly
from in vivo studies in animals.
Animal models continue to be the main system for
hazard identiﬁcation of low molecular weight food che-
micals, see Barlow and colleagues (2002) for more
extensive discussion. The advantages of in vivo studies
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whole organism, with its inter-related metabolic, circu-
latory, hormonal, neural and immunological functions
and organ systems intact, is the most appropriate model
for humans, the dosage can be exaggerated compared
with human exposures in order to increase sensitivity,
and the substance can be administered under well-
deﬁned experimental conditions by the oral route.
Once all adverse eﬀects associated with a substance
have been identiﬁed, there is a need to determine which
of these eﬀects, usually termed the critical eﬀect(s),
might be most relevant to the predicted human expo-
sure. This decision is based on the sensitivity of the tar-
get organ(s) and the relevance of the hazard to
anticipated exposed populations. In addition, the
hazard characterisation process needs to take into
account the fact that some hazards, such as genotoxi-
city, are evaluated by low-dose extrapolation while
other hazards may be characterised by the application
of uncertainty factors (see below). It is important in risk
characterisation to ensure that the advice to risk man-
agers focuses on the eﬀect(s) that could be produced at
the lowest human exposures.
Historically, diﬀerent approaches have been adopted
for the risk characterisation of threshold and non-
threshold eﬀects (Edler et al., 2002). In most cases, the
approach for both begins with an analysis of the avail-
able dose–response data for the critical eﬀect. This may
or may not involve curve ﬁtting, but the goal is to derive
a value close to the bottom end of the observed dose–
response curve (the starting point for any extrapolation
beyond the observable response range). Where the dose–
response data cover current human exposure levels from
food then the data can be used without extrapolation
outside the observed range. The aim is to predict risk in
the range of human exposures, or to predict an exposure
level considered to represent negligible risk.
5.2.5.2. Threshold approaches in hazard characterisa-
tion: The hazard characterisation approach for thresh-
old eﬀects involves the derivation of a health-based
guidance value, i.e. a level of exposure at or below
which there would be no signiﬁcant health risk if con-
sumed daily throughout life, for example the ADI, TDI,
or reference dose (RfD) or, over the period of one day
or one meal, the ARfD. However this approach pro-
vides little advice to risk managers about any risks
above the guidance value.
From a biological perspective a practical threshold in
the dose–response relationship would represent a cer-
tain dose, or range of doses, above which there are
substantial or biologically relevant changes that would
aﬀect the health of the organism and which would be
considered adverse. Below this dose range, no biologi-
cally signiﬁcant eﬀects are expected due to homeostatic
control processes. The presence of a threshold cannot be
proven from experimental data, since the absence of adetectable eﬀect at low doses could be either because the
dose is below a threshold in the dose–response, or
because the response is below the level that can be
detected by the test system. In consequence, conclusions
about the existence, or not, of a threshold are based on
biological plausibility and expert judgement of the
underlying biology of the test system.
All NOAELs, or other measures of potency/sensitiv-
ity (see Edler et al., 2002), from animal and other
experimental studies are listed for consideration. The
most sensitive of the relevant adverse eﬀects, i.e. that
occurring at the lowest dose relevant to the route and
duration of exposure, becomes the focus for detailed
consideration under hazard characterisation and is
termed the ‘‘critical eﬀect’’. The rationale for focusing
on this eﬀect derives from the assumption that any risk
to humans from other eﬀects detected at higher doses in
animals would also occur at higher doses in humans and
therefore a guidance value based on the critical eﬀect
will cover other adverse eﬀects. The rationale for the
selection of the critical eﬀect should be described clearly
as part of the risk characterisation, including supporting
evidence on biological plausibility, the shape of the
dose–response curve and the precision of the NOAEL.
Where an eﬀect that has been detected at low intakes is
excluded because it is not considered adverse, or is not
considered relevant to the risk characterisation that is
being undertaken, this should be stated clearly, together
with all information supporting this conclusion.
The diﬀerent starting points that are developed (e.g.
NOAEL, LOAEL or BMD) are used as indicative of an
intake in the experimental study (animal or human) that
would be close to the real biological threshold. Their
strengths and weaknesses have been reviewed in an
earlier FOSIE publication (Edler et al., 2002).
When a NOAEL can be derived from a study in
humans that has shown relevant eﬀects at higher doses,
then this would be utilised in the derivation of guidance
values or advice. The main issues regarding uncertainty
in a NOAEL derived from an observational epidemio-
logical study are the possible role of confounders and
the precision of both the incidence and exposure data.
For rare outcomes, only large studies with substantial
numbers of persons would be suitable to identify an
exposure-outcome relationship. The quality of the
exposure data and estimates need to be scrutinised, to
determine the conﬁdence with which any dose–response
relationship can be constructed. Uncertainty may be
reduced if the results of several similar or related high-
quality epidemiological studies are combined in a meta-
analysis to provide a reliable and statistically precise
indication of the relationship between dose and eﬀect.
The main problems with the use of either the NOAEL
or the LOAEL are that these values are critically
dependent on the study design, dose selection, group
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performed, and they are inﬂuenced little by the shape of
the overall dose-response relationship. These criticisms
can be avoided by the use of the BMD, advantages of
which are that the full dose-response data are used to
derive the value, and that use of the lower conﬁdence
interval will ‘‘reward’’ well-conducted studies, that have
narrow conﬁdence intervals, with a higher BMD.
Although there is often no signiﬁcant numerical diﬀer-
ence between a NOAEL and a BMD, the former allows
an easier or more facile explanation, because the start-
ing point is a ‘‘safe’’ intake under the conditions of the
experiment, whereas the BMD is estimated to be asso-
ciated with a response. In reality, this is a diﬀerence in
perception; because of its limitations the NOAEL does
not necessarily represent an intake with zero risk of
adverse eﬀects under the study conditions, but simply
an intake with no observed adverse eﬀects. The out-
comes of risk characterisations based on NOAELs are
not greatly diﬀerent from those based on BMDs that
represent the lower conﬁdence interval on the dosage
giving a 5 or 10% response.
The starting point from the dose-response data, for
example the NOAEL or BMD, is converted into a
health-based guidance value, such as an ADI, by the
use of uncertainty factors, which are applied to the
external dose expressed on a mg/kg body weight basis.
The uncertainty factors that have been used for the past
40 years were developed by the FDA and adopted by
the JECFA and are now accepted for the risk assess-
ment of threshold eﬀects. The usual default factors are
10-fold for species diﬀerences (when the NOAEL is
derived from a study in animals) and a further 10-fold
to allow for human variation. These factors are a part
of hazard characterisation, and are supported by scien-
tiﬁc data. There have been a number of reviews of the
use of the default uncertainty factors (see Edler et al.,
2002), and questions raised about the appropriateness
of using the same default factors, irrespective of the
test species and the metabolic fate and eﬀects of the
compound. Chemical-speciﬁc data on toxicokinetics,
physiologically-based toxicokinetic modelling, or mode
of action can be used to replace part of the default
factor with appropriate chemical-speciﬁc adjustment
factors (CSAFs) (Renwick, 1993; World Health Orga-
nization, 1994; Edler et al., 2002), however, there have
been few examples so far where appropriate data have
been available.
When diﬀerent adverse eﬀects are considered during
hazard characterisation, the diﬀerent possible guidance
values would be aﬀected by both the sensitivity of the
organism to each eﬀect, as indicated by the NOAELs,
LOAELs or BMDs, and the size of the uncertainty fac-
tor that would be applied to each eﬀect. It is therefore
necessary to take both the sensitivity and the uncer-
tainty factor into account in an iterative fashion before
ﬁnally selecting an overall critical eﬀect for deriving aguidance value and formulating advice to risk
managers. If a standard default uncertainty factor is
applied to all eﬀects then the critical eﬀect would be that
with the lowest NOAEL. Potential guidance values
obtained using the diﬀerent combinations of possible
adverse eﬀects and their respective uncertainty factors
need to be compared and the most appropriate guidance
value (usually the lowest of those meeting the relevant
criteria) adopted. This is particularly important when
both human and animal data are available, because the
overall uncertainty factor applied to human data will
usually be lower than that applied to data obtained
from studies in experimental animals. As an example,
consider a chemical that, in adequately conducted stud-
ies, produces histopathological eﬀects on a target organ
such as the heart in the rat, with a NOAEL of 1 mg/kg
body weight per day and also produces mild neurobe-
havioural eﬀects in human volunteers, with a NOAEL
of 0.3 mg/kg body weight per day. Obviously, the
human study could not provide comparable informa-
tion on potential eﬀects of the chemical on the target
organ identiﬁed in the rat. A potential guidance value
based on the critical eﬀect in the human study, with a
NOAEL of 0.3 mg/kg body weight per day and a
default uncertainty factor of 10-fold, would be 0.03 mg/
kg body weight per day. However, if the NOAEL from
the rat study were used, with a default uncertainty fac-
tor of 100-fold, this would give a potential guidance
value of 0.01 mg/kg body weight per day. As there is no
assurance that humans would not be sensitive to the
cardiac eﬀect observed in the rat, the guidance value
would be established at 0.01 mg/kg body weight per
day. Under such circumstances it is important that the
advice to risk managers explains clearly why data from
a study in rats has been used in preference to data from
a human study.
5.2.5.3. Non-threshold approaches in hazard character-
isation: The traditional position has been to consider
that there may not be a threshold dose for eﬀects invol-
ving genotoxicity. Thus, adverse health eﬀects originat-
ing from genotoxic events, such as heritable disorders
and some cancers, are generally assessed diﬀerently
from non-genotoxic responses.
Three non-threshold approaches have been used
historically in the formulation of advice for such
eﬀects:
 quantiﬁcation of the risk at diﬀerent levels of
human exposure,
 ranking the hazards from diﬀerent compounds
producing similar hazards, but without quantiﬁ-
cation of the risk at human exposure levels, and
 recommendation that the exposure should be
minimised, without any further use of either the
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For non-threshold eﬀects the starting point is usually
a ﬁxed response (e.g. a certain percentage tumour inci-
dence) within but towards the lower end of the dose-
response curve, that is derived by ﬁtting a mathematical
model to the data (Lovell and Thomas, 1996; Dybing et
al., 1997; Sanner et al., 2001; Van Landingham et al.,
2001). The ﬁxed response can be used directly to pro-
duce advice that allows comparisons to be made
between diﬀerent compounds producing the same
response in the same species and strain of animals.
Alternatively it can be the starting point for low-dose
hazard characterisation, down to a ﬁxed response such
as a lifetime risk of one in a million or one in one
hundred thousand (see Edler et al., 2002).
An important distinction between animal and epide-
miological studies, which is particularly relevant to the
detection of carcinogens, is that a 2-year rodent study
yields estimates of lifetime risk at each dose level. In
contrast, most epidemiological studies are partial-life-
time studies and do not involve suﬃciently long follow-up
to measure lifetime risks directly.
For non-threshold eﬀects, the quantitative risk esti-
mate can be calculated by extrapolation from a given
incidence in experimental studies, usually about 10 or
25%, down to a low predicted lifetime risk, such as one
in hundred thousand (105) or one in a million (106).
The selection of the starting point for extrapolation
from the animal data (for example the external dose
giving a 5% response) can be derived by modelling the
dose–response data in the experimental range (Edler et
al., 2002). In some risk assessments the external dose
has been converted to a human equivalent target organ
dose of the proximate carcinogen by the use of a PBTK
model. However, such scientiﬁc sophistication has little
impact on the resulting risk estimate, which is largely
determined by the mathematical low-dose extrapolation
model used. While determination of the starting point
and selection of the mathematical model are part of
hazard and risk characterisation, the ﬁnal output is a
quantitative estimate of risk, e.g. the intake associated
with an increased lifetime risk of developing cancer of 1
in 106—sometimes termed the virtually safe dose (VSD).
The acceptability of the estimated risk requires a risk
management or societal view.
Because this method provides a quantitative estimate
of the risks associated with speciﬁed exposures, it is
essential that the limitations and uncertainties are
clearly described under the risk characterisation advice
that is given to risk managers. There are considerable
uncertainties associated with the risk estimates derived
by low-dose extrapolation of animal data down to a
lifetime risk of 1 in 105 or 1 in 106. The dose–response
relationships for biochemical and pathological changes
over such a range are never known, and therefore
default assumptions are necessary. Historically a num-
ber of mathematical models have been proposed forlow-dose extrapolation (Lovell and Thomas, 1996), but
these can give widely diﬀering risk estimates, and it is
rarely known if the mathematical model selected reﬂects
the underlying biological processes for a particular sub-
stance. The debate on this issue continues (see for
example Lutz, 1998; Zito, 2001). The simplest and most
readily applicable assumption is that there is a direct
linear relationship between dose and biological
response. This approach is being used increasingly
because it is robust and readily applicable to a wide
variety of databases. However, it is increasingly ques-
tionable given our developing understanding and
knowledge about cytoprotective mechanisms and DNA
repair processes which could reverse any low-level gen-
otoxic eﬀects. Non-linearity in the dose–response rela-
tionship could arise at the high doses used in the animal
studies due to saturation of a detoxication or cytopro-
tective process (which would result in a steeper dose-
response relationship at high doses) or saturation of a
bioactivation process (which would reduce the slope at
high doses). Non-linearity can also arise from interac-
tions with other factors not present in experimental
conditions, but occurring widely in the human real-
world situation. Synergistic eﬀects could increase the
slope at all or only some dose levels; antagonistic eﬀects
could have the opposite eﬀect, reducing the slope at all
or only some dose levels. The uncertainties arising from
the mathematical extrapolation process are considerably
greater than the errors or uncertainties in the estimation
of the starting point, and it is important that the limi-
tations and assumptions are provided as part of risk
characterisation.
Despite these uncertainties, the advice to risk man-
agers from low-dose extrapolation can appear to oﬀer
mathematical precision. For example, hazard char-
acterisation may give an upper bound risk estimate of 1
in 106 for a daily intake of 3 mg; in reality, the risk
estimate associated with a daily intake of 3 mg could be
from zero to 1 in 106, but both risk managers and other
stakeholders tend to interpret the upper bound of the
risk estimate as if it were the central tendency. The
advice from risk characterisation should be suﬃciently
transparent that risk management decisions can take
into account the imprecision and conservatism built into
the estimation of risk.
A form of advice that avoids the uncertainties inher-
ent in low dose extrapolation, but which can be useful
to risk managers in the prioritisation of problems, is to
give a value that can be used to rank a series of com-
pounds that exhibit the same biological properties. For
this approach the starting point can be the direct com-
parison of the potency of chemicals sharing common
hazards, e.g. are both genotoxic and carcinogenic. As a
part of risk characterisation the ratio of the human
exposure to a common point on the dose–response
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absolute) magnitude of the risk for that substance com-
pared with others that share similar properties, i.e. an
exposure-potency index. Although low dose extrapola-
tion is not an explicit part of such an approach to risk
characterisation, the use of such information by risk
managers requires an assumption that there is no dif-
ference between compounds in the linearity, or the
extent of any non-linearity, in extrapolating from the
relative potency estimated from the animal study, down
to the predicted human exposure considered by the risk
manager.
The other advice that is sometimes given to risk
managers for compounds that show properties such as
genotoxicity is that the exposure should be reduced to
as low as reasonably achievable or practicable (ALARA
or ALARP). This approach does not run the chance of
over-interpreting the hazard characterisation data and
leaves it to the risk manager to decide the level of
reduction that may be technologically and ﬁnancially
practicable. However, it provides no practical advice to
risk managers and the same advice would be given for
compounds with high and low potencies. In contrast, an
exposure-potency index or low-dose extrapolation,
despite the limitations and assumptions, allows risk
managers to prioritise problems.
5.3. The nature of advice to risk managers
The advice to risk managers may be quantitative or
qualitative, dependent on problem formulation, data
availability and the nature of the compound or sub-
stance.
Quantitative advice can be in one of the following
forms:
 an estimate of the risks associate with diﬀer-
ent levels of exposure (e.g. for an unavoidable
contaminant);
 a health-based guidance value (e.g. for an addi-
tive, pesticide, veterinary drug or other avoidable
contaminant);
 as a ratio between the NOAEL in experimental
or epidemiological studies, and the estimated
amount of human intake/exposure, referred to as
a ‘‘margin of exposure’’;
 as a ratio between of the NOAEL and the actual
amount of human intake/exposure, referred to as
a ‘‘margin of safety’’ or a ‘‘safety margin’’;
 as recommended minimum and maximum
intakes (e.g. for vitamins, minerals and other
nutrients).
Qualitative advice can be in the following forms:
 a classiﬁcation of ‘‘ADI not speciﬁed’’ may be
allocated (e.g. for an additive when its additionto food under good manufacturing practice does
not need to be restricted, because of the absence
of any evidence of toxicity even at high dose
levels);
 approval may be use-speciﬁc, that is, the sub-
stance is considered safe in the context of the
intake that is estimated from a certain speciﬁed
use or uses (e.g. a vitamin, mineral or additive);
 to avoid certain foods (e.g. aﬂatoxin-con-
taminated nuts from certain sources);
 to avoid certain processes (e.g. use of ethylene
oxide for sterilisation of spices);
 to modify production processes (e.g. use of
a diﬀerent production method for hydro-
lysed vegetable protein to avoid formation of
chloropropanols);
 to minimise exposure to as low as reason-
ably achievable (e.g. for unavoidable toxic
contaminants);
 to reduce intakes (e.g. of certain types of fat);
 to reduce or avoid intakes by certain sectors of
the population (e.g. liver and vitamin A supple-
ments by pregnant women).
Any advice to risk managers should clearly explain
any key assumptions and the nature and magnitude of
any uncertainties in the risk characterisation. This
applies whether the assessment is based on epidemiol-
ogy or animal data and whether the eﬀect is considered
to be a threshold or non-threshold eﬀect. Where there
might be a range of options for risk management, the
advice should point out any scientiﬁc basis there might
be for pursuing one option rather than another.
5.3.1. Advice concerning individuals at increased risk
Risk characterisation should include information not
only on the general population, but also on any sub-
populations considered to be potentially susceptible.
‘‘Potentially susceptible’’ in this context includes those
who may be at greater risk of adverse eﬀects because
their particular dietary pattern results in greater intake,
and those who may be at greater risk because their
underlying physiological condition (e.g. life-stage or
disease) or a speciﬁc genetic factor results in a greater
internal dose or greater sensitivity.
If particular subgroups are at risk then advice should
focus on what is known about exposure/intakes in those
subgroups and identify any major information gaps. In
cases where the risk assessment indicates that the gen-
eral population or certain subgroups may exceed a
health-based guidance value, then risk managers may
need much more detailed information about the char-
acteristics of the exposure/intake distribution. Speciﬁc
advice may be recommended for subgroups of the
population when those individuals can recognise that
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for people with phenylketonuria, or reduction in con-
sumption of liver and vitamin A-only supplements by
pregnant women). Other potentially susceptible sub-
groups and individuals, who cannot be given usable
and meaningful speciﬁc advice, should be regarded as
part of the general population, and taken into
account in the risk characterisation for the general
population.
5.3.1.1. Consideration of individuals with high intakes:
Risk characterisation considers both individuals with
average exposures and those with high exposures. High
exposure may be related to life-stage, cultural aspects
and/or qualitative and/or quantitative food preferences.
Deﬁnition of individuals with high consumption of food
chemicals may be especially important when the hazard
characterisation process identiﬁes potentially sensitive
populations that should be investigated in exposure
studies, such as those that can be recognised by sex or
age, or by pre-existing conditions (diabetes) or dietary
habits (dieters, vegetarians, etc.).
The methods mainly used to determine individual
intakes are based either on point estimates, ‘‘simple’’
distributions, or probabilistic analyses. Each of these
approaches has its shortcomings but also its advantages.
Point estimates use single values for the amount of
food consumed and the concentration in the food of the
chemical in question. Simple distributions take account
of variation in consumption of the relevant food items,
but assume that the chemical in question is present in all
foods at a deﬁned maximum level (e.g. the maximum
permitted level for a food additive). Point estimates and
simple distributional approaches tend to use ‘worst case’
assumptions without taking into account the frequency
of occurrence of a chemical, the variation in concentra-
tions of the chemical in diﬀerent foods, or the variation
in food consumption, and therefore normally over-
estimate exposure.
Both ‘‘worst-case point estimates’’ and ‘‘worst-case
simple distributions’’, which assume that individuals
with high consumption of food chemicals not only eat
high amounts of the relevant foods but also that they
are always, or at least predominantly, exposed to pro-
ducts containing a high concentration of the substance
in question, are clearly unrealistic. Continuous high
consumption of high concentrations happens only
rarely in practice, and for most substances, the indivi-
duals with high consumption of relevant foods are
exposed to a normal distribution of concentrations of
the chemical under assessment. Exceptions to this
include dietary supplements and other foods with
instructions for consumption, and the regular con-
sumption of an unusually contaminated food supply.
Point estimates and simple distributions that assume
individuals with high consumption of relevant foods are
predominantly exposed to the mean concentration ofthe substance in question will generally overcome this
particular problem.
The deﬁnition of the intake by a ‘‘high consumer’’ is
usually the intake at the 90th, 95th or 97.5th percentile
of the intake distribution. The percentile selected is pri-
marily a risk management decision and will be inﬂu-
enced by consideration of a number of issues. These
include the length of the tail of the distribution curve,
whether the tail comprises an identiﬁable subgroup (e.g.
children or an ethnic group), and whether the critical
eﬀect used to derive the health-based guidance value is
mild or severe in nature. The decision is taken on the
understanding that health-based guidance values are
intended for people within the normal range of cultures
and lifestyles and that the deﬁnition of a ‘‘high con-
sumer’’ would not normally be expected to include
those with bizarre food preferences or habits. It should
also be borne in mind that when higher percentiles are
selected, the precision of the value is critically dependent
on the size of the database from which it is derived.
A major diﬃculty arises in calculating the high con-
sumer intake when a chemical is distributed widely in
the food supply. The high intake from one food can be
calculated as the concentration present multiplied by the
consumption of that food by a high consumer. Theore-
tically the total intake for a high consumer could be
calculated by the addition of the resulting high intakes
for all relevant foods, but this would grossly over-
estimate possible intake, because the same individual
would not be a high consumer for all relevant foods.
This diﬃculty can be overcome by the use of real intake
data based on food diaries, market basket methods or
biomarkers of exposure, or by the use of probabilistic
methods which allow for alternative selection choices.
Where such approaches may not be possible, an alter-
native strategy is to place a limit on the number of foods
from which high consumer intakes may be summed, for
example two or three foods only, then adding to these
the calculated average intakes from all remaining foods.
Probabilistic approaches model the distribution of
both the consumption of the relevant foods and the
presence and concentrations in the foods of the chemi-
cal to be assessed. Such approaches require suﬃcient
measurements of the concentrations present in foods
and the availability of food consumption databases to
make the assessments meaningful. In many cases, the
statutory requirements for monitoring do not allow
characterisation of distributions in a statistically mean-
ingful way. When scientiﬁcally sampled data are avail-
able, such models can be used to estimate the likelihood
that a deﬁned intake level for a substance will be excee-
ded. Providing that the available data are of suﬃcient
quality, probabilistic approaches are potentially the
most suitable methods to combine the concentrations of
the substance to be assessed in the foods with the con-
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providing a basis for realistic exposure assessment.
However, these methods for the estimation of exposure
require further reﬁnement, including a quantitative
measure of uncertainty.
When distinct groups of the population are identiﬁed
as having high intakes, the risk characterisation usually
focuses on that group(s). For example, infants may have
higher intakes of a particular substance because breast
milk or infant formula is the sole source of nutrition in
the ﬁrst few months of life. Similarly, consumption of
juices and fruits can be high in young children. Another,
and more general reason for higher intakes by infants
and children, is because of their higher calorie intake
relative to their body weight. In Europe and in the
WHO advisory bodies, the higher potential intake is
taken into account under exposure assessment and the
higher potential target organ sensitivity under hazard
characterisation, i.e. prior to their integration into risk
characterisation. In the USA the Food Quality Protec-
tion Act requires the use of an extra 10-fold uncertainty
factor for pesticides in the case of infants and children
because of their higher intakes and greater potential
susceptibility, unless there are comprehensive hazard
characterisation data available for the relevant age
group (Environmental Protection Agency, 1999a).
From a European Union (EU) perspective the United
States legislation applies the uncertainty factor as part
of risk characterisation, in contrast to other uncertainty
factors that are applied during hazard characterisation,
as part of the derivation of the health-based guidance
value. The formulation of advice to risk managers
should take into account those groups with highest
intakes and those predicted to have the greatest sus-
ceptibility, looking at the strengths, limitations and
uncertainties inherent in both aspects.
5.3.1.2. Consideration of individuals with high suscept-
ibility: The dose–response relationship from studies in
small groups of animals or small groups of human
volunteers would be unlikely to be representative of the
relationship in the widely diverse human population.
Inter-individual diﬀerences in the toxicokinetics are an
important source of variability in response. Such varia-
bility may arise from diﬀerences in genetic constitution
and environmental inﬂuences including diet, nutritional
status, physiological states, such as pregnancy, and
pathophysiological states. Data will only rarely be
available to address human variability in toxicokinetics,
but if so, the issue needs to be considered during hazard
characterisation.
The default uncertainty factor of 10 for inter-indivi-
dual human variability, which allows for both tox-
icokinetic and toxicodynamic diﬀerences, can be
subdivided into kinetic (3.16 or 100.5) and dynamic (3.16
or 100.5) components (World Health Organization,
1994). There is wide inter-individual variation inpolymorphic pathways of metabolism, for example
CYP2D6, CYP2C19 and N-acetyl transferase-2 (Dorne
et al., 2002 and 2003; Knudsen et al., 2001; Vineis et al.,
2001). Diﬀerences between extensive metabolisers (EM)
and poor metabolisers (PM) for substrates of CYP2D6
and CYP2C19 can greatly exceed the default uncer-
tainty factor of 3.16 or 100.5, which normally allows for
human variability in kinetics (Dorne et al., 2002 and
2003). In the case of CYP2D6 the diﬀerence in internal
dose between EM and PM subjects may exceed 30-fold
if the substance is metabolised exclusively by CYP2D6,
but the diﬀerence would be only about 2-fold if
CYP2D6 was responsible for the elimination of 10% or
less of the compound (Dorne et al., 2002). Replacement
of the default factor of 3.16 by a CSAF (see Edler et al.,
2002) for human variability requires selection of a per-
centage of the population that the CSAF would cover.
This is primarily a risk management decision, and is
analogous to selecting a point estimate, such as the 95th
or 97.5th percentile on the intake distribution curve to
represent a ‘‘high consumer’’. When a CSAF is calcu-
lated, the uncertainty related to the validity of the
default for the population would be replaced by uncer-
tainty for the individual, arising from human
variability.
Increased susceptibility associated with diﬀerent life-
stages is taken into account as part of hazard char-
acterisation by experimental studies in animals
throughout diﬀerent life-stages. Only rarely are there
data directly addressing the issue of human variability
in toxicodynamics, because of obvious ethical con-
siderations, and because the aim of hazard character-
isation usually is to establish exposures that would be
without adverse eﬀect in humans. However, knowledge
of the mode of action of the chemical in animals com-
bined with general physiological and biochemical
understanding, and/or in vitro data on the chemical
itself, could be used to assess likely human variability in
toxicodynamics. Biomarker data from studies in
humans could provide valuable information on varia-
bility in a reversible and/or a non-adverse response if
measured in a controlled clinical study, or for irrever-
sible eﬀects if measured as part of an observational epi-
demiology study, although such data will be inﬂuenced
by variability in exposure.
5.3.2. Advice related to simultaneous exposure to
diﬀerent chemicals in food
Studies undertaken for hazard identiﬁcation and
characterisation usually investigate the chemical in iso-
lation, and not in combination with other substances to
which humans may be exposed at the same time. How-
ever, food represents an extremely complex mixture of
substances, which includes nutrient and non-nutrient
chemicals that are an inherent part of the organism
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due the environment in which the food was grown,
chemicals that arise as a result of processing and heat
treatment, as well as man made chemicals, such as food
additives and pesticide residues.
5.3.2.1. Ways in which chemicals may interact: In recent
years, public concern has focused on possible eﬀects
arising from exposure to multiple chemicals in foods,
sometimes termed the ‘‘cocktail eﬀect’’. Recent concerns
were fuelled by publicity surrounding a publication
(Arnold et al., 1996) that reported large synergistic
interactions between combinations of xenoestrogens,
the magnitude of which was such as to raise questions
about the validity of risk characterisation based on data
for single substances. However, the data could not be
replicated by the original study authors nor by others
(Ashby et al., 1997; Wade et al., 1997) and the report
has since been withdrawn (McLachlan, 1997). However,
because substances are investigated as single entities,
and not in combination, this has raised a legitimate
question that needs to be considered as part of risk
characterisation. Most attention in the media has been
on combined exposures to man-made substances, but
risk characterisation needs to take a broader view and
consider whether other substances in food could act in
combination with the substance under evaluation to
inﬂuence safety. Any interaction between the substance
and the food matrix would be investigated under hazard
characterisation, to determine if this aﬀected either the
absorption or bioavailability of the substance, or its
potential for toxicity. Incorporation of any substance
into the diet of test species should allow for both com-
bined eﬀects and interactions between the substance and
the rest of the diet. Such interactions may represent a
hazard of potential concern for humans, for example
the impaired absorption of fat-soluble vitamins asso-
ciated with the fat replacer, ‘‘Olestra’’, or the impaired
absorption of minerals in the presence of dietary ﬁbre.
However, expert judgement is essential because incor-
poration of the test substance at high levels into the diet
of test animals may perturb the animals’ nutrition and
produce eﬀects that are irrelevant at the predicted or
known human exposure levels.
In principle, chemicals present in food could exhibit
combined eﬀects, such as joint similar or joint dissimilar
action, but these would not be described as interactions
because one substance does not alter the activity of the
other (see Dybing et al., 2002 for further explanation).
Interactions arise when one chemical alters the degree
and possibly also the nature of the potential eﬀects of
other individual food chemicals consumed around the
same time. Combined intake can arise when the diﬀer-
ent substances are in the same food, in diﬀerent foods
consumed in the same meal, or even diﬀerent foods
consumed within a short time frame, such as a period of
a few hours or days. The time-base that needs to beconsidered relates to the time over which the diﬀerent
chemicals may be present in the body and could pro-
duce a toxicokinetic interaction, and the duration of any
possible biological eﬀects, which could produce a tox-
icodynamic interaction. A toxicokinetic interaction
would be where one chemical alters the kinetics of a
second compound, for example by altering its absorp-
tion or by inhibiting its metabolism. A toxicodynamic
interaction would be related to the mode of action, and
could occur for example if one chemical interfered with
a cytoprotective process thereby increasing sensitivity to
another chemical.
Phenomena such as antagonism and synergism gen-
erally are seen only at exposure levels above the eﬀect
levels for the individual chemicals (Groten et al., 1997).
There is little likelihood that such interactions would
occur for the vast majority of man-made chemicals in
food because risk characterisation, based on NOAELs
and uncertainty factors, aims to ensure that the intake
of each individual chemical would be without signiﬁcant
eﬀects. However, in cases where chemicals have the
same mode of action on a common target, then con-
centration addition applies, and eﬀects could be pro-
duced, even when the concentrations of each individual
chemical is below its no-eﬀect level (Jonker et al., 1996;
Tajima et al., 2002), particularly when there may be
simultaneous exposure to a large number of chemicals
that share a common adverse eﬀect, such as xenoestro-
genicity (Rajapakse et al., 2001). Therefore attention
needs to be focused during risk characterisation on
substances that share a common mode of action.
Toxicity studies have only rarely investigated mixtures
of chemicals and there are problems of interpretation
when adverse eﬀects are detected. Although the available
scientiﬁc studies on interactions between substances do
not support the public concerns (Committee on Toxicity
of Chemicals in Foods, 2002), there are a number of cir-
cumstances where combined exposure should be taken
into account as part of risk characterisation. Risk char-
acterisation of combinations of chemicals is based on an
understanding of metabolic or mechanistic considera-
tions, rather than on direct experimentation. This has
been the approach adopted for food additives in the
establishment of group ADIs and for some contaminants
in the establishment of toxic equivalency factors for
combining intakes of structural analogues.
5.3.2.2. Additives: A group ADI may be set where addi-
tives display similar toxic eﬀects, providing that the
additives are in the same range of toxic potency; the
group ADI might be based on the average NOAEL or
the lowest NOAEL of diﬀerent members of the group
(World Health Organization, 1987). Historically group
ADIs have been set for compounds that are close struc-
tural analogues, or that share a common potentially toxic
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close structural analogues could show joint similar or
joint dissimilar action dependent on mode of action and
exposure level. As discussed above, joint dissimilar
actions or toxicokinetic interactions would be unlikely,
even in sensitive individuals providing that the intakes
were below their respective ADI values. In contrast, joint
similar action could result in dose addition and an
increased risk, if a number of additives shared a common
mode of action. Historically, this has not been considered
systematically in the sequential setting of ADI values for
diﬀerent food chemicals by advisory bodies. A review of
the adverse eﬀects produced by approved food additives
with numerical ADI values has concluded that this is not
a signiﬁcant concern (Groten et al., 2000).
5.3.2.3. Pesticides residues: The presence of multiple
pesticide residues on food crops has raised public con-
cern and has triggered work both in the USA and the
UK to look at the potential eﬀects of pesticide mixtures
(Environmental Protection Agency, 2001 and 2002;
Committee on Toxicity, 2002). Many of the reported
interactions between pesticides have been of a tox-
icokinetic nature, arising from the high doses used in the
interaction study. Toxicokinetic interactions can occur
when compounds compete for the same enzyme or pro-
cess, and are present in such concentrations that the
process becomes saturated. Another type of interaction
is when one compound increases the amounts of an
enzyme (induction) and thereby increases the rate of
metabolism of a second compound. This could be tox-
icologically important if the enzyme bioactivates the
second compound, but again would occur only at doses
high enough to induce the enzyme. While such interac-
tions are possible in high dose animal studies they are
very unlikely to occur at the much lower doses to which
humans are exposed, for example arising from multiple
pesticide residues on foods. The reason for this is that
foreign compounds are usually metabolised by high-
capacity enzymes and there is normally suﬃcient
enzyme available to metabolise both substrates, as if the
other one (or more) compounds were not present. The
review by the Committee on Toxicity (2002) concluded
that although several studies on mixtures of pesticides
have reported synergistic interactions, most had been
inadequately designed and that the interpretation of the
data had been based on an incomplete understanding of
the concepts. Nevertheless, there were data from a few
studies, which used high concentrations, that supported
either synergistic or antagonistic interactions.
Hitherto, combinations of multiple pesticides have
not been explicitly considered on a routine basis, despite
the fact that some, such as organophosphates and car-
bamates, share a common mode of action and a joint
similar action is to be anticipated. The potential for
combined eﬀects to be produced from exposure to a
mixture of pesticides that share a common mode ofaction (joint similar action) has stimulated recent initia-
tives to consider risks from both aggregate exposure and
cumulative exposure (Environmental Protection
Agency, 2001, 2002). The environmental protection
agency has deﬁned aggregate exposure and aggregate
risk as the combined exposure/risk for a single com-
pound via any route and from all sources, including
foods, drinking water, consumer products, as well as
occupational and environmental sources - air, soil,
water, indoor surfaces, etc. (Environmental Protection
Agency, 2001). In cases where there is exposure from
other sources, it may be critical, for example, to deter-
mine the relative intake from foods for individuals who
are also occupationally exposed to a substance in an
industrial or agricultural setting. While for someone
regularly handling a pesticide, the relative contribution
from residues in foods may be comparatively low, it
could still be relevant, either due to an incremental
increase in total exposure, or due to diﬀerences in the
relevance for risk of diﬀerent routes of exposure (oral,
dermal, inhalation). Co-exposure from other non-food
consumer products, such as home and garden pesticides,
cosmetics and household-products, may similarly be
relevant.
Cumulative exposure and cumulative risk represent the
exposure/risk from total exposure to substances with a
common mechanism of toxicity, irrespective of their
source or route of exposure (Environmental Protection
Agency, 2002). Pesticides exhibiting anticholinesterase
activity have now been subject to cumulative risk
assessment by the Environmental Protection Agency
(2002). In order to conduct such evaluations, the indi-
vidual exposure to each component contributing to the
cumulative exposure must be known and the estimate
adjusted to allow for diﬀerences in relative potency
before the exposures are summed. These analyses are
complex and require the establishment of toxic equiv-
alency factors (TEFs) for related compounds and the
adoption of probabilistic exposure estimates, in order to
avoid combining deterministic worst-case exposure esti-
mates for each pesticide into a totally unrealistic risk
characterisation.
5.3.2.4. Contaminants: Polychlorinated dibenzodioxins
(PCDDs), dibenzofurans (PCDFs), and certain PCB
congeners are ubiquitous contaminants which share a
common mode of action. The potential for joint similar
action is taken into account as part of risk character-
isation by the use of toxic equivalency factors (TEFs).
The health-based guidance value, derived under hazard
characterisation is based on the extensive toxicity data-
base on 2,3,7,8-tetrachlorodibenzo-p-dioxin (2,3,7,8-
TCDD), which is the most toxic and extensively studied
member. The toxic potency of each congener is calcu-
lated by comparison with 2,3,7,8-TCDD. Risk char-
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congener, which is multiplied by its TEF, and the com-
bined intake of all individual compounds, expressed in
2,3,7,8-TCDD equivalents, is then compared with the
health-based guidance value for the group (Scientiﬁc
Committee on Food, 2000b). Whereas there are inter-
nationally established methods for combining the
intakes of the 2,3,7,8-halogenated dibenzodioxins,
dibenzofurans and related analogues based on the use of
toxic-equivalency factors, similar approaches are still
under discussion for other food chemicals that may
share a common mechanism of toxicity, for example
polycyclic aromatic hydrocarbons.
5.3.2.5. Micronutrients: An area of food safety where
there is a potential for signiﬁcant toxicokinetic interac-
tions, but which has received limited consideration
relates to high doses of minerals in food supplements.
Unlike low-molecular-weight foreign compounds, which
have received considerable attention, and which usually
cross cell membranes by passive diﬀusion and are
metabolised by enzymes with high-capacity and low-
speciﬁcity, vitamins and minerals show homeostatic
mechanisms which are based on low-capacity transpor-
ters and enzymes, which may be involved in the home-
ostasis of more than one micronutrient. With such high-
speciﬁcity and low-capacity processes, a larger than
normal intake of one micronutrient might signiﬁcantly
aﬀect the absorption or plasma and tissue levels of
another nutrient.
An unusual possible interaction has come to light for
one dietary component, beta-carotene. While beta-car-
otene is not thought to be a carcinogen, it has been
identiﬁed as possibly associated with an increase in the
risk of lung cancer in smokers taking it in the form of
dietary supplements (Alpha-Tocopherol, Beta Carotene
Cancer Prevention Study Group, 1994; Omenn et al.,
1996). In the occupational ﬁeld it is notable that occu-
pational carcinogens, such as benzene and arsenic, have
primarily been identiﬁed in populations with high levels
of smoking, while the increases in risk among non-
smokers have been of lower magnitude. Whether the
activity of food-associated co-carcinogens would be
expressed primarily in smokers would be of interest to
those designing food-related epidemiology studies and
also to risk managers.
5.3.3. Advice related to diﬀerent duration and patterns
of human exposure
Guidance values generated during hazard character-
isation are usually derived from chronic bioassays or
multigeneration studies performed in animals, and
therefore relate to chronic human exposure. Whilst the
ADI or TDI is the most appropriate guidance value for
food additives and contaminants that may be wide-
spread and relatively constant constituents of the
human diet, it is of less value where the exposure to thechemical is either episodic or highly variable and the
compound shows acute toxicity.
The patterns of human exposure to chemicals in food
may be chronic (usually low-level), short-term (often
at higher levels) or chronic low-level with occasional
higher intakes. Short-term studies often only show
eﬀects at higher doses than those producing eﬀects dur-
ing chronic treatment. In addition, the nature of the
eﬀect may diﬀer qualitatively, for example changes
during short-term treatment may be precursors of
chronic eﬀects or may be acute eﬀects to which toler-
ance develops during chronic treatment. Therefore gui-
dance values related to chronic, or lifetime exposure to
the chemical, for example the ADI, may not be appro-
priate for risk characterisation for short-term intakes of
a compound, such as a pesticide. Because the doses
required to cause adverse eﬀects following acute expo-
sure are usually higher than those causing chronic toxi-
city, the acute-NOAEL and health-based guidance
value for acute exposure, would be higher than a gui-
dance value, such as an ADI, based on a chronic-
NOAEL.
5.3.3.1. Use of an acute reference dose: The need for an
alternative form of hazard characterisation to relate to
short-term human exposures arose primarily from the
recognition of the variability in residue levels of pesti-
cides within agricultural crops. Surveillance pro-
grammes generally measure the residue level in a
composite sample of a crop, but it is now recognised
that there can be signiﬁcant variation from unit to unit
(for example, carrot to carrot) within a particular batch
of a commodity. Thus, there may be a short-term high
intake over one day or even a single meal. This would
give a short-term peak of internal dose, and could the-
oretically give an acute eﬀect, but such high-level expo-
sure would not occur repeatedly, and there would be no
increase in the steady-state body burden that would
normally be associated with exposure to that chemical.
Whilst it is logical to compare the potential intake aris-
ing from average residue levels, i.e. that present in the
composite sample, with the guidance value related to
chronic exposure, i.e. the ADI, it would be overly con-
servative to compare the potential intake at the highest
residue level in a particular unit (e.g. one carrot) with
such a guidance value, because high-level exposure
would not occur repeatedly (Renwick, 2002). This has
been the stimulus for short-term guidance values and
has given rise to the concept of the acute reference dose
or ARfD.
The ARfD is used in risk characterisation of expo-
sures that are predicted to be both short-term and for
eﬀects that occur following acute exposure and are pre-
dicted to be reversible, e.g. inhibition of acet-
ylcholinesterase by organophosphate and carbamate
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Directorate, 2001; Codex Committee on Pesticide Resi-
dues, 2001) have stated that the need for an ARfD will
be considered for all pesticides in the future, and the
estimated short-term intake of pesticide residues will be
compared with the ARfD in order to interpret the pos-
sible risks associated with unit-to-unit variability in
residue levels.
The ARfD can be derived in a manner analogous to
the ADI, but based on short-term eﬀects. Acute toxicity
tests, as currently performed, are usually only of value
for identifying severe acute eﬀects at high dose levels;
they are of little value in hazard characterisation for
food chemicals and components because the studies are
not usually designed to establish NOAELs related to
short-term exposure. In most cases the ARfD is calcu-
lated by dividing the NOAEL for the critical eﬀect in
the short-term study by an appropriate uncertainty fac-
tor (usually the default value of 100). Where the eﬀect is
dependent on peak plasma concentration (Cmax), rather
than the total exposure, as estimated by the area under
the plasma concentration time curve (AUC), considera-
tion should be given to reducing the uncertainty factor,
as there are often smaller interspecies diﬀerences in Cmax
than in AUC (Renwick, 2000).
Recommendations for appropriate toxicological
studies have not been fully developed for the determi-
nation of ARfDs, and therefore the values calculated
under hazard characterisation for diﬀerent compounds
may be associated with diﬀerent types and extents of
uncertainty. If suitable studies of short duration of
exposure are not available it may be necessary to use
longer-term studies to derive an ARfD. Under these
circumstances, hazard characterisation needs to con-
sider the biological plausibility of the eﬀect occurring
after short-term exposure (deﬁned as over 24 h). For
example, haemolysis observed in a 28-day study would
be considered a possible acute eﬀect in the absence of
information to the contrary, whereas ﬁbrotic damage in
an organ would not. In some cases, speciﬁc studies may
need to be undertaken to characterise potential acute
eﬀects. The use of a speciﬁc study protocol would be of
value in cases where there is concern over short-term,
high level exposures. Suitable experimental protocols,
which involve acute, sub-lethal exposure of test animals
followed by detailed observational, biochemical and
histopathological follow-up for 1–2 weeks are currently
under discussion.
Risk characterisation may indicate the need for
ARfDs for compounds other than pesticides if the
exposure data show short-term or episodic peaks. Rea-
sons for high levels of intake may diﬀer with the type of
food chemical. For example the intake of an additive
can be inﬂuenced by brand selection, the intake of a
macronutrient can be inﬂuenced by individual food
preferences, and the intake of a contaminant will
depend on how widely it is distributed within the foodsupply and whether individuals consume locally grown
or nationally produced foods. In some cases, short-term
peaks for exposure may be intentional on the part of the
consumer, for example a very high intake of micro-
nutrients from high dose supplements may be taken to
prevent or treat a short-term condition, such as the use
of vitamin C to prevent a cold.
Neither the ADI nor the ARfD address the possibly
increased risks of chronic adverse eﬀects associated with
long-term low-level exposure, combined with occasional
peak exposures. Any increase in risk has generally been
handled by averaging the long-term low-level exposure
combined with the occasional peak exposure. Such
averaging makes the assumption that peak exposure is
not important and exposure averaged over the lifetime
is the major determinant of risk. Peak exposures on top
of low-level continuous exposure could be particularly
relevant to some hazards and some life-stages, for
example exposure during embryonic development, and
this is taken into account in setting the ARfD. This
possibility emphasises the importance of integrating
hazard characterisation and the exposure scenario
within risk characterisation.
5.3.3.2. Compounds with very long half-lives: Although
considerable attention has focussed recently on the
problems of high level but short-term exposure and the
development of ARfDs, a similar mismatch may occur
under risk characterisation when an ADI is used for
compounds with very long half-lives. Compounds such
as 2,3,7,8-TCDD accumulate in the body and chronic
toxicity correlates with the body burden at steady-state.
Periods of above average dietary intake that represent
only a small fraction of the half-life may not sig-
niﬁcantly aﬀect body burden (this is discussed further in
Section 5.3.4), and therefore both hazard characterisa-
tion and exposure assessment should relate to longer,
toxicologically relevant, periods. The half-life of 2,3,7,8-
TCDD in humans is about 7.6 years and, in recognition
of the need for risk characterisation to consider long-
term average intakes, the ﬁfty-seventh meeting of the
JECFA established a provisional tolerable monthly
intake of 70 pg/kg body weight (World Health Organi-
zation, 2002). In contrast, the SCF established a toler-
able weekly intake of 14 pg/kg body weight, (Scientiﬁc
Committee on Foods, 2001), while the UK committee
on toxicity of chemicals in food, consumer products and
the environment (COT) calculated a tolerable daily
intake of 2 pg/kg body weight (Committee on Toxicity
of Chemicals in Food, Consumer Products and the
Environment, 2001). The hazard characterisation was
similar in all three cases, and the apparent discrepancies
arise from the time base over which the exposure was to
be expressed, with the JECFA taking a long-term view,
the European commission’s scientiﬁc committee on food
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accumulates, and the COT using a daily basis because
that is the way that intakes are usually expressed. The
COT considered that a TDI would be more transparent,
and then, for clariﬁcation, indicated that occasional
exceedance of the TDI would not be expected to result
in harmful eﬀects. These diﬀerent outputs from hazard
characterisation need to be interpreted under risk char-
acterisation in relation to intakes averaged over a long
period of time, i.e. weeks or months. Each method of
expressing the guidance value needs to be interpreted
carefully, and adequate advice is an essential part of
both hazard characterisation and risk characterisation.
In reality, apart from intake by pregnant women and by
babies during breast feeding, the issue for dioxins is not
short-term high level exposures, but the fact that the
long-term intakes by a signiﬁcant proportion of the
population exceed the health-based guidance value.
Dioxins illustrate the need for some quantitative form
of hazard characterisation for threshold eﬀects to give
an estimate of the risk at intakes above the health-based
guidance value (see next section).
5.3.4. Advice when human exposure exceeds the
health-based guidance value
Health-based guidance values (such as the ADI for
threshold eﬀects or the dose associated with a calculated
low lifetime risk such as one in 106 for non-threshold
eﬀects) are estimates of intakes that could be considered
to be without signiﬁcant adverse health eﬀects. There-
fore, by deﬁnition, intakes that exceed such guidance
values cannot necessarily be assumed to be without
adverse health eﬀects and there is a need to provide
advice to risk managers, ﬁrstly on whether there are
likely to be any increased risks to health and, if there
are, the possible nature and magnitude of any increase.
When considering this issue the JECFA stated
‘‘Because in most cases, data are extrapolated from life-
time animal studies, the ADI relates to life-time use and
provides a margin of safety large enough for toxicolo-
gists not to be particularly concerned about short-term
use at exposure levels exceeding the ADI, providing that
the average intake over longer periods of time does not
exceed it.’’ (World Health Organization, 1987). The
JECFA did not give further details and clearly the
duration of excessive exposure would need to consider
the toxicokinetics of the compound and the mechanism
or mode of action. The signiﬁcance of a period of intake
above the ADI is diﬃcult to assess, and depends on
both the magnitude and the duration of excessive
intake, and whether toxicity is associated with the peak
concentration or the average concentration. For chronic
toxicity, the duration of excessive intake has to be con-
sidered in relation to the half-life of the compound and
the associated body burden at steady-state. In the case
of 2,3,7,8-TCDD, which has a very long half-life (see
discussion above), a short period of high dietary intakemay not produce a major change in body burden (Ren-
wick, 1999b; Vrijens et al., 2002; World Health Organi-
sation, 2002). Similarly, a short period of intake in
relation to the time-course for toxicity may be insuﬃ-
cient to produce any eﬀect, even if continued exposure
at the same dosage would result in toxicological chan-
ges. This would be applicable, for example, to a short-
term intake of a high level of cadmium from food.
Interpretation is more complex in the case of dioxins,
where there is potential for both short-term and long-
term eﬀects, and emphasises the importance of con-
sidering the exposure in relation to the hazard; a short
period of high exposure to 2,3,7,8-TCDD is not likely to
be signiﬁcant when the hazard of concern is cancer, but
could be a signiﬁcant issue where the hazard relates to
embryofoetal exposure, because short-term high levels
of maternal exposure could produce short-term high
concentrations in the embryo or foetus at a critical
period of development.
5.3.4.1. Non-threshold effects: For non-threshold
eﬀects, such as cancer, that have undergone risk char-
acterisation by the use of quantitative, low-dose risk
extrapolation, any increase in risk with increase in dose
can be readily interpreted using the same mathematical
model. Because all models approximate to a linear rela-
tionship at the low doses that would be relevant to
human exposures, a twofold increase in the exposure
would result in a twofold increase in calculated risk.
Thus, if the intake were twice that giving a predicted
lifetime risk of 1 in 106, then the predicted lifetime risk
would be 2 in 106. Although this analysis provides the
same apparent precision as the original calculation of
the virtually safe dose, it is subject to the same approx-
imations and potential errors.
5.3.4.2. Threshold effects: For threshold eﬀects, the risk
above the guidance value cannot be estimated by a
simple extension of the procedure adopted to calculate
the guidance value. There are two aspects to be taken
into account when considering intakes above the ADI:
 the relationship between the NOAEL, or other
starting point, and the true biological threshold
for the critical eﬀect that is used as the basis for
setting the guidance value and
 the use of uncertainty factors to allow for pos-
sible species diﬀerences and inter-individual
variability.
A continued intake above the ADI would have the
eﬀect of eroding the safety margin by the ratio of the
ADI to the predicted excess intake (Renwick, 1999a).
Advice given to risk managers could relate to the pro-
portion of the population that would exceed the ADI
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ADI can be exceeded without any likely risk (for exam-
ple based on the diﬀerence between the NOAEL and the
likely position of the true threshold), and the duration
of elevated intake considered necessary to produce an
increase in risk (International Life Sciences Institute,
1999a, 1999b).
The advice should be related not only to the critical
eﬀect but also to the possibility of a risk of other eﬀects.
The latter would require a re-evaluation of the hazard
database to identify eﬀects other than the critical eﬀect,
which occurred at doses just above the NOAEL/
LOAEL. Alternative approaches to the assessment of
the signiﬁcance of intakes above the guidance value are
provided by categorical regression analysis and prob-
abilistic methods (see Edler et al., 2002). In categorical
regression analysis toxicity data from multiple studies
can be combined to give an overall picture of the dose-
adverse eﬀect response data. A disadvantage of this
approach, especially when combining multiple studies,
is that considerable toxicological judgement is needed to
rate the severity of diﬀerent adverse eﬀects reported in
diﬀerent toxicological investigations in order to give a
uniform categorisation system. In addition, because
diﬀerent eﬀects and data for diﬀerent species may be
combined in the same regression analysis, the inter-
pretation of the output in terms of meaningful advice to
risk managers can be very diﬃcult. A better way to
address the risks at intakes above the guidance value is
the use of probabilistic methods, in which point esti-
mates for the NOAEL and the uncertainty factor(s) are
replaced by distributions (see Edler et al., 2002). Such
approaches require an extensive hazard characterisation
database, and even then involve assumptions that are
similar in nature to simpler considerations of the dose–
response for the critical eﬀect (see above).
Special consideration may need to be given to excee-
dance of the guidance value by particular groups. The
guidance value for long-term exposure (e.g. ADI, TDI)
is deﬁned with respect to the dose that is likely to be
without harmful eﬀect even if continuous exposure
occurs over a lifetime. Speciﬁc life-stages, such as
infancy and pregnancy (see Section 5.3.1.2), that have a
limited duration, are usually considered as part of
hazard characterisation and the ADI/TDI/RfD would
normally be calculated such that all life-stages are cov-
ered. In these circumstances, provided exposure is such
that the health-based guidance value is not exceeded,
even during critical life-stages, there is no cause for
concern.
In this context, it is worth noting that setting an ADI
on a life-stage that is particularly sensitive may result in
a value that provides a very wide margin of safety for
other life-stages. Therefore exceeding the guidance value
only during less sensitive life-stages could be without
any health implications. Equally there may be situations
where exposure averaged over a lifetime does not exceedthe guidance value, but does exceed the guidance value
during a speciﬁc life-stage. This situation can apply in
the case of exposure of infants to lipid-soluble con-
taminants via breast milk (e.g. 2,3,7,8-TCDD and other
organohalogen compounds). In these cases advice to the
risk manager requires very careful weighing of risks and
beneﬁts.
5.3.5. Advice related to uncertainties and sensitivity
analyses
The nature of the database on which any risk char-
acterisation is based is a key consideration. The range,
relevance and quality of the individual laboratory and
human studies and any information on exposure will all
have a bearing on the conﬁdence with which the risk
characterisation may be applied to humans. Also these
will inﬂuence the degree of uncertainty associated with
any numerical risk characterisation. The narrative that
accompanies the risk characterisation should explain the
strengths and limitations of the hazard characterisation
and intake data.
Uncertainty can be expressed numerically when
intake assessment and hazard characterisation are based
on mathematical calculations. Such numerical analyses
can also be subject to sensitivity analyses, to test the
contribution of diﬀerent aspects of the database to the
overall uncertainty. Sensitivity analyses can be useful in
formulating advice for risk managers, and also in iden-
tifying those parts of the database that would beneﬁt
most from reﬁnement and improvement. In most cases
the risk characterisation of food chemicals involves
threshold eﬀects, the determination of a starting point
for hazard characterisation, such as the NOAEL, and
the application of default uncertainty factors to allow
for aspects such as species diﬀerences and human
variability. Neither the NOAEL, nor the default uncer-
tainty factor is readily amenable to quantitative estima-
tions of uncertainty, or to sensitivity analysis. The
uncertainty that arises from aspects of study design,
such as dose spacing, sample size and biological varia-
bility on the BMD, could be assessed as part of a sensi-
tivity analysis. An assessment of the relative
contributions from various sources of uncertainty is
important in communications with the risk manager.
5.3.5.1. Uncertainties related to exposure/intake data: In
epidemiology studies, the quality of the exposure
assessment is contingent on the method used for quan-
tiﬁcation and the extent to which information on indi-
vidual variation is obtained and utilised. Shortcomings
in the quality of exposure assessment are a common
source of uncertainty in epidemiology-based risk char-
acterisation. Major uncertainties arise if exposures can-
not be assessed over the time period that is relevant for
the speciﬁc outcome. For example, for genotoxic
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exposures that occurred prior to the period of intake
assessment, and any change in intake prior to the
induction of the tumour would inﬂuence the resulting
risk characterisation. In contrast, recent intakes would
normally be important for adverse pregnancy outcomes,
because the critical window for risk is only a few weeks
or months, assuming the compound is not persistent.
However, if the compound is not excreted rapidly it may
continue to pose a risk for future pregnancies, as was
the case for the Yu Cheng incident in Taiwan, and the
Yusho incident in Japan, where cooking oil was
contaminated with PCBs (Schantz, 1996).
Many problems can be overcome if reliable bio-
markers of exposure are available. A recent example is a
risk assessment undertaken in the USA for 2,3,7,8-
TCDD based on a cohort study of workers in 8 chemi-
cal plants (Steenland et al., 2001). Serum 2,3,7,8-TCDD
levels were measured and the workers were followed up
for cancer mortality. Excess lifetime risk through age 75
was calculated using the relative risks associated with
serum 2,3,7,8-TCDD levels that were found in their
dose–response analysis, and applying these to back-
ground US all-cancer mortality rates. The excess risk of
dying of cancer associated with a 2,3,7,8-TCDD intake
of 1.0 pg/kg body weight per day was calculated to be
0.05-0.9% above a background lifetime risk of cancer
death of 12.4% in the USA (Steenland et al., 2001). The
results were consistent with those obtained from
another cohort that had measured serum 2,3,7,8-TCDD
levels (Becher et al., 1998), thereby increasing
conﬁdence in the association.
For compounds for which there is no intake prior to
approval, the uncertainties related to exposure at the
time of approval relate to the validity of the predicted
intake estimations. For this reason, initial assumptions
tend to be conservative and may considerably over-
estimate the actual intake occurring after the substance
is approved.
5.3.5.2. Uncertainties related to hazard characterisation:
The most usual starting point for risk characterisation
of threshold eﬀects based solely on animal data is the
NOAEL. The precision of the NOAEL from an animal
study depends on three variables related to the quality
of the study:
 the sensitivity of the toxicological endpoint and
the methods used to measure it,
 the group size studied, and
 the increment between doses.
The selection of the NOAEL is usually based on a
statistical consideration of the response data in the dif-
ferent treatment groups, although the decision may be
aﬀected by non-statistical considerations, for example
the shape of the dose–response curve at higher dosesand mechanistic data. The validity of the derived
NOAEL in representing adequately the true no-adverse-
eﬀect level (NAEL or threshold) is a function of both
the precision of the NOAEL, determined by the quality
of the data, and also the steepness of the dose-response
relationship. For the same size study and dose spacing,
a steep dose–response curve is usually associated with
narrower conﬁdence intervals of dose estimates corre-
sponding to prescribed eﬀect levels than is a shallow
curve, and this will aﬀect the conﬁdence with which the
experimental NOAEL can be considered to be a reliable
surrogate for the true NAEL. Although the accuracy of
the NOAEL will be greater with a steeper dose–
response relationship, proximity of the NOAEL to an
eﬀect level will also be greater, so that these two will
tend to balance out in relation to the conﬁdence in the
overall risk characterisation. A disadvantage of using
the NOAEL as a starting point for formulating advice
to risk managers is that it is not possible to quantify the
degree of variability and uncertainty that may be
present. All that can be said is that:
 with good toxicological methods, recommended
group sizes and narrow increments between dose
levels the NOAEL should be close to the true
NAEL,
 NOAELs from studies utilising poor tox-
icological methods and/or small group sizes may
be higher than the true NAEL,
 studies using wide increments between dose levels
may produce NOAELs that are considerably
lower than the true NAEL.
In practice, systematic characterisation of these
uncertainties is not routinely undertaken.
The problems of the undeﬁned precision in the
NOAEL are reduced if a mathematical model is ﬁtted to
the dose–response data in order to derive a more robust
starting point, such as the BMD. The selection of the
lower 95% conﬁdence limit on the dose giving a certain
level of response, such as a 5 or 10% response allows for
uncertainties associated with the dose–response data.
However, to date BMDs have not been used greatly for
food chemicals, and where they have been used it has
not been standard practice to provide information on
the associated uncertainty to risk managers as part of
risk characterisation.
The starting point for risk characterisation of non-
threshold eﬀects based solely on animal data is usually a
ﬁxed level of response, within or close to the lower end
of the experimental dose range. The numbers of animals
per dose group, the background rate for the tumour
type under consideration, the animal survival rate at
termination of the experiment and the quality of the
pathological examinations will all have a bearing on the
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lower conﬁdence limit on the level of response, rather
than the actual level of response, allows for some of
these uncertainties. For example, the 95% lower con-
ﬁdence limit on a dose giving a 10% extra risk of
tumours, adjusted for background tumour rate, in an
animal study has been used as the starting point for
dose–response extrapolation (Environmental Protection
Agency, 1999b).
5.3.5.2.1. Uncertainties related to epidemiological
data: The key characteristics for an epidemiological
study to be useful for the purpose of risk characterisa-
tion are valid methods that ensure that bias is small,
precision is high, and exposure is measured accurately.
Because epidemiology combines aspects of human
exposure and hazard characterisation, it is important to
describe the extent to which unmeasured confounders
could be contributing to the reported association, as
well as the magnitude of errors likely in the exposure
estimate.
In epidemiological research, it is common to include
sensitivity analyses that evaluate the impact of various
assumptions, such as model form, linearity of the dose–
response relationship, choice of cut-points for exposure
categorisation, data transformation, the presence of
interactions with other factors (e.g. age, gender, nutri-
tional status, occupational exposures) on the multi-
plicative or additive scale, and inclusion/exclusion of
extreme values.
Unknown confounders may represent an important
source of uncertainty, because by deﬁnition they would
not have been measured in the study, and cannot be
taken into account in data analysis. Both unknown
confounders, and the methods of correction for known
confounders are of greatest concern when the eﬀect size
is modest, e.g. there is less than twofold increase in
relative risk across the full range of exposure within the
study. For strong eﬀects (relative risk >3), unknown
confounders are less likely to explain the association
completely, as they would have to be strongly associated
with both the exposure of interest, and with the out-
come. Unknown confounders are of greater concern
when the health outcome has not been well studied
previously in relation to other possible causes, since
prior investigations would usually have identiﬁed any
strong confounding factors.
Risk characterisation is usually presented as the rela-
tive risk derived from comparing two exposure levels or
diﬀerent exposure conditions, for example duration.
The relative risk is the ratio of the risk (or rate) of an
outcome in the exposed group(s) to the risk (or rate) of
the outcome in the unexposed group in a speciﬁed time
period. For cohort studies, the diﬀerences in actual or
absolute risk or rate, known as the risk diﬀerence or
attributable risk can be estimated, as well as the relative
risk. Since risk characterisation aims to provide riskmanagers with information about additional disease
burden due to a speciﬁc exposure, it is more informative
if relative risks are converted to added risk, i.e. risk dif-
ference or attributable risk. An example of this is given
by the recent meta-analysis of the inﬂuence of the con-
sumption of alcoholic beverages on breast cancer in
women (Collaborative Group on Hormonal Factors in
Breast Cancer, 2002). The relative risk was shown to
increase by 7.1% for each additional 10g per day of
alcohol intake; based on this value and assuming that
the association was causal, it was calculated that alcohol
would be responsible for 4% of the breast cancer in
developed countries.
Although epidemiological studies do not directly
measure lifetime risks in the way that animal studies can,
the lifetime risk can be estimated from less-than-lifetime
studies in humans (Hertz-Picciotto and Holtzman, 1989;
Hertz-Picciotto and Hu, 1994). If age-speciﬁc data on
the background rates of disease are available, any
measure of association obtained from epidemiological
studies with less than lifetime follow-up (i.e. partial
lifetime follow-up) can be used to estimate lifetime risk
(van den Brandt et al., 2002), even if age-speciﬁc relative
risks have not been calculated. However, signiﬁcant
uncertainties may arise in the risk characterisation if
important life-stages are not studied in the epidemiology
investigation. The risk assessment of 2,3,7,8-TCDD
performed by Steenland and colleagues (2001, see
above) was based on data for workers in 8 chemical
plants. An important uncertainty in the risk character-
isation was whether the calculated excess lifetime risk
was appropriate for all life-stages including those not
part of the epidemiological database. Risk characterisa-
tions based on worker cohorts would not be appropriate
for neonates, infants or children, if these groups showed
diﬀerent susceptibilities and dose-response relationships.
5.3.5.2.2. Uncertainties related to human trial data:
Investigations in humans, such as clinical trials, can
provide a good basis for risk characterisation because
exposure can be controlled and precisely deﬁned, and
sensitive methods of response assessment can be used.
However, the applicability of such studies is limited by
obvious and necessary ethical considerations. Uncer-
tainties arise because of the normally limited numbers
of subjects, their restricted age range, the short duration
of administration of the food/chemical, and the short-
term follow-up for eﬀects. Uncertainty factors are nor-
mally applied as part of hazard characterisation, if the
study population is not fully representative of the
exposed population.
Biomarkers of response or of eﬀect, that have been
validated in human trials, and then applied to epide-
miology studies and/or animal studies can greatly
reduce the uncertainties associated with hazard
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5.3.5.2.3. Uncertainties related to animal data:
Although there are uncertainties associated with the use
of data from studies in animals to predict human risk, in
some cases animal data will comprise the majority of
hazard identiﬁcation and characterisation data available
(see Table 1 above). There is a wide consensus in the
scientiﬁc community that data from regulatory toxicol-
ogy studies in animals are valid. This consensus is based
on:
 the general interspecies similarities in physi-
ological and pathological processes, which are
being substantiated by genomic analyses,
 known examples of chemicals (mainly drawn
from the areas of food contaminants and human
drugs) where toxicity in animals and humans is
qualitatively, if not quantitatively similar, and
 the long experience that animal-based risk
assessments have served to protect public health
well to date.
Risk characterisation should aﬃrm the validity of
animal data in advice to both risk managers and other
stakeholders including the public.
When formulating advice to risk managers, the possi-
bility needs to be borne in mind that a hazard relevant
to human health could have been missed if the usual test
species were insensitive. In addition, some acute adverse
eﬀects from foods may manifest themselves in humans
in ways that are not assessable or not readily monitored
in animals, such as allergies or headaches. Identiﬁcation
of an allergenic hazard of new proteins, for example
those introduced via novel foods, relies mainly on theo-
retical considerations by comparing its structure with
those of known human allergens.
In vitro studies using animal and human tissues have
the potential to provide information that can reduce
uncertainty. For example, they can be used to deﬁne
diﬀerences in target organ sensitivity or to provide
metabolic data that can be incorporated into a PBTK
model. The criteria for the use of in vitro data to deﬁne
species diﬀerences in response have been the subject of
an International Programme on Chemical Safety
harmonisation project (2001a).
5.3.5.2.4. Uncertainties related to human variability:
There may be wide interindividual variability in both
the fate of substances in the body and their eﬀects at a
cellular level. In contrast to therapeutic drugs and ther-
apeutic responses, there are very few data that deﬁne the
variability within humans in response to exposure to
potentially toxic chemicals, including those in foods.
Increased susceptibility may arise from diﬀerences in
toxicokinetic or toxicodynamic processes. Incor-
poration of human variability in both toxicokinetics
and toxicodynamics will become increasingly importantas risk assessors move towards the use of CSAFs and
probabilistic approaches to risk characterisation.
Groups in the population may show a heightened
susceptibility because of genetic diﬀerences, pattern of
exposure, life-stage or, in the case of allergy, prior
exposure to the compound. Furthermore people with
chronic diseases/nutritional deﬁciencies and those on
long-term medication may be particularly susceptible.
The diﬀerence between normal human variability and
susceptible groups is that the former is a continuum,
whilst the latter represent subjects who show identiﬁable
characteristics that clearly diﬀerentiate them from the
rest of the population. This can inﬂuence the nature of risk
characterisation; the advice to risk managers may relate to
speciﬁc subgroups with greater susceptibility providing
that the individuals at increased risk can recognise for
themselves that they represent part of the subgroup.
Genetic diversity. It is increasingly recognised that
there is a wide genetic diversity in many of the enzymes
involved in the inactivation and bioactivation of foreign
chemicals, with many of the pathways in humans having
bimodal or trimodal distributions indicative of poly-
morphism. It is probable that cellular processes
involved in the generation of an adverse eﬀect will also
show similar wide inter-individual variability due to
genetic diﬀerences in the nature of the enzyme, the cell
component, or the extent of expression of the cellular
target. Initiatives, such as the SNP Consortium, are
rapidly increasing the number of polymorphisms known
to be present within the human genome. An important
need for future risk assessment will be an understanding
of the potential impact of such genetic diﬀerences on the
activation, inactivation and eﬀects of chemicals in the
human body.
Knowledge on the inﬂuence of human genetic poly-
morphisms on toxic responses is advancing rapidly (see
earlier discussion). There is increasing concern that the
default uncertainty factor may not provide adequate
protection in the case of certain polymorphisms. The
extent to which such polymorphisms erode current
safety margins is not yet clear, but should relevant tox-
icokinetic information be available on diﬀerences
between phenotypes, either for the speciﬁc compound
or for other compounds metabolised by the same
polymorphic enzyme, then this information needs to
be taken into account in deriving a guidance value.
Advice to risk managers usually has to cover the
whole population, although speciﬁc advice may be
given to recognisable subgroups, for example patients
with phenylketonuria are given advice related to the
consumption of aspartame which is a source of phenyl-
alanine. Population-wide screening for genetic poly-
morphisms is not currently conducted and so the
possible inﬂuence of certain genetic polymorphisms may
need to be highlighted as an additional uncertainty in
the advice that is given to the risk manager.1246 A.G. Renwick et al. / Food and Chemical Toxicology 41 (2003) 1211–1271
Intolerance including allergy. Under some circum-
stances the proposed guidance value(s) will not be pro-
tective of all recognisable subgroups within the
population. Guidance values cannot allow for individuals
who show extreme sensitivity, for example due to allergy to
a food constituent. For such individuals, the only way of
avoiding risk may be to avoid exposure. Under such cir-
cumstances the advice to risk managers should discuss the
need to include adequate product labelling.
Life-stage. For some life-stages, e.g. the embryo and
foetus, selection of the critical eﬀect will have included
consideration of sensitivity of that life-stage during
hazard identiﬁcation, and hence the proposed guidance
value should provide adequate protection. Because of
the lack of maturity of organs and metabolic systems in
very young infants, the ADI is considered not to be
applicable to infants under the age of 12 weeks (Inter-
national Life Sciences Institute, 1992; Scientiﬁc Com-
mittee on Food, 1998). Available data indicate that
neonates have reduced ability to metabolise foreign
compounds, e.g. via CYP1A2 oxidation (Dorne et al.,
2001a) and glucuronidation (Dorne et al., 2001b). Such
variability should be taken into account in risk char-
acterisation of chemicals that pass into breast milk or
may be present in infant formulae. In contrast to neo-
nates, most other groups of the population, including
older infants and children, would be adequately covered
by the default toxicokinetic uncertainty factors applied
in the risk characterisation process for threshold
toxicants (World Health Organization, 1999).
Current hazard identiﬁcation and characterisation
approaches may not adequately test for the possibly
greater sensitivity of neonatal and pre-weaning infants
with respect to contaminants in infant formula. There
are no standard protocols for tests to assess the safety of
chemicals proposed for use in, or present as a con-
taminant in, infant formula. In conventional reproduc-
tion studies, the newborn and pre-weaning animals can
receive chemicals via maternal milk, but this will reﬂect
maternal metabolism and does not mimic the mode of
delivery to infants ingesting a chemical in infant for-
mula directly. This uncertainty may be most relevant to
eﬀects such as neurobehavioural changes because cer-
tain aspects of brain development take place postnatally
in rodents, but occur prenatally in humans. In addition,
human brain development also extends over a much
longer period of time postnatally as compared to
rodents. Uncertainty arising from diﬀerences in the
nature of the material delivered to the neonatal animal
can be overcome by direct administration of the chemi-
cal by oral gavage to pre-weaning animals, but this can
present practical diﬃculties. A number of studies of this
nature have been performed to investigate develop-
mental neurotoxicity, and the limited results available to
date suggest that the current testing strategies are
adequate to protect the developing foetus and infant.5.3.6. Advice relating to very low risks for irreversible
hazards such as cancer
Cancer is the hazard that raises the most public concern,
but neither epidemiological studies nor animal studies are
capable of directly measuring a level of risk suﬃciently low
that it could be described as negligible, such as a lifetime
risk of 1 in 106. In consequence, risk estimates for cancer
are perhaps the most controversial issue in discussions on
uncertainties in risk characterisation.
Few epidemiological studies are capable of identifying
risk increases of the order of 1 in a 1000, much less 1 in
a million. For example, it was estimated that when the
background risk (cumulative probability) of developing
lung cancer in United States men over age 15 is 0.06, an
occupational study of 4343 workers would be needed to
detect an excess risk of 1 in a 100 and a study of 396
million workers would be needed to detect an excess risk
of 1 in a million (Stayner et al., 1999). Thus, epidemio-
logical studies have limited power to detect levels of risk
that are of concern to regulators and the public.
In animal carcinogenicity studies, the number of ani-
mals per dose per sex is usually no more than 50 and a
risk-speciﬁc dose corresponding to a maximum risk of 1
in a million is on average 380,000 times below the max-
imum tolerated dose given in the animal study (Gold et
al., 1992). Thus, the actual risk at low exposures cannot
be observed in the animal study and has to be derived
by extrapolation which, as discussed in Section 5.2.5.3.,
introduces considerable uncertainty around the extra-
polated value.
It is important that the advice to risk managers pro-
vides a narrative description of the nature of the evi-
dence and the conﬁdence intervals associated with the
risk at deﬁned human exposures or the exposures
calculated to be associated with deﬁned risks.
5.3.7. Advice when data are sparse but indicate serious
hazard
Sometimes it may not be possible to carry out a
science-based risk assessment, either because data of the
required type and quality are not available, or because
the current state of the science precludes the possibility
of gathering the necessary data. In such circumstances,
it is the task of the risk assessor to indicate clearly to the
risk manager if there is the possibility of serious harmful
eﬀects on health. The risk manager then has to decide
whether to adopt ‘‘the precautionary principle’’ and put
in place appropriate risk management measures to
ensure health protection.
Regarding application of the precautionary principle,
the Commission of the European Communities (2000)
has stated:
‘‘The precautionary principle, which is essentially
used by decision-makers in the management of risk,
should not be confused with the element of caution that
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Recourse to the precautionary principle presupposes
that potentially dangerous eﬀects deriving from a phe-
nomenon, product or process, have been identiﬁed, and
that scientiﬁc evaluation does not allow the risk to be
determined with suﬃcient certainty.
The implementation of an approach based on the
precautionary principle should start with a scientiﬁc
evaluation, as complete as possible, and where possible,
identifying at each stage the degree of scientiﬁc uncer-
tainty. Maintenance of the measures depends on the
development of scientiﬁc knowledge in the light of
which they should be re-evaluated’’.
It is important that the precautionary principle, which
is adopted in the absence of data on intake and/or
hazard, is not confused with the conservative/cautious
approaches that are adopted as a normal part of risk
characterisation and which have been discussed above.
5.4. Special considerations for particular food categories
The principles of risk characterisation for chemicals in
food and diet have been extensively discussed in
Sections 5.1.–5.3. In this section the applicability of
these principles to the diﬀerent food categories given in
Section 2.4 is discussed and any special considerations
highlighted.
Data from toxicological studies (in vitro and in
laboratory animals) and from human studies (absorp-
tion, metabolism, excretion, tolerance trials and epide-
miology) can all contribute to risk characterisation of
chemicals in any food category. Nevertheless, it is
recognised that the toxicological approach particularly
lends itself to risk characterisation of low molecular
weight chemicals and non-nutrients, while the epide-
miological approach may be better suited for the risk
characterisations of micronutrients, supplements, macro-
nutrients, and whole foods.
The basis for risk characterisation is common to all
food categories in that there has to be adequate char-
acterisation of any hazard and suﬃcient dose-response
data to establish intakes that would not result in an
adverse eﬀect, together with adequate exposure data.
The main diﬀerence between the various food categories
is the likelihood of developing a numerical, health-based
guidance value and the methods used to convert the
starting point (NOAEL, BMD, etc.) into a guidance
value for adverse eﬀects with an assumed threshold.
5.4.1. Deﬁned single chemical entities of low molecular
weight
This category includes low molecular weight sub-
stances deliberately added to food, such as additives and
ﬂavourings, substances present in food as residues, such
as pesticides, veterinary medicines, migrants from food
contact materials and processing aids, and substances
present in food as inadvertent (and often unavoidable)contaminants, such as natural toxicants, inorganic and
organic environmental chemicals and chemicals gener-
ated by processes such as frying. Toxicological studies
play a prime role in risk characterisation of low mole-
cular weight chemicals. A proposed decision tree on the
special considerations for risk characterisation of low
molecular weight chemicals is provided in Fig. 6.
5.4.1.1. Hazard identification and hazard characterisa-
tion aspects: There are well-established regulatory
requirements on the range of in vitro and in vivo
laboratory animal studies that should be undertaken
prior to approval, together with guidelines on protocols
for conducting such studies, for deﬁned single chemical
entities of low molecular weight such as additives, ﬂa-
vourings, substances used in food contact materials,
pesticides and veterinary medicines. Such studies are
designed to identify the hazards associated with all life
stages. Information on human metabolism and from
human trials and/or epidemiological studies may also be
available, but it is often the case that only data from in
vitro and animal toxicity studies will be available for
deﬁned single chemical entities of low molecular weight,
particularly where pre-marketing approval is being
sought. For such compounds, regulatory bodies may
require gaps in the database to be ﬁlled before approval.
Other low molecular weight compounds, such as natural
toxicants (e.g. mycotoxins, phytoestrogens, glycoalk-
aloids) and organic and inorganic food contaminants
(e.g. dioxins, PCBs, heavy metals) are also amenable to
study by in vitro, animal and human approaches, but
the availability of animal and human data varies con-
siderably. Thus, there may be considerable uncertainties
in the risk characterisation of contaminants due to gaps
in the database.
It has to be acknowledged that the practical and ethi-
cal limitations on the number of animals and species
that can be studied in hazard characterisation of low
molecular weight chemicals contribute to uncertainty
about whether all possible eﬀects have been detected.
There are also uncertainties regarding qualitative and
quantitative interspecies diﬀerences which need to be
acknowledged in any extrapolations that are made
between animals and humans. These should be dis-
cussed in the advice to the risk manager.
5.4.1.2. Exposure assessment aspects: The methods used
to make exposure assessments for low molecular weight
chemicals and the matching of the exposure assessment
with the hazard characterisation have been discussed
earlier (see Sections 5.2.2.1. and 5.2.2.2.). The relation-
ship between exposures used in animal toxicity studies
and those encountered by humans is an important issue
for low molecular weight chemicals. In animal studies the
doses and duration of exposure are clearly deﬁned and
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higher than anticipated human exposure. This is done in
order to enhance hazard identiﬁcation, however it com-
plicates the interpretation of the signiﬁcance of animal
ﬁndings for human health, particularly where they
occur only at high doses. There are, for example, con-
siderable uncertainties surrounding extrapolation from
high to low doses, especially in cases where protective
metabolic pathways may have been saturated. There
may also be uncertainties if the route (e.g. non-oralrather than oral) or mode of administration (e.g. gavage
rather than diet) in the animal studies diﬀers from that
in humans. These situations have been discussed in
Section 5.2.4. These uncertainties need to be highlighted
in the risk characterisation when trying to match actual
or predicted human exposure to that for which hazard
characterisation data are available.
Information on adverse eﬀects in humans may be
available from the literature on human poisoning cases,Fig. 6. Decision tree outlining the special considerations for risk characterisation of low molecular weight chemicals. (This is not intended to cover
all eventualities but to indicate some matters of particular concern; it should be recognised that this is an iterative process that, depending on the
availability of data in appropriate categories, may need to be revisited.)A.G. Renwick et al. / Food and Chemical Toxicology 41 (2003) 1211–1271 1249
but the quantiﬁcation of exposure may be undetermined
or unreliable. In epidemiological studies, if exposure
cannot be measured in individuals directly (e.g. by
measuring quantitative biomarkers of exposure), reli-
able intake estimations can only be made if extensive
data are available on the diet consumed and the actual
concentrations of the low molecular weight chemical in
all the relevant foods.
5.4.1.3. Nature of the guidance values and other advice to
risk managers: For low molecular weight chemicals that
require pre-marketing approval, the basis for the initial
risk characterisation is usually a health-based guidance
value with which predicted exposures can be compared.
The derivation of guidance values has been common
practice since the early 1960s for the safety assessment
of food additives and contaminants by the JECFA and
is widely used by other regulatory and advisory bodies
throughout the world, including the FAO/WHO Joint
Meeting on Pesticide Residues (JMPR), the USA FDA
and the EC SCF (see: International Life Sciences Insti-
tute, 2000b). As described earlier, the starting point for
derivation of a health-based guidance value is usually
the NOAEL. Default uncertainty factors or CSAFs are
then applied to the NOAEL to derive a guidance value
(see Sections 5.2.5.2. and 5.3.1.2.). The use of default
uncertainty factors or CSAFs results in a deterministic
estimate that does not indicate the uncertainty asso-
ciated with the resulting guidance value. In most situa-
tions this is not a problem since the chemical is only
approved for marketing under deﬁned use conditions
(e.g. types of food, crops, maximum levels of use, pre-
scribed veterinary product withdrawal period, etc.)
where it can be shown that the health-based guidance
value is unlikely to be exceeded. However, even for
chemicals requiring pre-marketing approval, their
intakes after marketing may exceed the guidance value,
albeit rarely on a regular basis. In such cases, the nature
of the advice to risk managers about the possible health
implications of exceeding the guidance value requires
careful consideration and discussion (see Section 5.3.4.).
The uncertainty factors chosen for derivation of a
guidance value also require discussion in the risk char-
acterisation. Reviews of uncertainty factors (Dourson
and Stara, 1983; Calabrese, 1985; Beck et al., 1993;
Dourson et al., 1996; Renwick and Lazarus, 1998;
Dorne et al., 2001a; Walton et al., 2001) have concluded
that use of the 1010 (100-fold) default factor to
account for interspecies and inter-individual diﬀerences
is appropriate in the absence of chemical-speciﬁc data,
but that diﬀerent situations could arise where these
default factors would be either excessive or inadequate.
For instance, there may be individuals with high inter-
nal exposure to a food chemical because of either
enhanced absorption or reduced elimination. If this is
combined with enhanced sensitivity due to either greaterbioactivation or reduced cytoprotection, then those
individuals might not be adequately covered by the
default uncertainty factor of 10 for inter-individual dif-
ferences. On the other hand, it may not be necessary to
use an uncertainty factor greater than 1 for human
variability when the hazard characterisation is based on
a large study in humans, which includes a suﬃcient
number of individuals from the age ranges that will be
consuming the substance to cover possible diﬀerences in
sensitivity. The use of additional uncertainty factors to
compensate for deﬁciencies in the database has been
discussed earlier (see Section 5.1.1.). In risk character-
isation, the reasons for deviations from default values
and the use of additional uncertainty factors should be
fully discussed.
For low molecular weight chemicals to which there is
only intermittent exposure and which do not bioaccu-
mulate, a guidance value based on lifetime exposure
may be overly conservative. If the risk characterisation
shows that intermittent intakes, on the days that they
occur, exceed the guidance value, then consideration
must be given to the minimum duration of exposure
necessary to induce the critical toxic eﬀect on which the
guidance value is based and the dose at which acute
eﬀects from exposure during one day may occur (see
Section 5.3.3.1. for discussion on ARfD). It may be that
further toxicological studies using diﬀerent durations of
dosing will be needed to provide a more secure basis for
the risk characterisation.
5.4.1.4. Risk characterisation based on margin of safety:
Alternative approaches used for deﬁned single chemical
entities of low molecular weight are the ‘‘margin of
safety’’ (MOS) or ‘‘margin of exposure’’ (MOE)
approaches. The MOS is the ratio between the NOAEL
(from animal or human studies) and the actual amount
of human intake/exposure. The MOE is the ratio
between the NOAEL and the estimated amount of
human intake/exposure. These approaches are normally
used when limited toxicological data or human data
exist but the hazard identiﬁcation and hazard char-
acterisation data are insuﬃcient to set a health-based
guidance value. Thus it is used most often for natural
toxicants and other inadvertent food contaminants for
which the hazard database may be sparse. Assessment
of the adequacy of an MOS or MOE is done on a case-
by-case basis. The acceptability of an MOS or MOE
depends on its magnitude and is ultimately a risk man-
agement decision. To aid that decision, the nature of the
toxicity involved and the uncertainties, from both the
toxicological and exposure perspectives, involved in the
derivation of the MOS or MOE should be clearly
described in the risk characterisation. In some cases the
data may even be insuﬃcient to establish a NOAEL,
but do indicate a LOAEL. Assessment of the adequacy
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estimated exposures requires the same case-by-case
considerations as the MOS/MOE.
In the case of some additives with good toxicity data-
bases, but which do not show adverse eﬀects even at the
highest doses tested, the advice to risk managers may be
that normal uses of such a substance (according to good
manufacturing practice) would not represent a risk and
that a numerical guidance value is not necessary. Such
substances may be allocated an ‘‘ADI not speciﬁed’’ by
JECFA (World Health Organization, 1987). Examples
include modiﬁed starches and gums used as thickeners
and stabilisers. It should be noted that ‘‘ADI not speci-
ﬁed’’ is sometimes misinterpreted as meaning that an
ADI had not been allocated because of toxicological
concerns. An ‘‘ADI not speciﬁed’’ is only allocated
when there are suﬃcient data to conclude there is no
risk to be expected.
5.4.2. Micronutrients
Micronutrients comprise vitamins and minerals that
are essential for normal growth, and physiological and
biochemical functioning. The methods used for risk
characterisation of low molecular weight chemicals are
applicable in many respects to micronutrients, which are
also deﬁned chemical entities of low molecular weight.
However there are some unique aspects, the most
obvious ones being that some intake is essential for life
and the margins between essential intakes and toxic
intakes may be small, as is the case, for example, with
vitamin A or sodium. A proposed decision tree on the
special considerations for risk characterisation of
micronutrients is provided in Fig. 7.
5.4.2.1. Hazard identification and hazard characterisa-
tion aspects: There may be considerable prior knowl-
edge on micronutrients, concerning chemical
characterisation, absorption, distribution, excretion and
metabolism, and physiological eﬀects including beneﬁts.
However, hazard identiﬁcation and hazard character-
isation data are often deﬁcient, which severely hampers
the risk characterisation. Because of the importance of
micronutrients for human health and nutrition, human
trials and epidemiological data are much more likely to
be available for micronutrients, including micro-
nutrients administered as drugs, than for other types of
low molecular weight chemical. However, such studies
generally do not utilise high doses so, while they give
clear indications of the doses that are nutritionally ade-
quate or nutritionally inadequate, they provide only
limited dose-response data and may provide little
insight into whether higher doses cause adverse eﬀects.
This gap in essential knowledge for the risk character-
isation cannot always be ﬁlled by data from laboratory
animals. For many micronutrients there are only very
limited hazard identiﬁcation and hazard characterisa-
tion data from studies using animal models (e.g. vitaminB12). In some cases it is known that some animal models
are inappropriate for human risk assessment, for
instance rodents do not absorb beta-carotene to the
same extent as humans.
Since both deﬁciency and excess of a micronutrient
can cause health problems, hazard characterisation
requires the establishing of two separate dose-response
curves. The ﬁrst one is related to the intake required to
satisfy minimal nutritional needs, in which the low end
of the dose-response curve describes adverse eﬀects
from no intake or low intakes. Advice on this aspect
is usually provided by specialists in nutrition. The
second type of dose-response curve describes any
adverse eﬀects from intakes above those needed to
satisfy nutritional needs. Advice on this aspect is
usually provided by nutritionists and toxicologists
working together.
Where animal studies are conducted for hazard iden-
tiﬁcation, the generally narrow margin between the
essential intake and a toxic intake has implications for
dose setting. To properly explore a narrow margin, the
number of doses used in a toxicity study may need to be
increased and/or the range spanned by the doses may be
smaller than in a conventional toxicity study for low
molecular weight chemicals.
In laboratory studies attention must also be paid to
possible interactions between micronutrients, especially
minerals when these are given at levels in the diet that
may saturate common transport and metabolic
mechanisms. In some cases useful knowledge about the
potential toxicity of micronutrients has been derived
from ﬁeld observations following poisoning or over-
supplementation of farm animals (e.g. with molybde-
num or selenium).
A further unique aspect of hazard identiﬁcation and
hazard characterisation of micronutrients is that not
only does the potential toxicity of the nutrient itself
need to be considered but also, for some micronutrients
used for food fortiﬁcation or in dietary supplements, the
potential toxicity of the chemical form in which it is
consumed should be considered. Micronutrients may be
added or used as such, or as derivatives such as salts,
enriched yeasts, pro-vitamins, acetylated amino acids,
etc. Not only does the inherent toxicity of the chemical
form of a micronutrient need to be considered, but also
the bioavailability of the nutrient from the chemical
form in which it is consumed. Either low or high bioa-
vailability of a micronutrient from its source (compared
with its bioavailability when naturally present in food)
may aﬀect the risk characterisation.
The mode of intake may also trigger the requirement
for a particular type of risk characterisation. For
example, risk characterisation of dietary supplements,
taken as bolus doses in the form of tablets or capsules,
may need to consider acute toxicity (see Section 5.3.3.1.
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5.4.2.2. Exposure assessment aspects: Given the often
small margin between essential intakes and toxic intakes
of micronutrients, it is particularly important that
intakes from all sources are taken into account. Micro-
nutrients are found in foods, fortiﬁed foods, dietary
supplements and drugs. Exposure information on
micronutrients in whole foods is readily available from
food composition tables that are traditionally focused
on micro- and macronutrients. Information on levels of
micronutrients in processed foods, the doses available inthe form of dietary supplements (and who is consuming
them) may be less readily available. Biomarkers of
exposure, such as blood concentrations of nutrients may
be valuable in determining total intakes.
5.4.2.3. Nature of the guidance values and other advice to
risk managers: Since both deﬁciency and excess of a
micronutrient can cause health problems, two guidance
values for a micronutrient may be expressed. One type
of guidance value refers to the recommended dailyFig. 7. Decision tree outlining the special considerations for risk characterisation of micronutrients. The parenthetical comments in the legend to
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amount below which there is risk of deﬁciency or sub-
optimal functioning, such as the Population Reference
Intakes (PRIs) for micronutrients elaborated by the
EC’s Scientiﬁc Committee for Food (1993), or the
Dietary Reference Intakes (DRIs) elaborated by the
USA and Canada (Institute of Medicine, 1997). The
other type of guidance value is a UL, which is deﬁned
as the maximum level of daily chronic intake of a
nutrient from all sources judged to be unlikely to pose
a risk of adverse health eﬀects to humans (Scientiﬁc
Committee on Food, 2000c). The setting of a UL
includes consideration of what is physiologically toler-
able as well as consideration of the probability of an
adverse eﬀect occurring at some speciﬁed level of
exposure.
If UL guidance values for micronutrients are based on
animal studies, it is often not possible to use the usual
default uncertainty factor of 100 that is applied to
experimental NOAELs in the case of low molecular
weight chemicals, despite the fact that the same uncer-
tainties are inherent in the use of such data for risk
characterisation. While it may be possible to administer
relatively high doses to animals for the purposes of
hazard identiﬁcation and characterisation, use of the
usual default uncertainty factors could result in a UL
below the recommended daily amount for nutritional
needs. For this reason, margins of safety of between 1
and 10 are often considered appropriate; the size of the
factor chosen depends on the quality of the database and
whether the NOAEL is from human or animal studies.
Interpretation of the adequacy of the margin of safety
requires expert judgement on a case-by-case basis, taking
into account the nature of the material, the potential
hazard, if any, at high doses, and the highest potential
exposure. In using low uncertainty factors, it is implicit
that the risk characterisation may underestimate the true
risk and this should be pointed out in the advice to risk
managers. When margins of safety are small, the advice
to risk managers should include a discussion of the nature
of the adverse eﬀect(s) and the dose-response, together
with any uncertainties in the exposure estimates.
It should also be noted that both the lower and upper
guidance values for micronutrients may diﬀer for dif-
ferent human subpopulations, such as infants, children,
pregnant women and the elderly. This is because of their
diﬀering physiological states and therefore diﬀering
nutritional requirements and susceptibilities to adverse
eﬀects at diﬀerent life stages. Thus, the risk character-
isation may need to consider a number of PRI/DRI and
UL values for various population subgroups and ensure
that the exposure estimate for the relevant subgroup is
integrated with the appropriate guidance values.
A challenge for the interpretation of observational
epidemiology studies is that the high correlation among
micronutrients in the human diet makes it diﬃcult to
distinguish eﬀects of speciﬁc vitamins or minerals. Thisproblem arises because some nutrients cluster within
foods or food groups. A large epidemiological study
may be able to disentangle these factors, if the corre-
lation between nutrients is not too high. However, sta-
tistical collinearity may represent an intractable
problem. This problem has sometimes been addressed
by examining food groups, rather than micronutrients;
but this alters the question addressed, and does not
provide risk characterisation for an individual nutrient.
5.4.3. Macronutrients
Macronutrients include dietary lipids, proteins and
carbohydrates, their sub-components and macro-
nutrient substitutes. The term ‘macronutrients’ does not
refer to molecular size but derives from the fact that
they are present in the food/diet in substantial quan-
tities. They may be currently available macronutrients
or new types of macronutrient (see Section 5.4.4. below
for comment on scope with respect to novel foods). A
proposed decision tree on the special considerations for
risk characterisation of macronutrients is provided in
Fig. 8.
5.4.3.1. Hazard identification and hazard character-
isation aspects: In the hazard characterisation of
macronutrients consideration needs to be given to
tolerance, toxicological potential and nutritional impact.
As with micronutrients, there may be considerable
prior knowledge about macronutrients, particularly
concerning chemical characterisation, absorption, dis-
tribution, excretion and metabolism and nutritional
eﬀects. Human studies play a prime role in risk char-
acterisation of macronutrients. Local eﬀects on the gut,
such as changes in the microﬂora, and on the absorp-
tion of other nutrients may be important for hazard
characterisation.
A primary consideration is whether the macronutrient
can be shown to be equivalent to a traditional food
counterpart. If this is the case, prior knowledge and
chemical characterisation may obviate the need for ani-
mal or human hazard characterisation studies. For
example, a new type of fat replacer comprising micro-
particulated egg and milk proteins was approved for use
by the UK Advisory Committee on Novel Foods and
Processes (ACNFP), based on existing knowledge about
the raw materials and the production process (Advisory
Committee on Novel Foods and Processes, 1989). Even
in cases where there is a close traditional counterpart,
consideration may need to be given to the presence of
new toxicants or changed levels of existing toxicants.
Hazard identiﬁcation and hazard characterisation
using animal studies may not be possible because addi-
tion of bulk macroingredients to experimental diets, in
amounts that are exaggerated relative to the human diet,
may render them unpalatable and/or cause nutritional
imbalance. Under these circumstances, attribution ofA.G. Renwick et al. / Food and Chemical Toxicology 41 (2003) 1211–1271 1253
cause to any adverse eﬀect observed becomes diﬃcult,
as does interpretation of its signiﬁcance for human
health. The issue of the utility of animal studies for
macroingredients has been considered in some detail in
an earlier FOSIE publication (Dybing et al., 2002).
Tests for low molecular weight chemicals deliberately
use high doses to compensate for a limited number of
test animals: the dilemma for macronutrients could
perhaps be partly mitigated by the use of larger num-
bers of animals to detect low incidence eﬀects, but this
would have animal welfare implications and may give
only a small information gain at a high cost. In the
absence of appropriate human data, a better approach
might be the selection of an animal model that had
similar gastrointestinal physiology to humans (e.g.the minipig), thereby reducing the uncertainties of
interspecies extrapolation.
Because of these and other considerations, the role of
human trials and observational studies are widely
viewed as particularly important for macronutrients.
However, it should be stressed that the utility of human
trials is not primarily for establishing safety but for
investigating aspects such as absorption, metabolism
and excretion, nutritional issues and tolerance. Human
trials should be conducted only when other considera-
tions have given suﬃcient reassurance that untoward
reactions are unlikely. In both animal and human stud-
ies on bulk components, careful consideration needs to be
given to ways of obtaining as much information as pos-
sible, what endpoints and biomarkers (see Section 5.2.4.)Fig. 8. Decision tree outlining the special considerations for risk characterisation of macronutrients. The parenthetical comments in the legend to
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might be used and how any measurements are to be
interpreted in the risk characterisation. Apart from dif-
ferences in metabolism by the gut ﬂora, major species
diﬀerences in the handling of macroingredients (bioki-
netics) are not expected, because they would be meta-
bolised by the constitutive enzymes of intermediary
metabolism and not by enzymes which can show wide
interspecies diﬀerences, such as the cytochrome P450s.
However, the suitability of the animal model needs to be
considered; for example, rats do not handle fat in the
same way as humans. Thus, the possibility of inter-
species diﬀerences and human variability in the relevant
metabolising enzymes need to be examined in each case
in order to predict any likely exceptions.
Adverse eﬀects in humans may be identiﬁed from the
results of epidemiological studies. Human trials can also
be used, in conjunction with prior knowledge on possi-
ble adverse eﬀects, to look at relevant health endpoints
in order to provide conﬁrmation of the absence of
adverse eﬀects. For example, biomarkers of risk factors
for coronary heart disease have been followed when fats
are administered, or changes in serum beta-carotene
levels with sustained consumption of phytosterol-enri-
ched foods (Scientiﬁc Committee on Food, 2002a). In
vitro or in silico studies can provide information on
digestibility of macronutrients and assess the likely
impact on gut microﬂora. In the case of proteins, parti-
cularly those resistant to pepsin digestion, ultimately
only human data will establish any potential to cause
allergy. However, in the case of new types of proteins, a
theoretical consideration of sequence homologies and/
or structural similarities to known allergens can be
made, which may provide an alert about the possibility
of allergic reactions.
5.4.3.2. Exposure assessment aspects: As with micro-
nutrients, exposure information on macronutrients in
existing whole foods is readily available from food
composition tables. Information on levels of macro-
nutrients in processed foods is also frequently available
from nutritional labelling. In the case of a new type of
macronutrient, exposure will need to be estimated from
proposed uses, in which case, the exposure considera-
tions for future use/exposure discussed earlier will
apply, see Section 5.2.2.2 and Table 1. Accurate predic-
tion of the likely commercial success, and therefore
intakes, of a new type of macroingredient is particularly
diﬃcult and post-launch monitoring can play an
important role in checking whether the risk character-
isation was appropriate to actual exposure. New types
of macroingredients may also be incorporated into a
wider variety of foods after approval than those origin-
ally anticipated. In such cases aggregate risks may need
to be assessed (see Section 5.3.2.3.) as has been done, for
example, for multiple dietary sources of phytosterol
esters (Scientiﬁc Committee on Food, 2002a).5.4.3.3. Nature of the guidance values and other advice to
risk managers: Macronutrients are similar to micro-
nutrients in that there may need to be more than one
guidance value. One would be based on the minimal
requirements to meet nutritional needs, for example,
guidance values on protein, lipid and carbohydrate
contents of infant formula to meet growing infants’
nutritional requirements (Scientiﬁc Committee for
Food, 1984). The other type of guidance value would be
analogous to a UL and based on knowledge of any
adverse eﬀects at high intakes, such as a recommended
upper limit for the daily intake of saturated fats in rela-
tion to the risk of cardiovascular disease, or an upper
limit for the daily intake of alcohol in relation to the
risk of breast or other cancers.
In some cases, a guidance value is not established, for
example when the substance is a close analogue of a
natural macronutrient and/or appropriately performed
studies have not identiﬁed an adverse eﬀect. Under such
circumstances, a margin of safety approach may be
preferable, since it is not possible in animal studies to
exaggerate the dosage suﬃciently to accommodate the
usual uncertainty factors. Comparison of the potential
human intake with experimental data showing no
adverse eﬀects will give the margin of safety. For essen-
tially ‘‘non-toxic’’ macronutrients the experimental data
may not show any adverse eﬀects at the doses tested, in
which case the calculated margin of safety can be
regarded as the minimum likely value. As discussed
earlier, see Section 5.4.2.3., interpretation of the ade-
quacy of the margin of safety requires expert judgement
on a case-by-case basis. Alternatively, the advice to risk
managers may be that normal uses of the macronutrient
would not represent a risk and that a numerical
guidance value is not necessary.
5.4.4. Whole foods
Whole foods may be deﬁned as single foods, which
are usually complex mixtures that may or may not be
modiﬁed by processing. They may form a high propor-
tion of the diet for some consumers, with possible
undesirable nutritional impacts, depending on amounts
consumed. Their metabolism is complex and some
interactions with other dietary components can be
expected. They may be foods currently on the market or
new types of foods not yet on the market for which
approval is being sought under novel foods legislation.
A proposed decision tree for assessing the special data
needs for risk characterisation of whole foods is provided
in Fig. 9.
5.4.4.1. Hazard identification and hazard characterisa-
tion aspects: Whole foods, like macronutrients, need
consideration of the matter of tolerance, toxicological
potential and nutritional impact during the hazard
characterisation. As part of problem formulation, itA.G. Renwick et al. / Food and Chemical Toxicology 41 (2003) 1211–1271 1255
should be considered whether assessment of the whole
food could be done by breaking it down into its indivi-
dual components, since there is likely to be prior
knowledge on many of the components. Hazard char-
acterisation can then proceed by exclusion of tradition-
ally safe components from further consideration (unless
present in higher amounts than in traditional foods) and
focusing on the remaining component(s). If the remainingcomponents fall into other food categories, i.e. low
molecular weight chemicals, micronutrients, or macro-
nutrients, and are amenable to separate evaluation, then
the hazard characterisation should be appropriate to the
relevant food category. A fractional approach to testing
may be possible, with the advantage of better identify-
ing any hazardous components, but there are as yet no
formal guidelines for such an approach. Even in casesFig. 9. Decision tree outlining the special considerations for risk characterisation of whole foods. The parenthetical comments in the legend to Fig. 6
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where there is a close traditional counterpart, con-
sideration may need to be given to the presence of new
toxicants or changed levels of existing toxicants.
Part of the hazard characterisation may need to focus
on the potential for interactions of substances within the
food. One such example would be the potential of the
amino acid asparagine in potatoes to interact with other
naturally-occurring components to form acrylamide
when the potato is cooked at high temperatures such as
in frying (Mottram et al., 2002). The hazard character-
isation may also need to consider interactions between
the whole food and other dietary components. For
example, whole foods may interact with mineral micro-
nutrients in other foods, altering the bioavailability of
the mineral, as in the case of ﬁbrous foods reducing
mineral bioavailability, or orange juice enhancing the
absorption of iron. Hazard identiﬁcation and char-
acterisation may also need to consider the presence of
natural toxicants.
Methods for hazard characterisation of new types of
foods have been discussed in national and international
fora (Advisory Committee on Novel Foods and Pro-
cesses, 1991, 1992; Health Canada, 1994; Scientiﬁc
Committee for Food, 1997; Life Sciences Research
Oﬃce, 1999), but as yet there is no world-wide con-
sensus on the most appropriate approaches, other than
to recommend that a case-by-case consideration is nee-
ded. The initial approach for new types of foods
requires consideration of the extent to which the novel
food diﬀers from any traditional counterpart, or other
related products, and hence whether it can be con-
sidered as safe as traditional counterparts/related pro-
ducts. Where a food is deemed novel because it has not
hitherto been consumed in EU countries, there may be
relevant hazard characterisation data from other areas
of the world where the food has been consumed.
As for macronutrients, hazard identiﬁcation and
hazard characterisation using animal studies may not be
possible because addition of bulk foods to experimental
diets of rodents, in amounts that are exaggerated rela-
tive to the human diet, may cause problems. Other ani-
mal models with gastrointestinal physiology closer to
that of humans may need to be considered.
Human trials on whole foods, including novel foods,
will only be performed when no serious adverse eﬀects
are expected. Trials may be blinded or unblinded,
involve cross-over, in which the eﬀects of the food are
compared with a conventional counterpart in the same
individuals, or randomised controlled trials. Advantages
of randomised controlled trials are that the exposure
can be well characterised and the substance can be
administered in a blinded way, in order to remove par-
ticipant and observer bias. Additionally, random allo-
cation to exposure groups reduces the probability of
confounding, particularly in large trials. Such studies
may be particularly suitable for the pre-launchassessment of novel foods. Post-launch monitoring can
be used to survey the occurrence of unexpected hazards
associated with new products or ingredients.
As for macronutrients, observational epidemiological
data may also be available, identifying adverse eﬀects,
including allergic reactions. For novel foods that con-
tain proteins, in vitro digestibility and sequence homol-
ogy and/or structural similarity to known allergens may
provide clues about possible adverse eﬀects.
5.4.4.2. Exposure assessment aspects: Exposure infor-
mation on whole foods currently on the market will be
available from dietary surveys. Where the food is novel,
exposure will need to be estimated from proposed uses,
in which case, the exposure considerations for future
use/exposure discussed earlier will apply, see Section
5.2.2.2 and Table 1. As for novel macronutrients, accu-
rate prediction of the likely commercial success, and
therefore intakes, of a novel food is particularly diﬃcult
and here post-launch monitoring can play an important
role in checking whether the risk characterisation was
appropriate to the exposure.
5.4.4.3. Nature of the guidance values and other advice to
risk managers: Advice on whole foods does not usually
involve guidance values, but instead takes the form of
recommendations, which may include a quantitative
element. For example, advice may be to increase or
decrease daily intakes (e.g. to decrease the consumption
of red meat). For novel foods, the advice to risk man-
agers is usually whether to approve its use or not, but
may also include advice about recommended maximum
daily intakes.
The advice to risk managers may need to include an
explanation of why higher margins of safety are used for
low molecular weight chemicals, whereas for whole
foods and novel foods margins are lower between the
amounts normally/likely to be consumed and the
amounts which may have been tested and found to be
without eﬀects in animal or human trials. Acceptance or
not of these lower margins of safety is a risk management
decision, but historically acceptance of lower margins of
safety has been common for whole foods (as well as for
nutrients and micronutrients). Both whole foods and
novel foods may also have known or claimed beneﬁts and
these will need to be taken into account by risk managers
in reaching a decision on the balance of risks and beneﬁts.
5.4.5. Food processing
The eﬀects of processing on foods require a separate
evaluation from the safety assessment of the unpro-
cessed food itself. New food processes, such as ohmic
heating for food sterilisation, in which an alternating
current is passed through foods resulting in their heat-
ing up due to their resistance (Advisory Committee on
Novel Foods and Processes, 1992), or established foodA.G. Renwick et al. / Food and Chemical Toxicology 41 (2003) 1211–1271 1257
processes, such as the inﬂuence of cooking practices on
polycyclic aromatic hydrocarbon formation (Scientiﬁc
Committee on Food, 2002b) may require risk char-
acterisation. The risk characterisation is strongly
weighted towards characterisation of the processed
material itself, with a view to identifying any changes in
components as a result of the processing, assessing the
potential variability of the process and any resulting
variability in product characterisation. Novel processes
should be compared with any comparable existing pro-
cesses to establish the nature of any diﬀerences and
whether these may need further evaluation.
The advice to risk managers in such cases needs to
focus on any nutritional, toxicological or micro-
biological consequences of the process for food safety,
rather than on the safety of the process itself. It will
need to address the extent to which the foods processed
remain the same and the extent to which the process
results in any constituents that are usually present dis-
appearing, while other chemicals not normally present
may be newly generated. Some of the constituents that
disappear may be important micronutrients, such as
heat-labile vitamins. Some processes may induce the for-
mation of undesirable substances, for example acrylamide
from frying, grilling and baking of carbohydrate-con-
taining foods (Swedish National Food Authority, 2002).6. Gaps and research needs
In the previous sections various areas of the risk char-
acterisation process have been identiﬁed as requiring
either further developments of methodology or
improvements in background scientiﬁc knowledge in
order to strengthen the outcome of the overall process.
In this section the key research needs identiﬁed are sum-
marised. Some research needs have been included that
are not directly related to the risk characterisation pro-
cess, however, if these were to be satisﬁed, they would
provide a more secure foundation for the process. These
research needs are grouped into categories covering:
1. Structured approaches to risk assessment,
2. Methodology of hazard identiﬁcation,
3. Methodology of intake estimation,
4. Assessment of critical endpoints,
5. Increased use of mechanistic knowledge
6. Use of critical endpoints in determining guidancevalues for food chemicals,
7. Use of probabilistic approaches and categoricalregression,
8. Risk/beneﬁt.The research needs within each category are priori-
tised with the higher priority items at the head of the
list. The research will require a multidisciplinaryapproach involving the co-operation of, for example,
toxicologists, epidemiologists, mathematicians, model
developers and risk assessors.
6.1. Structured approaches to risk assessment
The introduction of new procedures into the risk
characterisation process will increase its complexity and,
in order to improve its transparency, will require that it
should be reported in a manner that will be easily com-
prehended by individuals not directly involved in the
process. Various steps could be taken to reduce the
uncertainties in the risk assessment process and to
increase the transparency:
1. Improvement of the scientiﬁc basis for quantita-
tive risk assessment methodologies for thre-
sholded and non-thresholded toxicity to allow
the prediction of risks and thus enable risk
managers to decide better what measures are
appropriate.
2. Replacement of general default uncertainty fac-
tors, e.g. 10 for diﬀerent species and 10 for
human variability, by the development and vali-
dation of appropriate uncertainty factors that are
related to the metabolic fate of the compound
and its mechanism/mode of action.
3. Development of a concept to combine aspects of
uncertainty (safety) factors and nutritional
homeostasis, in particular for micronutrients,
macronutrients, novel foods and whole foods.
4. Development of methodologies on Good
Evaluation Practice.
5. Development of a narrative framework for
describing critical conclusions on, e.g. mechanism,
absenceof threshold, and species speciﬁcityof eﬀect.
6.2. Methodology of hazard identiﬁcation
There is a need for the development and validation of:
1. Better interspecies extrapolations by close colla-
boration of nutritionists, toxicologists, epide-
miologists and mathematicians, particularly in
areas such as peri- and postnatal development
(see also Section 6.1., items 2 and 3).
2. Improved methods for the detection of delayed
onset toxicity and, in particular, better models
for human neuropsychological syndromes.
3. Animal models for the identiﬁcation of acute
adverse reactions to foods and food chemicals,
which are classiﬁable as intolerance or allergy.
4. Animal models for common disease states in
humans to allow targeted evaluation of the eﬀect
of such states on the toxicity of foods and food
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6.3. Methodology of intake estimation
There are requirements for the development of:
1. Improved harmonisation of European food
consumption survey methods in order to provide
better assessments of exposure to food chemicals,
with particular emphasis on the determination of
reasonable values for extreme exposure and
potential under-reporting.
2. Improved procedures for the assessment of
exposure arising from intake by diﬀerent routes,
or by the intake of diﬀerent chemicals with
similar modes of action.
3. A harmonised pan-European food composition
database comprising all food categories and speci-
fyingappropriate samplingandanalyticalmethods.
4. Models for the study of the eﬀects of variation of
the food matrix on the absorption of individual
chemical components of that food.
5. A better understanding of the eﬀects of proces-
sing on food constituents in so far as it aﬀects
exposure assessment.
6. Models for exposure to allergens and methods to
predict the probability of adverse eﬀects arising
from such exposures (e.g. by including the
incorporation of variables representing indivi-
dual susceptibility in probabilistic models).
7. Procedures to provide a link between models of
exposure that evaluate the amount of a chemical
entering the digestive tract and those models that
estimate internal exposure.
6.4. Assessment of critical endpoints
There is a need for reﬁnements related to critical
endpoints, from either human or animal studies (possi-
bly supported by retrospective analysis of existing data)
to provide or improve:
1. Identiﬁcation and development of reliable and
sensitive molecular or clinical biomarkers of
toxicologically-relevant endpoints (including
those in the ﬁelds of genomics and proteomics).
These biomarkers should be eﬀective in short-
term studies, predictive of the risk of disease, and
capable of being used in epidemiological studies
on a relatively large scale at low cost.
2. Knowledge of the shape of the dose-response
curve at low doses of genotoxic and non-geno-
toxic carcinogens (see also Section 6.1., item 1).
3. Further development of a parallelogram
approach based on the comparison of in vitro
assays utilising animal and human cells, and of
biomarker-based analysis of both animal and
human exposure data.4. Development of an accepted framework for the
classiﬁcation of eﬀects as either adverse or
adaptive.
5. Optimisation of study design with respect to the
numbers of animals and doses used.
6.5. Increased use of mechanistic knowledge
For extrapolation of the consequences of adverse
eﬀects from observations in animals to predictions in
humans it is necessary to have a good understanding of the
diﬀerences between species of the manner in which adverse
eﬀects may be induced; some key points are the need for:
1. Improved understanding of the biological basis
for the extrapolation of diﬀerent endpoints to
humans by including toxicokinetics and target
dose estimation in a combined toxicokinetic/
toxicodynamic model.
2. Increased insights into the processes that lead to
certain toxic endpoints, such as those related to
reproduction, the immune system and the central
nervous system, in order to assess an endpoint’s
reliability and relevance in human risk assessment.
3. Improved understandingof the biological basis for
combination eﬀects of two or more compounds.
6.6. Use of critical endpoints in determining guidance
values for food chemicals
Having determined critical endpoints and been satis-
ﬁed that there is no mechanistic evidence that would
exclude an endpoint from occurring in humans, the
group undertaking the risk assessment would proceed to
the establishment of guidance values for the food com-
ponent involved. At this stage various aspects would
beneﬁt from further investigation:
1. Identiﬁcation and application of practical
‘‘thresholds’’ for genotoxic compounds, based on
data from epidemiological studies of unavoidable
contaminants.
2. Development of a structured approach to the
application of data on known polymorphisms in
humans and animals in the risk assessment
process.
3. Role of genetic inheritance and its interaction
with other factors (e.g. nutritional health,
microbial disease status, gut ﬂora, age, gender,
physiological status) in accounting for variation
and the values of relevant uncertainty factors to
be applied.
4. Reassessment of the validity of the default
uncertainty factors by analysis of historical data
on diﬀerences between humans and experimental
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5. Identifying circumstances for which it would be
appropriate to derive acute reference doses for
compounds other than pesticides.
6.7. Use of probabilistic approaches and categorical
regression
Alternative probabilistic approaches within the risk
assessment process may allow better use of the available
data, and could provide a basis for the validation of the
overall process:
1. Introduction and validation of probabilistic
approaches to exposure assessment, estimation of
the dose-response curve, toxicokinetic and tox-
icodynamic parameters, measures of human
variation and the precision of the data would
provide a more rational and realistic framework
for risk characterisation and facilitate the
integration of toxicology and epidemiology.
2. Evaluation of the contribution of techniques of
sparse data analysis in study design and inter-
pretation for hazard characterisation and
exposure assessment.
3. Development of criteria for the assignment of
categories of severity of eﬀect (magnitude of
eﬀect, not nature of eﬀect) and for combining
studies (e.g. by weighting small and large scale
studies) in order to apply categorical regression.
6.8. Risk/beneﬁt
The FOSIE project addressed the overall process of
risk assessment but did not address the issue of risk-
beneﬁt analysis. It became clear during the course of the
FOSIE discussions that there is a need to consider the
development and validation of methods to combine
assessment of risk and beneﬁts:
1. Development and validation of methods to
combine health risks and health beneﬁts. Since
exposures can be protective for particular dis-
ease(s) whilst enhancing the risk of other dis-
eases, the further development and use of
composite public health measures will be valu-
able in the estimation of optimal ranges of
exposures.
7. Conclusions
Risk characterisation is the process that brings toge-
ther the available data on hazard characterisation and
exposure assessment, the nature, quantity, and quality
of which will vary from substance to substance. In con-
sequence it is not possible, or even desirable, to providedetailed guidelines or a check list for how to perform
risk characterisation. This paper has therefore discussed
the key features of risk characterisation for food che-
micals; whilst the focus has inevitably been on low
molecular weight chemicals, about which there is most
knowledge, the applicability of the paradigm to other
food categories has been discussed.
Risk characterisation is an iterative process to which
all stakeholders should contribute, as appropriate, and
which may evolve as the hazard and exposure data are
collected and assessed. Central to risk characterisation
is the scientiﬁc evaluation of data on hazard identiﬁca-
tion and characterisation, and on exposure. It is impor-
tant that the scientiﬁc evaluation is independent and not
inﬂuenced by outside interests, such as industrial spon-
sors or pressure groups, or by risk management con-
siderations. However it is also important that the output
of the process is usable by risk managers, and is in a
form that can be communicated to, and understood by,
all stakeholders.
The output of risk characterisation may take various
forms including:
 Advice that current intakes or patterns of use do
not represent an appreciable risk to human health,
 Derivation of a health-based guidance value,
such as an ADI, to indicate a level of intake that
could be consumed daily over long periods
without appreciable risk to human health,
 A quantitative estimate of the risks associated
with diﬀerent levels of intake,
 Advice on the ratio between doses known not to
produce adverse eﬀects in experimental systems
and the estimated human intake, i.e. a margin of
safety, and
 Advice that, because of the nature of the hazard,
an intake that would be without appreciable risk
to human health cannot be determined.
For low molecular weight compounds, the extents of
hazard and exposure data considered to be necessary for
adequate risk characterisation are related to the pre-
dicted exposure. For substances such as ﬂavours and
packaging migrants, for which human intakes are
extremely low, it may be possible to undertake risk
characterisation and formulate advice in the absence of
chemical-speciﬁc toxicity data. In contrast, an extensive
hazard identiﬁcation and characterisation database
would be necessary for compounds that may be present
in signiﬁcant amounts in food due to intentional uses in
the food chain or from direct addition to food. Risk
characterisation for contaminants may be required in
situations when the available data may not be adequate
for a comprehensive evaluation, and under these cir-
cumstances additional areas of uncertainty would need
to be taken into account.1260 A.G. Renwick et al. / Food and Chemical Toxicology 41 (2003) 1211–1271
The advice to risk managers should describe clearly
the nature of the available hazard identiﬁcation and
characterisation data, and the way that the data have
been interpreted to derive the advice given to risk man-
agers. There are always uncertainties in the interpreta-
tion of toxicity data, such as extrapolation of data from
high dose to lower intake levels, inter-species extrapola-
tion, and consideration of human variability and
subgroups of the population. The method(s) by which
uncertainties have been taken into account, for example
by the use of default uncertainty factors, should be
described as part of the advice to risk managers.
There are also uncertainties in intake estimations,
such as prediction of the extent of use for a substance
prior to its approval, or the consistency of individual
patterns of food intake over time; for example, average
intakes from periods as short as one week are used as
estimates of average long-term intake. Again the nature
and extent of any uncertainty and imprecision in the
intake part of the risk characterisation should be iden-
tiﬁed in the advice to risk managers.
In practice any uncertainties inherent in risk char-
acterisation are taken into account by the use of con-
servative assumptions and approaches. As more
information becomes available on a substance, then
uncertainties are reduced and default approaches can be
replaced by chemical-speciﬁc information. However, the
generation of chemical-speciﬁc information cannot be
produced without costs in terms of the need for more
studies in humans and/or animals. Therefore some
degree of uncertainty will remain a constitutive part of
risk characterisation. Reﬁnements to default approachesand assumptions will provide a more secure basis to risk
characterisation. A number of areas of generic research
have been identiﬁed in this report that could improve
the process of risk characterisation without the need for
an increase in chemical-speciﬁc information.Acknowledgements
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Term: Deﬁnition and Reference.
The majority of the deﬁnitions used in
this glossary have been selected from
existing glossaries as indicated in the
references. Some of these deﬁnitions
have been adapted in minor ways to
make them consistent with the other
terms.)Acceptable
daily intake:
Estimated (maximum) amount of an
agent, expressed on a body mass
basis, to which a subject may be
exposed daily over his lifetime with-
out appreciable health risk (Organi-
sation for Economic Co-operation
and Development, 2002). Related
term: Reference Dose.Acceptable risk: The probability of suﬀering an
adverse eﬀect that will be tolerated by
an individual, group, system or
population. The acceptability of the
risk depends on scientiﬁc data, social,
economic, and political factors, and
on the perceived beneﬁts arising from
exposure to an agent (Organisation
for Economic Co-operation and
Development, 2002).Accumulation: Repeated doses of an agent which
results in progressive increase in the
concentration of that agent in an
organism, organ or tissue leading to
potentially more marked eﬀects with
successive doses (Duﬀus, 2000).Acute toxicity: Adverse eﬀects occurring within a
short time of administration of a sin-
gle dose of an agent, or immediately
following short or continuous expo-
sure, or multiple doses over 24 hours
or less (Duﬀus, 2000).Additivity: Consequence of two or more agents
acting together. It is the simple sum
of the eﬀects acting independently
(Duﬀus, 2000).Acute reference
dose:
The estimated amount of a substance
in food or drinking-water, expressed
on a body weight basis, that can be1266 A.G. Renwick et al. / Food and Chemical Toxicology 41 (2003) 1211–1271
ingested over 24 hours or less, with-
out appreciable health risk to the
consumer on the basis of all the
known facts at the time of the eva-
luation (Joint Meeting on Pesticide
Residues, 2002).ADME: Absorption, distribution, metabolism,
and excretion. The processes that
determine the disposition and fate of
an administered agent (Hayes, 2001).Adverse eﬀect: Change in the morphology, physiol-
ogy, growth, development or life span
of an organism, system or (sub)
population that results in an impair-
ment of functional capacity, an
impairment of the capacity to com-
pensate for additional stress, or an
increase in susceptibility to other
external inﬂuences (Organisation for
Economic Co-operation and Devel-
opment, 2002).Aggregate risk
assessment:
Term introduced under the Food
Quality Protection Act 1996 in the
USA, to describe risk assessment
taking all sources of intake of a given
pesticide into account (Committee on
Toxicity of Chemicals in Food, Con-
sumer Products and the Environ-
ment, 2002).Antagonism: Combined eﬀect of two or more
agents that is smaller than the solitary
eﬀect of any one of those agents
(Duﬀus, 1993).Assessment: Evaluation or appraisal of analysis of
facts and inference of possible con-
sequences concerning a particular
object or process (Organisation for
Economic Co-operation and Devel-
opment, 2002).Assessment
Factor:
Numerical adjustment used to extra-
polate from dose-response relation-
ships to estimate the agent exposure
below which an adverse eﬀect is not
likely to occur (Organisation for
Economic Co-operation and Devel-
opment, 2002). Related terms: Uncer-
tainty Factor and Safety Factor.Bench Mark
Dose (BMD):
The lower conﬁdence limit on a dose
associated with a speciﬁed level of
response (Hayes, 2001).Bioavailability: The fraction or percentage of the
administered dose what enters the
general circulation as the parent
compound (Hayes, 2001).Biomarker: Measurement that indicates exposure
to an agent, the eﬀect of such expo-sure, or susceptibility to eﬀect of such
an exposure (Hayes, 2001).Carcinogenicity: Process of induction of malignant
neoplasms by an agent (Duﬀus,
1993).Case Control
Study:
A study in which the past histories of
those with a speciﬁc disease (the
cases) are compared with those who
do not have the disease (the controls)
(Hayes, 2001).Chronic
toxicity:
Adverse eﬀects occurring as a result
of repeated dosing of an agent on a
daily basis, or exposure to that agent,
for a large part of an organism’s
lifespan, usually more than 50%
(Duﬀus, 2000).Cohort Study: Method of epidemiology study in
which a group of people (a cohort) is
assembled, none of whom has experi-
enced the outcome of interest. On
entry to the study, people in the
cohort are classifed according to their
observed exposure and other char-
acteristics that might be related to
outcome. These people are then fol-
lowed over time to see which of them
experience the outcome. In a pro-
spective cohort study, the exposure is
deﬁned before the outcome events
occur. This ensures that the time
relationship between exposure and
outcome is appropriate; the follow-up
procedures allow direct measurement
of the incidence rate of the out-
come(s) in each of the exposure
groups studied (Fletcher et al., 1988).Confounder: An alternative cause for the disease in
question that is unequally distributed
among those exposed and non-
exposed to the putative agent of
interest (Hayes, 2001).Cumulative risk
assessment:
Term introduced under the Food
Quality Protection Act 1996 in the
USA, to describe risk assessment tak-
ing intake of more than one pesticide
into account (Committee on Toxicity
of Chemicals in Food, Consumer Pro-
ducts and the Environment, 2002).Cumulative
exposure:
The sum of exposures of an organism,
system or (sub) population to an
agent over a period of time (Environ-
mental Protection Agency, 1997).Dietary reference
intakes (DRI’s):
Reference values that can be used for
planning and assessing diets for heal-
thy populations and for many other
purposes (Institute of Medicine, 1997).A.G. Renwick et al. / Food and Chemical Toxicology 41 (2003) 1211–1271 1267
Dose: Total amount of an agent adminis-
tered to, taken or absorbed by an
organism, system or (sub) population
(Organisation for Economic Co-
operation and Development, 2002).Dose–response
assessment:
The determination of the relationship
between the magnitude of exposure to
risk source(s) and the magnitude or
frequency and/or severity of asso-
ciated adverse eﬀect(s) (European
Commission, 2000).Dose–response
curve:
Graphical presentation of a dose–
response relationship (van Leeuwen
and Hermens, 1996).Dose–response
relationship:
Relationship between the amount of
an agent administered to, taken or
absorbed by an organism, system or
(sub) population and the change
developed in that organism, system or
(sub) population in reaction to the
agent (Organisation for Economic Co-
operation and Development, 2002).Ecological Risk
Assessment:
Risk Assessment process that evalu-
ates the likelihood that adverse eco-
logical eﬀects may occur or are
occurring as result of exposure to one
or more stressors (Organisation for
Economic Co-operation and Devel-
opment, 2002).Eﬀect: Change in the state or dynamics of an
organism, system or (sub) population
caused by the action of an agent
(Organisation for Economic Co-
operation and Development 2002).Eﬀect
Assessment:
Combination of analysis and infer-
ence of possible consequences of the
exposure to a particular agent based
on knowledge of the dose-eﬀect rela-
tionship associated with that agent in
a speciﬁc target organism, system or
(sub) population (Organisation for
Economic Co-operation and Devel-
opment, 2002).Expert
judgement:
Opinion of an authoritative person
on a particular subject (Organisation
for Economic Co-operation and
Development, 2002).Exposure: Concentration or amount of a parti-
cular agent that reaches a target
organism, system or (sub) population
in a speciﬁc frequency for a deﬁned




The process of estimating or measur-
ing the intensity, frequency, andduration of exposure to an agent.
Ideally, it describes the sources, path-
ways, routes, magnitude, duration,
and pattern of exposure; the char-
acteristics of the populations exposed;
and the uncertainties in the assess-
ment (International Programme on
Chemical Safety, 2001b).Exposure
scenario:
A set of conditions or assumptions
about sources, exposure pathways,
amount or concentrations of agent(s),
and exposed organism, system or
(sub) population (i.e. numbers, char-
acteristics, habits) used to aid in the
evaluation and quantiﬁcation of
exposure(s) in a given situation
(Organisation for Economic Co-
operation and Development, 2002).Fate: Pattern of distribution of an agent, its
derivatives or metabolites in an
organism, system or (sub) population
or compartment of concern as a result
of transport, partitioning, transfor-
mation or degradation (Organisation
for Economic Co-operation and
Development, 2002).Food: Any substance or product, whether
processed, partially processed or
unprocessed, intended to be, or rea-
sonably expected to be ingested by
humans. ‘‘Food’’ includes drink,
chewing gum and any substance,
including water, intentionally incor-
porated into the food during its man-
ufacture, preparation or treatment
(European Commission, 2002).Genotoxic: Property of an agent to cause harmful
changes to DNA (Duﬀus, 2000).Good
laboratory
practice:
Fundamental rules incorporated in
national regulations concerning the
process of eﬀective organisation and
the conditions under which labora-
tory studies are properly planned,
performed, monitored, recorded, and
reported (Duﬀus, 1993).Good evaluation
practice:
Principles concerning the eﬀective
organisation and the conditions
under which risk assessments are
properly planned, performed, mon-
itored, recorded and reported (Mal-
mfors et al., 2001)Hazard: The potential of a risk source to cause
and adverse eﬀect(s)/event(s) (Eur-
opean Commission, 2000).Hazard
characterisation:
The quantitative or semi-quantitative
evaluation of the nature of the1268 A.G. Renwick et al. / Food and Chemical Toxicology 41 (2003) 1211–1271
adverse health eﬀects to humans and/
or the environment following expo-
sure to a risk source(s). This must,




The identiﬁcation of a risk source(s)
capable of causing adverse eﬀect(s)/-
event(s) to humans or the environ-
ment species, together with a qualita-
tive description of the nature of these
eﬀect(s)/event(s) (European Commis-
sion, 2000).Homeostasis: Inherent tendency in an organism
toward maintenance of physiological
and psychological stability (Duﬀus,
2000).Interaction: A result in which chemicals in a mix-
ture produce an increased or diﬀerent
response as compared with the sum of
the responses of the individual che-
micals present in the mixture (Com-
mittee on Toxicity of Chemicals in
Food, Consumer Products and the
Environment, 2002).Internal dose: Amount of an agent penetrating the
absorption barriers via either physical
or biological processes (Hayes, 2001).In vitro: Study carried out in isolation from
the living organism in an experi-
mental system (Duﬀus, 2000).In vivo: Study carried out within the living
organism (Duﬀus, 2000).Irreversible: Persisting change in structure or
function (Duﬀus, 1993).Lowest observed
adverse eﬀect
level (LOAEL):
Lowest amount or concentration of
an agent, found by experiment or
observation, that causes an adverse
alteration of morphology, functional
capacity, growth, development or life
span in an organism, system or (sub)
population (Duﬀus, 1993).Margin of
exposure
(MOE):
Ratio of the critical no observed
adverse eﬀect level (NOAEL) to the
theoretical, predicted or estimated
exposure dose or concentration
(Organisation for Economic Co-
operation and Development, 2002).Margin of
safety (MOS):
Ratio of the critical no-observed-
adverse-eﬀect level (NOAEL) to the





that is related to the valued character-
istic chosen as an assessment point(Organisation for Economic Co-oper-
ation and Development, 2002).No observed
adverse eﬀect
level (NOAEL):
Greatest concentration or amount of
an agent, found by experiment or
observation, that causes no detectable
adverse alteration of morphology,
functional capacity, growth, develop-
ment or life span in an organism,
system or (sub) population (Duﬀus,
2000).PBTK model: Physiologically based toxicokinetic
model: a mechanistic model that
describes quantitatively the uptake,
distribution, metabolism and excre-
tion of an agent in an organism, sys-
tem or (sub) population (Hayes, 2001).Population
reference intake
(PRI):
The intake that is enough for vir-




Assessment of the amount and pat-
tern of human intake and determina-
tion of the nature and degree of
expected and unexpected eﬀects after
the introduction of a new product on
the market (van den Brandt et al.,
2002).Problem
formulation:
Process by which the issues and
questions are deﬁned and the plan for
analysing and characterising risk is
developed. (This article, see Section
2.1)Prospective
(cohort) study:
See: Cohort studyQSAR: Quantitative structure–activity Rela-
tionship: Quantitative analysis of the
dependence of the biological eﬀects of
an agent upon its molecular structure
(Duﬀus, 2000).Reference dose: An estimate of the daily exposure
dose that is likely to be without
appreciable health eﬀect even if con-
tinued exposure occurs over a lifetime
(Organisation for Economic Co-
operation and Development, 2002).
Related term: Acceptable Daily
Intake.Response: Change developed in the state or
dynamics of an organism, system or
(sub) population in reaction to expo-
sure to an agent (Organisation for
Economic Co-operation and Devel-
opment, 2002).Risk: The probability and severity of an
adverse eﬀect/event occurring to man
or the environment following expo-
sure, under deﬁned conditions, to aA.G. Renwick et al. / Food and Chemical Toxicology 41 (2003) 1211–1271 1269
risk source(s) (European Commis-
sion, 2000).Risk analysis: A process consisting of three com-
ponents: risk assessment, risk man-
agement and risk communication
(European Commission, 2000).Risk assessment: A process of evaluation including
identiﬁcation of the attendant uncer-
tainties, of the likelihood and severity
of an adverse eﬀect(s)/event(s) occur-
ring to man or the environment fol-
lowing exposure under deﬁned
conditions to a risk source(s). A risk
assessment comprises hazard identiﬁ-
cation, hazard characterisation,




The quantitative or semi-quantitative
estimate, including attendant uncer-
tainties, of the probability of occur-
rence and severity of adverse eﬀect(s)/
event(s) in a given population under
deﬁned exposure conditions based on
hazard identiﬁcation, hazard char-
acterisation and exposure assessment
(European Commission, 2000). Risk
characterisation is the fourth step in
the risk assessment processRisk
communication:
The interactive exchange of informa-
tion and science based opinions con-
cerning risk among risk assessors, risk
managers, consumers and other
actual or potential stakeholders (Eur-
opean Commission, 2000).Risk estimation: Quantiﬁcation of the probability,
including attendant uncertainties,
that speciﬁc adverse eﬀects will occur
in an organism, system or (sub) spe-
ciﬁc eﬀect population due to actual or
predicted exposure (Organisation for
Economic Co-operation and Devel-
opment, 2002).Risk
management:
The process of weighing policy alter-
natives in the light of the result of a
risk assessment and other relevant
evaluation and, if required, selecting
and implementing appropriate con-
trol options (which should, where
appropriate, include monitoring/sur-
veillance) (European Commission,
2000). Risk management consists of
three parts: risk evaluation; emission
and exposure control; risk monitoring.Risk monitoring: Process of following up the decisions
and actions within risk managementin order to ascertain that risk con-
tainment or reduction with respect to
a particular hazard is assured (Orga-
nisation for Economic Co-operation
and Development, 2002).Risk source: Agent, medium, commercial/indus-
trial process, procedure or site with
the potential to cause and adverse
eﬀect(s)/event(s) (European Commis-
sion, 2000).Safety: Practical certainty that adverse eﬀects
will not be caused by an agent under
deﬁned circumstances (Organisation
for Economic Co-operation and
Development, 2002).Safety factor: Reductive factor by which an
observed or estimated no observed
adverse eﬀect level (NOAEL) con-
centration or dose is divided to arrive
at a criterion or standard that is con-
sidered safe or without appreciable
risk (Organisation for Economic Co-
operation and Development, 2002).




Qualitative analysis of the depen-
dence of the biological eﬀects of an
agent upon its molecular structure
(Duﬀus, 2000).Subchronic
toxicity:
The adverse eﬀects occurring as a
result of the repeated daily dosing of
a chemical to experimental animals
for part (not exceeding 10 per cent) of
the life span (Organisation for Eco-
nomic Co-operation and Develop-
ment 1998).Threshold: Dose or exposure concentration of an
agent below which a stated eﬀect is
not observed or expected to occur
(Organisation for Economic Co-
operation and Development, 2002).Threshold of
toxicological
concern (TTC):
Human exposure threshold value for
classes of substances in the diet below
which there is no signiﬁcant risk to
human health (Kroes et al., 2000).Tolerable daily
intake (TDI):
Analogous to acceptable daily intake.Tolerable
(daily weekly,
monthly) intake:
Estimate of the amount of an agent
that can be ingested or absorbed in
the period speciﬁed, over a life time




The maximum level of total chronic
daily intake of a nutrient (from all
sources) judged to be unlikely to pose
a risk of adverse health eﬀects to1270 A.G. Renwick et al. / Food and Chemical Toxicology 41 (2003) 1211–1271
humans. ’Tolerable intake’ in this
context connotes what is physio-
logically tolerable and is a scientiﬁc
judgement as determined by assess-
ment of risk, i.e. the probablity of
an adverse eﬀect occurring at some
speciﬁed level of exposure. ULs may
be derived for various groups in the
population (Scientiﬁc Committee on
Food, 2000c).Toxicant: An agent capable of causing an
adverse eﬀect in a biological system
(van Leeuwen, 1996)Toxicity: Inherent property of an agent to
cause an adverse biological eﬀect
(Organisation for Economic Co-
operation and Development, 2002).Toxic
equivalence
factor (TEF):
Factor obtained by taking the ratio
of the POD (point of departure) of
the index compound to that of
each of the other members in a
group with a common mechanism
of toxicity. Exposure to each
chemical in the group is then multi-
plied by the appropriate TEF to
express all exposures in terms of the
index compound (Wilkinson et al.,
2000).Toxicodynamics: The process of interaction of chemical
substances with target sites and the
subsequent reactions leading to
adverse eﬀects (World Health Orga-
nization, 1994).Toxicokinetics: The process of the uptake of poten-
tially toxic substances by the body,
the biotransformation they undergo,
the distribution of the substances and
their metabolites in the tissues and
the elimination of the substances and
their metabolites from the body. Both
the amounts and concentrations of
the substances and their metabolites
are studied. The term has essentially
the same meaning as pharmacoki-
netics, but the latter term should be
restricted to the study of pharmaceu-
tical substances (World Health Orga-
nization, 1994).Upper level
(UL):
The maximum level of total chronic
daily intake of a nutrient (from all
sources) judged to be unlikely to pose
a risk of adverse health eﬀects to
humans (Scientiﬁc Committee on
Food, 2000c).Uncertainty: Imperfect knowledge concerning the
present or future state of an organ-
ism, system or (sub) population under
consideration (Organisation for Eco-
nomic Co-operation and Develop-
ment, 2002).Uncertainty
factor:
Synonymous with Safety FactorXenobiotic: A chemical which is not a natural
component of the organism, system
or (sub) population exposed to it
(Duﬀus, 2000).A.G. Renwick et al. / Food and Chemical Toxicology 41 (2003) 1211–1271 1271
